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Abstract 
 
Polyhydroxyalkanoates (PHAs) are polyesters composed of (R)-3-hydroxy-fatty acids. 
A variety of gram-positive as well as gram-negative bacteria and some archaea are able 
to produce these biopolymers as energy and carbon storage materials. In times of 
unbalanced growth, when carbon is available in excess but other nutrients are limited, 
PHA inclusions are formed. These granules are water-insoluble, stored intracellularly 
and can be maintained outside the cell as beads. The key enzyme for the formation of 
PHA inclusions is the PHA synthase PhaC, which catalyses the polymerization of (R)-
3-hydroxyacyl-CoA to PHA with the concomitant release of CoA. 
The PHA synthase from Ralstonia eutropha (currently Cupriavidus necator), which is 
covalently bound to the PHA granule surface, tolerates fusions to its N terminus 
without loss of activity. In this study it was investigated if it would also tolerate 
translational fusions to its C terminus. A specially designed linker was employed, 
aiming at maintaining the hydrophobic surroundings of the R. eutropha synthase C 
terminus to allow proper folding and activity. Two reporter proteins were tested as 
fusion partners, the maltose binding protein MalE and the green fluorescent protein 
GFP. As GFP is a hydrophobic protein itself, no additional linker between the PHA 
synthase and the reporter protein was necessary to produce PHA granules displaying 
the functional fusion protein on the surface. Principally, the PHA synthase PhaC 
tolerates translational fusions to its C terminus but the nature of the fusion partner 
influences the functionality. 
Recently, PHA granules have often been acknowledged as bio-beads. A one-step 
production allows the formation of functionalised beads without the need for further 
cross-linking to impart desired surface properties. PHA beads displaying a gold- or 
silica-binding peptide at the N terminus of PhaC were constructed and tested for their 
applicability. Additionally, these beads were able to bind IgG due to the ZZ domain of 
the IgG binding protein A, which was employed as a linker sequence. These 
functionalised beads can be used as molecular tools in bioimaging and biomedicine, 
combining organic core with inorganic-binding shell structures.  
 
 
 
Abstract 
ii 
In a different biomimetic approach, the display of ten lysine residues at the granule 
surface was achieved using the phasin protein PhaP as the anchoring matrix. Extensive 
work was performed in an attempt to also employ the synthase protein, but was 
unsuccessful. These positively charged bio-beads can be used for dispersion or cross-
linking experiments as well as silica binding. 
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Natural Polyesters 
 
Three different organic polyesters are naturally produced on earth. Polymalic acid is 
only produced in eukaryotic microorganisms. Cutin and suberin are polymer matrices 
for lipophilic cell wall barriers in plants and polyoxoesters are produced in prokaryotic 
bacteria and archaea. All these polyesters are formed naturally without any outside 
intervention, e.g. genetic engineering, and are therefore investigated for their potential 
to be exploited, improved or modified to be applicable in modern technology. 
 
Polymalic Acid 
Malic acid is an organic compound with the formula HO2CCH2CHOHCO2H. L-malic 
acid units are covalently linked by ester bonds between the hydroxyl group and the 
carboxyl group in the β position to form poly(β-L-malic acid). The carboxyl group in 
the α position points away from the polyester chain (Fischer et al., 1989). The ionized 
form of the polymer is poly(β-L-malate) or PMLA and is highly water soluble. This 
carboxylic-functionalised polyester can be produced by either chemical synthesis or 
fermentation of myxomycetes and certain filamentous fungi (Lee et al., 2002). Natural 
production of poly(malic acid) was first reported for Penicillium cyclopium where it 
inhibits acid proteases (Shimada and Matsushi, 1969; Shimada and Matsushima, 1967; 
Shimada et al., 1969). Some work has been published regarding its production in 
Aureobasidium pullulans (Liu and Steinbüchel, 1996; Liu and Steinbüchel, 1997; 
Nagata et al., 1993) but most of the studies were performed with Physarum 
polycephalum (Fischer et al., 1989; Göttler and Holler, 2006; Korherr et al., 1995; Lee 
et al., 2002; Rathberger et al., 1999). The slime mould Physarum polycephalum 
differentiates into several cell forms during its life cycle (Burland et al., 1993) but only 
the plasmodium, a giant polynuclear cell, produces PMLA. There it accumulates to 
high concentrations comparable to the level of DNA in the naturally synchronous 
nuclei (Angerer and Holler, 1995; Fischer et al., 1989; Schmidt et al., 1996). All 
myxomycetes species examined so far contained PMLA in their plasmodia. The 
polymer level in the nuclei remains constantly high during the cell cycle; excess 
amounts of PMLA are secreted into the culture medium. The unique physiological role 
of this unconventional biopolymer is currently being investigated for the plasmodium 
of Polycephalum and although the underlying biochemical connections are not fully 
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understood, it appears that PMLA functions as a storage and carrier molecule to 
maintain an even distribution of histones, DNA polymerases and other nuclear proteins 
within this giant cell (Angerer and Holler, 1995; Doerhoefer et al., 1998). Furthermore, 
it has been assumed that by assuring an equal distribution of nuclear proteins, PMLA is 
involved in the coordination of the synchronous replication of DNA during the cell 
cycle (Fischer et al., 1989). Poly(β-L-malate) was discovered for its ability to bind and 
reversibly inactivate DNA polymerase α (Fischer et al., 1989; Holler et al., 1992). Later 
it was shown that DNA polymerases δ and ε could also be bound and inactivated by 
PMLA whereas DNA polymerase β was not inhibited (Achhammer et al., 1995; 
Doerhoefer et al., 1998; Doerhoefer et al., 2002). The distance between the negative 
charges in PMLA is responsible for the specificity of the binding and inactivation. This 
distance is comparable to that between the phosphate groups in the DNA backbone, 
explaining the competitive binding of PMLA and DNA to the polymerases (Holler et 
al., 1992). Because DNA polymerase α of Physarum polycephalum is constitutively 
expressed during the cell cycle (Fischer, 1987; MacNicol et al., 1987) and histones are 
only synthesized during the S phase, it was proposed that PMLA, histones, polymerase 
and newly replicated DNA interact competitively during the cell cycle with the DNA 
polymerase being active during the S phase and inactive during the G2 phase. 
Following the hypothesis, histone synthesis starts at the beginning of the S phase 
(Carrino et al., 1987) and the newly formed histones compete with the DNA 
polymerase α for PMLA binding and eventually succeed. The displaced polymerase 
starts DNA replication until the histone synthesis ends and the histone proteins are used 
to form energetically highly favourable nucleosomes with the newly replicated DNA. 
Free PMLA again binds DNA polymerase α – which marks the beginning of the G2 
phase – and DNA synthesis is therefore terminated (Holler et al., 1992). 
PMLA is constitutively formed in the plasmodium (Schmidt et al., 1996) and NMR 
studies revealed that different biosynthesis routes are employed, depending on the 
nutrients available (Lee and Holler, 1999; Lee et al., 1999). Recently, the polymer has 
also been investigated regarding its use in biotechnology. It is available from 
sustainable feedstock which can be maintained with renewable resources (Holler 1997) 
and is biodegradable and biocompatible. PMLA is a bioresorbable compound and gets 
metabolized in the mammalian tricarboxylic acid cycle (Braud et al., 1985; Fournie et 
al., 1990; Vert and Lenz, 1979). In biomedicine PMLA is investigated as a non-toxic, 
nonimmunogenic drug delivery system especially for antitumor applications 
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(Abdellaoui et al., 1998; Fujita et al., 2007; Heun et al., 1999; Lee et al., 2006; 
Ljubimova et al., 2008; Mueller et al., 2008; Portilla-Arias et al., 2008). 
 
Cutin and Suberin 
Life on earth originated in water but more than 400 million years ago the first plants 
moved from a wet environment onto land (Kenrick and Crane, 1997). In order to 
survive in the dryer surroundings, plants developed a protective barrier, known as a 
“cuticle”. Cuticles cover all air exposed exteriors of plants and are composite materials, 
basically made of cutin (Kolattukudy, 1980, 2001). Cutin is an insoluble polymer, 
consisting of hydroxy-fatty acids and their derivatives linked by ester bonds. The most 
common monomers in cutin are 16-hydroxypalmitate and 9,16 or 10,16-
dihydroxypalmitate and 18-hydroxyoleate as well as 9,10-epoxy-18-hydroxystearate 
and 9,10,18-trihydroxystearate. These monomers are produced and modified in the 
epidermal cells of plants (Kolattukudy, 2001). There is not much known about the 
concrete structure of cutin, whether it is a distinct polymer of unknown molecular 
weight, possibly anchored to the cell wall at a few points, or whether it is a highly 
cross-linked continuum (Pollard et al., 2008). As cutin is part of the water-resistant 
protective outside layer, it is presumed to participate in controlling non-stomatal water 
and gas exchange and host-plant interactions (Kolattukudy, 2001; Nawrath, 2006). It 
has also been proposed that cutin is involved in plant morphology (Hoffmann-Benning 
and Kende, 1994) and in controlling organ identity by counteracting organ fusion 
(Sieber et al., 2000). 
The other type of polyester found in plants is suberin, the main constituent of cork, 
named after the cork oak Quercus suber L. (Graca and Pereira, 2000b). Suberin is a 
waxy substance, highly hydrophobic and consists of two domains: polyaromatic and 
polyaliphatic (Bernards, 2002; Kolattukudy, 2001). The aromatic domain is a 
polyphenolic substance, derived from cinnamic acid and its derivatives, mostly ferulic 
acid. The aliphatic polyester domains are composed of C16 and C18 fatty acids and 
their elongation products, similar to those of cutin (Bernards and Lewis, 1998; Bernards 
et al., 1995; Bernards and Razem, 2001; Gandini et al., 2006; Kolattukudy, 2001). It 
was shown previously that glycerol is part of suberin (Kolattukudy, 1980; Kolattukudy, 
2001; Kolattukudy and Espelie, 1989), but only recently it was detected to be an 
essential building block (Bernards and Lewis, 1998; Graca and Pereira, 1997; Graca 
and Pereira, 1999; Graca and Pereira, 2000a, b, c). There is no “unique” chemical 
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structure of suberin and over the years numerous models have been proposed (Gil et al., 
1997; Lopes et al., 2000; Sitte, 1962). In recent years newly developed methods 
allowed first insights into linkages within the polymer and the following model was 
designed: From glycerol as a basis, suberin grows two- and three-dimensionally due to 
the formation of ester linkages between monomers of the aliphatic domain. At the 
periphery of this glycerol-based polymer, ferulic-acid covalently links the aliphatic 
polyester to the aromatic domain, which itself is thought to form a connection to the 
carbohydrates of the cell wall (Franke and Schreiber, 2007; Kolattukudy, 1977, 1981; 
Lopes et al., 2000b). The main function of suberin is to protect against desiccation, 
which was essential when plants first moved from the wet to a dry environment. The 
most prominent example for suberin deposition in the cell wall is the Casparian strip or 
Casparian band in endodermal root cells. This structure prevents the water and nutrients 
taken up by the roots from moving through the apoplast, instead, they must pass the cell 
membrane and traverse through the symplast. This selection tool is mostly determined 
by the aliphatic domains of the polymer (Hose et al., 2001; Zimmermann et al., 2000). 
Mangroves use suberin to minimize salt intake from their habitat. The importance of 
suberin in salt stress tolerance was also shown for Arabidopsis (Beisson et al., 2007). 
Suberin is also synthesized as wound response, where healthy tissue is protected by 
suberin accumulation at the wound edges (Kolattukudy, 2001). The fact that suberin 
deposition occurs only in specific tissues and in response to environmental changes 
indicates a complex regulation of the polymer synthesis for which the molecular 
processes are so far unknown (Franke and Schreiber, 2007). 
 
Bacterial Polyoxoesters 
Polyhydroxyalkanoates (PHAs) were discovered at the beginning of the 20th century, 
when Lemoigne first found poly(3-hydroxybutyrate) (PHB) inside bacterial cells 
(Lemoigne, 1926). PHAs are biopolyesters synthesized by many bacteria and some 
archaea in phases of carbon excess but limitation of other nutrients (Hoffmann and 
Rehm, 2005; Kim et al., 2004; Kuchta et al., 2007). The polyesters are stored in the 
form of water-insoluble spherical inclusions or granules inside the cell and serve as 
energy and carbon storage (Rehm, 2006). Approximately 150 different 
hydroxyalkanoic acids are known as constituents of PHAs (Steinbüchel and Valentin, 
1995) and the most investigated PHA is poly(3-hydroxybutyrate), mainly studied in 
Cupriavidus necator (formerly Ralstonia eutropha) (Peoples and Sinskey, 1989; Slater 
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et al., 1988). Recently, PHB and related co-polymers attracted interest because of their 
thermoplastic and elastomeric properties and biodegradability, and are being 
thoroughly investigated regarding their qualification to replace petroleum-derived 
plastics. Additionally, several biomedical and biotechnological applications have been 
investigated and assessed (Grage et al., 2009; Philip et al., 2007). Intracellularly formed 
PHA granules can be stably maintained outside the cell as PHA beads. The following 
two chapters provide further detailed insights into the applications of PHA and 
especially PHA beads. Also, current knowledge of the emergence and formation of 
PHA granules as well as a short description of associated proteins will be presented. 
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Biopolyester particles: preparation and applications 
 
I. A. Rasiah, N. Parlane, K. Grage, R. Palanisamy, A. C. Jahns, J. A. Atwood and 
B. H. A. Rehm 
 
Abstract 
 
Over the past few decades, there has been a growing awareness of the potential uses of 
biodegradable polymers in biotechnology and medicine. In particular, micro- and nano-
sized particles which are made from natural resources, exhibiting biodegradability, 
biocompatibility and low toxicity have been the subject of intense research and 
development in many areas. Apart from their beneficial material properties, these 
particles allow variations in structure and composition to be designed, thereby tailoring 
them for specific applications. This review presents a broad overview of the main 
categories of biopolyester particles described in the literature, with emphasis on the 
composition and preparation of each group, followed by the wide variety of 
applications and potential uses described to date.  
 
Introduction 
 
Biopolyester particles are micro- and nanometer sized particles made from natural and 
renewable resources. In the past few decades, great advances have been made in the use 
of such particles throughout various fields of science and medicine, mainly due to their 
properties such as biodegradability and biocompatibility (1, 2). In particular, the area of 
drug delivery has been highly impacted with the range of polymeric biomaterials which 
have been processed into micro- and nano-spheres as well as capsules with the specific 
purpose of encapsulating or attaching pharmacologically active substances (3). The 
main goal in the design of such particles has been the controlled release of a bioactive 
agent to a specific site at a therapeutically optimal rate (4).  
Several categories of biodegradable polymer particles have been conceived for various 
applications. These include (i) naturally occurring particles such as the 
polyhydroxyalkanoate (PHA) granules produced intracellularly by many bacteria (5, 6), 
(ii) particles which are chemically synthesized from extracted PHA (7), (iii) micro- and 
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nano-particles based on polylactide (PLA) (3), (iv) co-polymers of PLA with glycolic 
acid, such as PLGA (8) and particles produced from polymalate (poly(β-malic acid), 
PMLA (9) (Figure 1). While these categories are by no means exclusive, they represent 
the major types of biotechnologically relevant as well as long-circulating, particulate 
carriers which have now taken a leading position in drug formulation and delivery. 
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Figure 1: Overview of different biopolyester constituents 
 
The use of particles as carriers has several advantages over traditional oral and 
intravenous methods of drug administration, including high stability, ability to carry 
and administer several drugs at the same time at a specific site and the possibility of 
several routes of administration, such as oral or topical administration as well as 
inhalation (10). As vaccine delivery systems, the advantages include the administration 
of multiple antigens in a one-off immunization allowing the simultaneous uptake of 
various antigens by the respective immune cells, protection of the antigen in vivo and 
control over the rate of release (11, 12).  
One of the fundamental requirements of particles used in therapeutic applications is 
biodegradation of the polymer within the human body. PLA and PLGA degrade in vivo 
by hydrolysis into lactic acid and lactic acid plus glycolic acids, respectively, which get 
incorporated into the cellular tricarboxylic acid cycle and hence oxidised (13). 
Similarly, PMLA is degradable by simple hydrolysis of the ester bond of the main 
chain, yielding malic acid which is in turn completely biodegraded to carbon dioxide 
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and water (14). The degradation behaviour of these polymer materials has been the 
subject of much research (1, 15, 16), especially with regard to the mechanisms of 
degradation (14) and factors affecting the degradation processes in vivo (17, 18). 
In addition to the growing number of medical applications, particles derived from 
biological polymers are well known for their use in biotechnological settings. In 
particular, particles made of the PHA, polyhydroxybutyrate (PHB), have been widely 
investigated.  These include (i) particles which have been synthesized from extracted 
PHA (19, 20) and (ii) granules which are intracellularly formed in recombinant bacteria 
and subsequently isolated (6). PHA particles have been successfully engineered to 
functionally display specific biotechnologically relevant fusion proteins on their surface 
such as streptavidin (21), binding peptides for inorganic materials (22) an antibody (23) 
and to immobilize a thermostable α-amylase (24). These novel, functionalized beads 
are considered to be valuable tools for various applications in biomedicine and industry. 
This review provides an overview of the main categories of biodegradable polyester 
particles used in biotechnological and therapeutic applications. Each type of particle, 
the composition of the respective biopolymer and the preparative methods for particle 
formation will be discussed. Finally, attention will be drawn to the wide variety of 
biomedical applications of each group, thus highlighting the level of progress achieved 
in this area in the past few decades. 
 
Polyhydroxyalkanoates 
 
Background 
PHAs are bacterial storage compounds which are formed in times of imbalanced 
nutrient availability when a carbon source is available in excess but other nutrients have 
been depleted. They are deposited as water-insoluble spherical inclusions or PHA 
granules inside the cell and can be mobilized when conditions are suitable. PHA 
accumulation is quite common among both Gram-negative and Gram-positive bacteria 
and has even been shown to occur in some members of the Archaea (25-30). 
Depending on the synthesizing organism (and to some extent on the substrate) PHAs 
are composed of monomers of different chain lengths and have been divided into short 
chain length (PHASCL) and medium chain length PHAs (PHAMCL). PHASCL is mainly 
found as poly(3-hydroxybutyric acid) (PHB). While physical and thermal properties of 
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the different PHAs vary, they are all biocompatible and biodegradable (31, 32). There 
is considerable interest in applications of PHA, but due to the relatively high production 
costs compared to oil-based plastics, PHAs are currently mainly attractive for use in the 
medical field, e.g. for sutures or implants like heart valves (33, 34).  
PHB biosynthesis has been extensively investigated in the Gram-negative bacterium 
Cupriavidus necator (formerly Ralstonia eutropha) where it involves three steps 
starting from acetyl-coenzyme A (CoA) (35-37). Two molecules of acetyl-CoA are 
condensed to acetoacetyl-CoA by the enzyme β-ketothiolase (PhaA). Acetoacetyl-CoA 
reductase (PhaB) reduces acetoacetyl-CoA to (R)-3-hydroxybutyryl-CoA and these 
hydroxyacyl-CoA monomers are subsequently polymerized by PHB synthase (PhaC). 
The PHA synthase is the key enzyme of PHA biosynthesis in general; for PHAs other 
than PHB different hydroxyacyl-CoA percursors derived from different metabolic 
pathways are used. Nascent polyester chains assemble to form the PHA granule, with 
the PHA synthase remaining covalently bound to the polyester molecule and thus 
immobilized at the granule surface (38, 39). Other proteins that associate with the 
granule surface in a non-covalent manner are PHA depolymerising enzymes (PhaZ in 
C. necator), regulatory proteins (PhaR in C. necator) and structural phasins (PhaP in C. 
necator) (40-50).  
PHAs can be recombinantly produced e.g. in Escherichia coli by heterologous 
expression of the required PHB biosynthesis genes while providing appropriate 
cultivation conditions (51-54). PHA production in plants has also been considered (55, 
56). Recently, native PHA granules and in vitro synthesized PHA beads have been 
increasingly considered for applications as functionalized micro- or nanobeads in 
biotechnology and biomedicine (57).  
 
Preparation of PHA particles 
PHA micro- and nanoparticles can be prepared chemically/in vitro from extracted PHA 
or be produced in vivo inside the (mainly bacterial) cell and subsequently isolated. In 
both cases a protein of interest can be immobilized at the bead surface through fusion to 
a granule-associated protein. However, in case of in vitro synthesized beads proteins 
are also bound in vitro to pre-fabricated beads, whereas protein binding to in vivo 
produced beads occurs during PHA granule formation inside the cell. In vitro bead 
preparation is usually the method of choice for drug loading/encapsulation. 
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In vitro production 
As PHA has long been considered as an alternative plastic, a range of methods have 
been developed for the extraction of PHA from cells, the aim being the isolation of the 
material and not the preservation of its spherical nature / granule shape (58-60). 
Extraction is usually preceded by biomass harvest and, depending on the method, cell 
disruption. A common method to isolate PHA from the biomass is solvent-based 
extraction. Cells (generally lyophilized) are resuspended in a solvent such as 
chloroform or methylene chloride in which PHA is soluble (61, 62). After all other cell 
debris has been removed, for example by filtration, the PHA can be precipitated with 
methanol or ethanol. Non-chlorinated solvents such as acetone have also been used, 
however, acetone only solubilises PHAMCL, not PHB (63). While solvent-based 
extraction yields PHA of high purity without affecting molecular weight, it is necessary 
to use large volumes of solvent, which is expensive and might also be undesirable for 
other reasons. Water-based extraction methods comprise digestion and/or solubilization 
of non-PHA cellular material. Hypochlorites, in general sodium hypochlorite, have 
been used in this method and were found to enable relatively cheap extraction of very 
pure PHA, but do significantly degrade PHA in the process (64, 65). The combined use 
of sodium hypochlorite and chloroform was reported to reduce degradation while still 
enabling isolation of high purity PHA (66, 67). Similarly, hypochlorite has also been 
used in combination with surfactants (68). Several other protocols have been developed 
which use different combinations of detergents and/or enzymes to solubilise cell 
components (69-71). Extraction of PHA with supercritical fluids, mainly supercritical 
carbon dioxide, has been reported to be particularly effective for removing lipid 
contaminants, resulting in extremely pure PHA containing only low levels of endotoxin 
(72). 
Starting from purified PHA, micro- or nanoparticles for subsequent functionalization 
can be prepared by variants of the oil-in-water emulsion method (7). Lee and coworkers 
(73) and Wang and coworkers (74) used slightly varied versions of the oil-in-water 
emulsion method to generate microbeads from PHB and nanobeads from poly(3-
hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx), respectively. In both cases, the 
polymer was dissolved in chloroform and an aqueous solution with or without 
surfactant added. The separate phases were emulsified with a homogenizer or by 
sonication, and PHB or PHBHHx beads harvested by evaporation of the chloroform 
and/or centrifugation, followed by repeated washing. According to Horowitz et al., the 
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addition of surfactant results in the formation of beads containing amorphous PHA, 
which crystallizes upon removal of the surfactant, i.e. by washing with water (7). 
Omission of the surfactant leads to crystallization of the PHA as soon as the chloroform 
evaporates. 
Yao and coworkers generated PHBHHx nanoparticles loaded with the lipid dye 
rhodamine B isothiocyanate (RBITC) by a modified oil-in-water solvent diffusion 
technique (75). RBITC and PHBHHx were dissolved in dichloromethane and the 
dichloromethane mixture was slowly added to a sonicated poly(vinyl alcohol) solution. 
After further sonication and extended gentle stirring, the particles were collected by 
centrifugation and subsequently washed in water. 
For drug delivery, microcapsules and microspheres of poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) containing different chemicals/drugs have been prepared by 
slightly varied solvent emulsion/evaporation techniques, all using dichloromethane as 
solvent and poly(vinyl alcohol) as emulsifier (76, 77). In addition, double 
emulsification methods (water-in-oil-in-water and oil-in-water-in-oil) were developed 
(78), and different copolymer compositions and molecular weights were investigated 
(79, 80). The primary aim of this research was to understand how the polymer 
properties and the preparation technique (81) influence the physical properties of the 
resulting microspheres as well as drug loading and release (see below). 
 
In vivo production 
In order to exploit the advantage of having proteins naturally immobilized at the bead 
surface, it is possible to use in vivo produced PHA granules as functionalized micro-
/nanobeads. In this case, isolation conditions have to be gentler to preserve granule 
shape/properties and protein functionality. Production generally happens in 
recombinant strains, not necessarily natural PHA producers, but this does not impact on 
the (common) isolation methods. These methods usually involve a form of density 
gradient centrifugation, using either a glycerol or a sucrose gradient.  
In earlier publications, native PHA granules were prepared by repeated centrifugation 
of cell lysates layered onto glycerol, using swing-out rotors (82, 83). Much purer 
granule preparations were obtained when glycerol gradients, consisting of four layers 
with glycerol concentrations between 10.5 and 9.0 M, centrifuged at 90,000 x g were 
used for further purification (38). Alternatively, glycerol gradient centrifugation can be 
performed with only two layers of 88% and 44% (v/v) glycerol at 100,000 x g (84). 
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Both linear and discontinuous sucrose gradients have been used for the isolation of 
native PHA granules (85-87). Preparation of a linear gradient can be a complex 
procedure (88), but it has also been generated without the need for a special apparatus 
by freezing a discontinuous gradient (consisting of 2 M, 1.66 M, 1.33 M and 1 M 
sucrose layers) in liquid nitrogen and then thawing it at 4°C (87). Alternatively, PHA 
granules have been isolated on a discontinuous sucrose gradient consisting of two 
layers of 20% and 15% (w/w) sucrose (86). In both cases centrifugation was done at 
110,000 x g. 
For some applications of functionalized PHA beads in protein purification, no prior 
isolation of the beads is required (see below) (89, 90) 
 
Applications of PHA particles 
PHA beads, naturally or artificially derived, are very versatile and can be used for a 
broad range of applications, mostly in biotechnology and biomedicine. Over the years, 
different strategies of how the PHA system can be used for protein purification have 
been evolved. All these different approaches have focussed on efficiency of purification 
and low costs compared to commercially available chromatography systems. In the 
recently published applications the granule-associated phasins were employed as the 
basis for the purification of the desired proteins. In a very simple approach, the N- 
terminal granule binding domain of PhaF, a phasin from Pseudomonas putida GPo1 
(48), was used as a binding/purification tag called BioF (91). The protein of interest 
was co-expressed as a fusion protein with the BioF purification tag under PHA 
accumulating conditions. Thus the protein of interest was produced bound to PHA 
granules and could be released by mild detergent treatment. The released protein still 
contained the purification tag (91). Further developed methods have used inteins for 
facilitated release of the target protein (19). Inteins, or INTervening protEINS, are 
naturally occurring protein sequences that are capable of post-translational self-excision 
from a precursor protein, employing a process called splicing (19). Proteins of interest 
are fused via an intein linker to the phasin protein PhaP and therefore attached to the 
natively formed granules inside the cell. For better attachment, multiple copies of PhaP 
were employed. The protein of interest is released using the intein cleaving site. This 
system was successfully established in the natural PHA producer C. necator as well as 
in engineered E. coli.  This does not necessarily require isolation of the engineered 
particles (89, 90), because the crude cell extract containing the particles can be directly 
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used for protein purification. Recently, a slightly modified purification method was 
published. It is still based on the PhaP-intein-X fusion, with X being the protein of 
interest, but it separates the protein production from the actual purification process, 
resembling common chromatography techniques. The PHA particles which serve as 
purification matrix are artificially (in vitro) made out of chemically purified PHA. The 
crude extract of the recombinantly produced PhaP-tagged protein is then incubated with 
the artificially prepared matrix. PhaP mediated binding and subsequent intein cleavage 
leads to purification of the protein (92). A completely different approach was employed 
by Brockelbank et al. (2006), in which the ZZ domain of protein A from 
Staphylococcus aureus was fused to the PHA synthase PhaC, enabling affinity 
purification of antibodies of the IgG class (93). These engineered beads performed 
equally when compared to commercially available protein A beads. In this last example 
the protein to be purified did not need a special purification tag, whereas in all other 
methods the protein of interest was tagged with a granule-binding protein to enable 
attachment to the purification matrix. 
Micro- and nano-PHA beads displaying certain functionalities are very valuable and 
beneficial, especially for biotechnological applications. In most cases these beads are of 
non-biological origin and the production involves chemical cross-linking (20). Several 
studies have described the one-step production of functionalized PHA beads in 
engineered E. coli. In all examples the N terminus of the PHA synthase was fused to 
the respective protein that should be displayed at the bead surface, for example 
streptavidin (21) or β-galactosidase (21, 84) and α-amylase (24) as examples of 
immobilized enzymes. These beads are functional tools for various applications, 
ranging from bio-labelling using the strong binding between streptavidin and biotin to 
supplementing washing detergents with a starch hydrolysing enzyme that shows high 
temperature stability. 
Because of its biodegradable and biocompatible properties, PHA is being investigated 
for its applicability in biomedicine. Immunoassays are an especially widely used tool. 
For these assays, the proteins must be in a functional state, but immobilized. These 
criteria can be easily fulfilled using PHA beads. E. coli has been engineered to display 
the PhaP-bound mouse interleukin-2 (IL2) or the myelin oligodendrocyte glycoprotein 
(MOG) on PHA granules (5). These eukaryotic proteins were functional albeit their 
production in a prokaryotic host and performed successfully in fluorescence activated 
cell sorting (FACS). The PHA beads were produced in one step. An enterokinase site 
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between the PhaP protein and the respective fusion partner allowed cleavage of the 
fusion partner and could hence be used for protein purification. In a related study it was 
shown that two independent functionalities can be displayed at the PHA bead surface 
either in the form of two functionalized proteins or one bifunctional protein (94). Beads 
displaying the separate GFP-PhaC and PhaP-MOG fusion proteins, as well as the GFP-
PhaP-MOG bifunctional fusion protein showed discrete signals in FACS analysis and 
no overlapping or interference could be observed. Lee et al. (2005) immobilized 
proteins on artificially derived PHA particles, using the substrate binding domain 
(SBD) of the PHA depolymerase (73). The SBD tagged proteins were produced in E. 
coli and then bound to the PHA particles in a way described previously for some of the 
protein purification methods (73). This method also resulted in functionally displayed 
proteins and FACS analysis could be successfully performed. 
Biopolyester particles are already being used for applications in the delivery of drugs or 
similar compounds. PHA particles are just emerging in this area. PHA copolymers, 
especially PHBV, have been investigated with regard to encapsulation and release of 
different types of drugs (76, 77, 80, 81, 95-97). These studies have mainly focussed on 
the formation of drug-loaded particles, distinguishing between monolithic microspheres 
and reservoir-type microcapsules. Interestingly, stabilizers, e.g. gelatine, had a big 
influence on the drug-release properties of the particles. The dispersion of the drug in 
gelatine, followed by the encapsulation of the drug-gelatine mixture in PHBV proved to 
be disadvantageous for medical applications. These particles showed a triphasic release 
pattern, typically for microspheres, with alternating periods of slow and more rapid 
drug release (78, 97). The release properties could be changed to a zero order kinetics 
profile, when the drug was encapsulated in PHBV and the whole particle coated with 
gelatine. These particles showed a linear release profile over a period of 30 days, which 
would be more favourable for biomedical applications (78). Recently, Yao et al. (2008) 
(75) described the use of prefabricated PHA beads for targeted drug delivery to 
macrophages. The mannosylated human α1-acid glycoprotein and the human epidermal 
growth factor were attached to PHA particles by using PhaP as binding domain as 
described above. To mimic the drug load the PHA particles were stained with a lipid- 
soluble dye. It was reported that macrophages recognized the attached proteins with 
their specific receptors. The particles were ingested by endocytosis, suggesting 
potential applications in targeted drug delivery.  
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Another biomedical application of PHA particles in the diagnostic area was recently 
described. Multifunctional PHA beads, displaying an IgG binding domain and a special 
peptide sequence for binding inorganics (gold or silica) were proposed as useful tools 
for bioimaging and diagnostics. It could be shown that both functionalities reacted 
independently from each other and no inhibition or interference could be detected. 
These beads allow the antibody based targeted delivery of a contrast agent to selected 
tissues (22). Furthermore, beads displaying the single-chain variable fragment (scFv) of 
an anti-β-galactosidase antibody were engineered, using the PHA synthase as anchoring 
motif (23). These functionalized beads were successfully used for the purification of β-
galactosidase as an example of a custom-made high affinity purification matrix. Once 
again, formation of these beads resulted cost-effectively from a microbial one-step 
production process. The displayed antibody fragment was correctly folded and instantly 
active and did not require any additional cross-linking. These examples demonstrate the 
versatility of functionalized PHA beads either derived from extracted PHA or directly 
formed inside engineered microbial cells for applications in biotechnology and 
medicine. 
 
Polylactides 
 
Background 
PLA, a biopolymer derived from lactic acid (2-hydroxypropionic acid), has been widely 
studied for its applications in the medical field and also for use in the food packaging 
industry. PLA is biodegradable (1), bioresorbable (3) and exhibits properties such as 
low immunogenicity and toxicity, which have led to FDA approval for its use in human 
injections (98).  In addition, lactic acid-based polymers have tensile strength and 
rheological properties suitable for applications as packaging materials and food 
containers (99) as well as various films, fibres and homeware (100). 
Lactic acid, the basic unit of PLA, is produced by microorganisms, animals and plants 
in nature (101). Lactic acid exists as two optically active forms, namely the L(+) and 
D(-) isomers. While both forms are produced by fermentation in bacteria, only the L(+) 
isomer is found in mammalian systems. Since lactic acid is present in the biochemical 
pathways of most living organisms, polymers based on this organic material will 
degrade to natural metabolic compounds (102, 103). 
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PLA is usually produced as a mixture between the isomeric forms and therefore the 
nature of the polymeric material formed varies depending on the ratio between these. 
The process of PLA formation is a stereocomplex crystallization or racemic 
crystallization and has been described by Tsuji (104). PLA made purely from L(+) 
lactide is called poly(L-lactide), or PLLA, while PDLA is the corresponding lactide 
made from D(-) lactide. PLLA is a semicrystalline powder with a melting temperature 
of about 180oC, whereas introduction of the D(-) isomer reduces the melting 
temperature and the degree and rate of crystallization (100). Thus, the degree of 
crystallinity determines the physical and mechanical properties of the polymer (105) as 
well as its degradation rate (106).  
High molecular weight PLA (about 100,000 Daltons) can be produced by different 
routes (for schemes see Sodergard and Bhardwaj as well as Mohanty (101, 105)), 
namely (a) direct condensation polymerization which initially produces a low 
molecular weight pre-polymer that is then polymerized by chain coupling agents (105, 
107, 108), (b) azeotrophic dehydrative condensation (99, 105) and (c) ring opening 
polymerization (ROP). The ROP route involves generation of the cyclic dimer lactide 
(3,6-dimethyl-1,4-dioxane-2,5-dione) which is polymerized to high molar mass 
polymers using ring-opening reactions (101). ROP is the most commonly used method 
for PLA production, as this chemical process can be controlled and the properties of the 
polymers varied for different applications (104, 109). ROP is also used to incorporate 
other ring formed monomers such as glycolide into the lactide polymer. These 
copolyesters are described later in this review. 
Due to the diverse properties of PLA polymers caused by its constituent lactide and the 
various polymerisation methods, PLA has been processed for a variety of different 
applications in the biomedical field (110). These include suture lines (111), orthopedic 
implants (112) and microspheres (3, 113). Among these applications, the microspheres 
have been reported as being of most interest, because of their unique structure and 
tailorable properties (114). The remainder of this section will therefore focus on 
particles made of PLA, their preparation and applications. 
 
PLA particles 
PLA-based particles are now widely used in medicine as long-circulating carriers for 
the controlled release of pharmacological substances (115) such as drugs (116, 117), 
hormones (118) and for the delivery of proteins and antigens (11, 119, 120). One of the 
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most important features of particles used for this purpose is the amount of control over 
the release rate of the desired substance in the recipient tissues. To this end, structural 
properties of the particles are often tailored and much research has been conducted in 
this area (98, 116, 121). PLA can be formulated into particles of a wide size range, 
from nanoparticles and nanocapsules to microspheres and microcapsules. The term 
microsphere is generally used to describe small, porous spheres from 1-500 µm in 
diameter, whereas nanoparticles are generally 10-1000 nm in size (2). In drug delivery, 
particle size is a fundamental parameter which determines the route of administration of 
the drug (3). Microspheres can be administered intramuscularly or subcutaneously 
(122) but for intravenous administration and transport via blood circulation or across 
the mucosal membrane, and in the case of oral administration, particles in the nm range 
(and particularly less than 500 nm) are required (2, 3, 122).  The significance of particle 
size is basically related to the rate and extent to which the particles are removed from 
the circulation and their distribution in tissues (123). The size of the particles also 
affects loading of the drug and its release from the particles into the tissues. Katare et 
al. (11) investigated the size of PLA microparticles in a study of the delivery of the 
tetanus toxoid (TT) by a single point intramuscular injection in rats. Parameters such as 
antigen load and the use of extra adjuvant were also considered for eliciting the optimal 
antibody response. Size ranges for the PLA particles with entrapped antigen were 50-
150 µm, 10-70 µm, 2-8 µm and less than 2 µm. They reported that the greatest 
encapsulation efficiency (60.4%) and TT load (53.2 µg /mg) were obtained with the 
particle size range of 2-8 µm. Serum antibody titres varied extensively depending on 
the size of the particles. Once again, particles of 2-8 µm elicited the highest titres 
whereas in the largest size particle range the titre was considerably lower. Interestingly, 
particles of less than 2 µm exhibited a low titre. The authors suggested that the 
differences were related to the uptake of the particles by macrophages, and that since 
the upper limit for this was considered as 5 µm, the 2-8 µm range was optimal. The 
lower response of the smallest group of less than 2 µm was thought to be due to less 
efficient antigen processing.  
Apart from size, factors which influence the performance of microparticles include 
porosity (and the related % solid content) (114, 116), surface charge (124) and 
hydrophobicity (125). As with size, the optimum degree for porosity will depend on the 
situation for which they are prepared. For example, microspheres with a highly porous 
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interior structure are considered as more advantageous than non-porous particles for the 
administration of inhaled drugs. The large size to density ratio of porous microspheres 
has been reported to generate a more easily aerosolized particle, resulting in a higher 
uptake of the inhaled drug (114). On the other hand, for the treatment of arthritic 
conditions, a less porous particle type has been reported as more suitable by Cui et al. 
(116). This study compared the entrapment and release of the drug melittin, by particles 
of PLA and the polylactide-glycolide copolymer PLGA. The level of porosity of the 
two types of polymer particles was different, with the pure PLA particles being more 
porous and sponge-like, whereas increasing the molar fraction of the glycolide in the 
PLGA particles resulted in a harder, smoother surface. Although the results showed a 
significant “initial burst” release in both particle types, it was particularly high for the 
pure PLA, suggesting a diffusion of the substance through the pores and indicating the 
lesser efficiency of pure PLA particles in this instance. 
The ability to control the rate and extent of the release of the substance is of paramount 
importance for PLA and other particles used in drug/antigen delivery systems. For this 
reason, PLA particles are frequently coated with carbohydrates (126, 127), electrolytes 
(128), polyethylene glycol (129) and other substances to increase stability (130), period 
of release (128) and blood-circulation time, and to reduce initial burst (131). 
 
Preparation of PLA particles 
Several methods are available for the preparation of PLA micro- and nano-particles. It 
is important to note that the method of preparation and the experimental parameters 
involved will directly influence the particles produced and their ability to interact with 
the drugs/antigens to be delivered (3, 114, 132). The three main preparation methods 
are the (a) emulsion-based solvent evaporation methods, (b) the spray-drying method 
and (c) nanoprecipitation. Usually, adaptations of the first two methods are used for the 
microencapsulation of proteins and drugs in PLA particles. Emulsion-based methods 
consist of four steps: (i) dissolution of the bioactive compound in an organic solvent (ii) 
formation of an emulsion of the organic solvent phase with an aqueous phase (iii) 
extraction of the solvent by evaporation which hardens the droplets into solid 
microparticles and (iv) drying of the microsphere particles (133). The solvent 
extraction/evaporation method has been used extensively, for example to prepare 
microspheres coated with collagen (114), enclosed pesticides (113), adsorbed vaccine 
antigens (134), and encapsulated drugs (135-137) among other medical applications of 
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PLA particles. In the study of Takei et al. (113), this method was used to encapsulate a 
pesticide acetamiprid into PLA microspheres. The entrapment efficiency of the 
pesticide decreased with increasing concentration of this chemical in the oil phase. An 
important part of the process in the solvent emulsion method is the addition of 
stabilizing agents to the initial droplets and to the final particles. Examples of such 
surfactants are sodium dodecyl sulfate and cetyltrimethyl ammonium chloride (115), 
alginate, polyvinylpyrrolidone and gelatin (122, 132). In terms of particle size, PLA 
nanoparticles and nanospheres are produced by the same methods as microparticles and 
microspheres, with the manufacturing parameters adjusted to generate nanometer sized 
droplets, essentially by using a smaller ratio of the droplet phase to the suspension and 
a much higher stirring rate (138). 
The spray-drying method for preparation of PLA particles involves dispersion of the 
drug in an organic solution of the PLA polymer, followed by immediate nebulization in 
a hot air flow (3). This method was used by Blanco et al. (2006) (15) to prepare 
microspheres of PLA and other co-polymeric (various ratios of PLA:PLGA) particles. 
The PLA was dissolved in 2% dichloromethane with constant stirring, then sprayed 
through the nozzle of a spray-drying device. The microspheres were collected in the 
separator of the spray-dryer and dried in a vacuum oven. PLA particles produced by 
this method were small (1.3 µm), slightly porous and with a smooth surface. The 
particles were analyzed for their degradation rates, and it was apparent that the pure 
PLA particles showed the slowest rate of degradation. Bishara et al. (139) used a 
similar method from D,L-PLA, producing PLA particles of 2-4 µm. It has been 
suggested that while this method may be suitable for industrial-scale production of 
microspheres, the non-uniform particle sizes would be a likely limitation (3). 
The nanoprecipitation method for the preparation of PLA particles is a relatively easy 
method, in which an organic solution of the polymer is simply added to water. PLA 
particles will immediately form by precipitation, following which the organic solvent 
can be removed by evaporation (106, 123). Mainly hydrophobic compounds are 
entrapped by this method (3). Peltonen et al. (140) used nanoprecipitation to investigate 
improved entrapment efficiency of the bronchoconstriction-reducing drug sodium 
chromoglycate, within PLA nanoparticles. They reported that the loading of the 
hydrophilic drug into the hydrophobic nanoparticles was difficult but that it was 
improved by lowering of the pH of the outer medium. Hyvonen et al. in their 
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nanoprecipitation study of PLA nanoparticles reported that the crystallinity of the 
particles decreased upon nanoprecipitation (141). 
 
Applications of PLA particles 
While the physicochemical, chemical and mechanical properties of PLA polymers 
make them more suitable than other non renewable source based polymers for 
manufacturing products for industrial packaging, their use in the medical device market 
as drug delivery and therapeutic devices has greatly appreciated over the past few 
decades (142-145). In particular, micro and nanospheres, particles and capsules made 
of PLA on its own or combined with other polymers have received tremendous 
attention as a means of delivering drugs (1, 4, 146). The advantages of using 
biodegradable polymers lie in controlling the release of drugs or proteins and their 
stability. Moreover, their degradation by simple hydrolysis of the ester bond and does 
not require the presence of enzymes to catalyse this hydrolysis. 
Previously, micellar oil-dispersions, liposomes and hydrophilic polymer-
photosensitizer conjugates have been used as potential drug carriers with varying 
degrees of success. PLA and their copolymers have now become the most important 
polymers for drug delivery systems and were approved by the Food and Drug 
Administration (147). This is because their biodegradation leads to pharmacologically 
inactive substances, which are absorbed by the body or removed by the metabolism 
(148).  
Biodegradable PLA makes it an appropriate carrier to deliver drugs which are lipophilic 
in nature. In ovarian cancer diagnosis, the photodetection (PD) method using 
photosensitizers (PS) is used to accurately pinpoint the location of malignant tissue and 
scattered micrometastases in advanced cancer stages (149).While selective 
accumulation of the drug by tumor to muscle is essential, avoiding the loss of drugs 
from normal vessels and lowering of PS accumulation in the healthy surrounding 
tissues is equally important to decrease the side effects such as skin photosensitivity. 
Also, due to the lipohilic nature of the exogenous PS such as Hypercin (Hy), systemic 
administration is problematic. This can be mitigated by entrapping PS in biodegradable 
polymers as carrier materials. Zeisser-Labouebe (150) used PLA nanoparticles loaded 
with Hy to study the fluorescence PD of ovarian metastases in Fischer 322 rats bearing 
ovarian tumours. They observed that using PLA nanoparticles resulted in higher 
selective accumulation and bioavailability of the drug within ovarian micrometastases 
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when compared to using the free drug, thereby improving PS availability within 
tumours. In addition, lower concentrations of Hy were found in healthy surrounding 
tissues and their concentration decreased faster when PLA nanoparticles were used, 
confirming rapid elimination of Hy from the surrounding healthy tissues.  
The selectivity of PS loaded PLA nanoparticles is also favourable for Photo Dynamic 
Therapy (PDT). PDT is a method in cancer treatment in which the cancer cells and 
tissues are destroyed by the uptake of PS, followed by photoirradiation (146). PLA 
nanoparticles would allow targeted delivery because of the possibility to chemically 
cross-link specific proteins to their surface (117, 151).  
In parenteral administration, the PLA nanoparticles are opsonised by mononuclear 
phagocytes, removed from the blood stream and sequestered in organs such as liver and 
spleen, avoiding the effective delivery of the nanoparticles to organs other than those of 
the reticuloendothelial system (152). In a study by Bazile (153) a radiolabelled PLA 
coated with human serum albumin ([14C]-PLA50, where 50 refers to the percentage of 
L-forms of lactic acid within the chains) was synthesized to follow the fate of this new 
drug carrier after intravenous administration to rats. From whole-body autoradiography 
and quantitative distribution experiments they observed that the 14C-labelled polymer is 
rapidly accumulated in liver, bone marrow, lymph nodes, spleen and peritoneal 
macrophages. To control the opsonization process and to improve the surface properties 
of the system, the surface of the nanoparticles was modified by either attaching or 
coating with a hydrophilic polymer such as polyethylene glycol (PEG) (4, 154).  
Despite its advantages, the hydrophobic nature of PLA tends to result in adsorption of 
non specific proteins, which reduces the effectiveness of the drug delivery. This 
uncontrolled protein adsorption to the lipophilic PLA was combated by synthesizing a 
diblock copolymer with hydrophilic PEG (155). Also, in oral administration of drugs, 
there is evidence that PLA nanoparticles are degraded by enzymes in the body fluids 
such as intestinal fluids and that this degradation is affected by the surface composition 
of the particles (153). In a study by Landry et al. (156), degradation of albumin coated 
PLA50 was performed in simulated gastric and intestinal fluids (USP XXII) in order to 
model the degradation process. These authors observed that once the readily digestible 
albumin coat was digested by gastric and intestinal fluids, the exposed PLA50 was 
degraded, mainly due to an enzymatic cleavage process. They concluded that coating 
PLA with slowly digestible or non-digestible agents would be beneficial in a drug 
delivery system. 
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Quantum dots (QD) or semiconductor nanocrystals are nanoparticles with a typical 
diameter of 2-8 nm that possess unique luminescent properties (157, 158). QDs have 
been used as novel fluorescent markers in biological labelling and diagnostics (159, 
160). Since QD molecules are neither water soluble, biocompatible or have functional 
groups linked with biomolecules, many of these applications require a combination of 
the QDs with polymers (157, 161). The polymers are versatile surface modifiers 
because of their processability and multiple chemical functionalities (162). In a study 
by Guo et al. (163), CdSe (Cadmium and Selenium) QDs were modified to make them 
water soluble and emit strong fluorescence, by incorporating the CdSe QDs with PLA. 
The fluorescence of the modified CdSe QDs was stable for more than 30 days in vitro. 
They suggested that the use of PLA could reduce the possibility of QDs loss from the 
particles. The results demonstrated that PLA particles encapsulated with CdSe QDs had 
high potential for biological labelling especially in aqueous biological conditions. QDs 
are known for their cytotoxicity, due to desorption of free Cd (QD core degradation), 
free radical formation, and interaction of QDs with intracellular components (159). 
Polyethylene glycosylated (PEG) QDs have been shown to have reduced cytotoxicity, 
but modification of these to produce PEG-amine for biological activity renders them 
cytotoxic once again (164). To overcome the problem of cytotoxicity, Guo et al. (165) 
modified CdSe QDs by incorporating these into poly(D, L)-lactide (PDLA) 
nanoparticles. The resulting luminescent nanoparticles were coated with a layer of 
different molecules including F-68, cetyl trimethyl ammonium bromide (CTAB) and 
sodium dodecyl sulphate (SDS). The results suggested that CdSe QDs surface modified 
with F-68 have low cytotoxicity. 
 
Poly(lactic-co-glycolic acid) 
 
Background 
PLGA is a co-polymer which is used in a host of Food and Drug Administration (FDA) 
approved therapeutic devices, owing to its biodegradability and biocompatibility. 
Unlike the homopolymers of lactic acid (polylactide) and glycolic acid (polyglycolide) 
which display poor solubilities, PLGA can be dissolved by a wide range of common 
solvents, including chlorinated solvents, tetrahydrofuran, acetone or ethyl acetate. 
PLGA nanoparticles are biodegradable, biocompatible and approved for human use by 
the FDA. PLGA is hydrolysed to lactic and glycolic acids, both of which are by-
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products of various metabolic pathways in the body. By altering the ratio of the 
monomers used during synthesis, the degradation rate can be controlled (1), making 
PLGA a common choice in the production of a variety of biomedical devices such as: 
grafts, sutures, implants, prosthetic devices, micro and nanoparticles.  
 
Preparation of PLGA nanoparticles 
While there have been differing techniques employed to produce nanoparticles, the 
emulsification-diffusion technique was developed in 1996 to overcome toxicity issues 
with solvents and low yields obtained with gelatine stabilisers. There are single (oil-in-
water) and double (water-in-oil-in-water) emulsification techniques (49). Each 
methodology results in a different release profile of the drug. Propylene carbonate (PC) 
was added as an alternative low toxicity stable solvent for the polymers (166).  In this 
method, the polymer is dissolved in PC and then emulsified via homogenization with 
an aqueous surfactant added.  The addition of water while stirring allows the PC to 
diffuse out of the polymer emulsion into the water causing precipitation of the polymer 
into nanoparticles. The size of the nanoparticles reportedly decreased as the stabiliser 
concentration increased up to 5% w/v but ultimately the size was determined by the 
globule size throughout the process of emulsification. The nanoparticle size is therefore 
influenced by the concentration of the polymer, the rate the emulsification solution is 
stirred and the concentration of the stabilizer (166).  
Various techniques are used to form drug-polymer micro- or nano-particles. A 
weakness with the use of implants is that the preparative process involves high or 
elevated temperatures, non uniform content and large variations in individual drug 
release patterns and of course the surgery required to implant them (167). 
Biodegradable microparticles developed to overcome this are usually formed by solvent 
evaporation or organic phase separation, spray drying or supercritical fluid technology, 
all of which involve several steps within each process and many formulation factors to 
be controlled (167). Again, rapid release, difficulty with injecting the viscous solution 
and concerns about the toxicity of the solvents used has led to alternative production 
methods involving a polymer phase emulsified into an external phase. The partial water 
miscibility of the organic solvents allowed the properties of the microparticles to be 
manipulated resulting in porous microparticles due to the polymer solidifying and 
trapping organic solvents within (167). It was found that by having an external oil 
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phase, precipitation of the polymer was significantly lower than in implants resulting in 
reduced initial drug release (167). 
The size also affects the distribution of targeted and non-targeted nanoparticles. A study 
by Cheng et al. (168) demonstrated that there were at least four parameters to consider: 
the concentration of polymer, the drug loading, the water miscibility of the solvent used 
and the ratio of water to solvent. Likewise, aggregation can be triggered by temperature 
using pluronics as solvents and particle size can be predicted from the concentration of 
PLGA used (169). 
Differences in formulation can affect the in vivo uptake of drugs (8) and similarly 
polymer degradation is influenced by a number of factors: co-polymer composition, 
molecular weight and size of particles (1). These are all optimised for the drug used and 
the therapeutic requirements. In addition to the above applications, modifications and 
polymer combinations expands the realm of PLGA uses. PLGA can be combined with 
chitosan to decrease the drug release rate while enhancing particle uptake by cells (170, 
171). Cationic drug delivery has been investigated using PLGA based particles 
incorporating polyvinyl sulphonate-covinyl alcohol-graft-PLGA [P(VS-VA)-g-PLGA] 
(74). In this study degradation rate was determined by sulphonation. 
Surfactants may be used in the formulation of PLGA variants. Polysorbate or 
poloxamer 188 coated PLGA allows some drugs to be transported across the blood-
brain barrier (172). Sodium dodecyl sulphate was used by Xu and Czernuszka (173) 
while Feczkó et al. (174) compared the effect of three different surfactants on the 
preparation of PLGA. In addition, pluronics, non-ionic macromolecular surface active 
agents, are used for the solubilisation and controlled release of drugs and have been 
incorporated into PLGA to produce an amphiphilic co-polymer which enhances protein 
loading and stability (173). 
 
Application of PLGA in drug delivery 
PLGA is a good candidate for therapeutic agent delivery. Drug delivery is often limited 
by the ability to target drugs to a specific site or tissue. In addition, efficient cytosolic 
delivery is difficult because the receptors for the drugs are in the cytosol or an organelle 
must transport the drug to the site. The surface of the nanoparticle and the way it 
interacts with the cell affects the uptake and subsequent intracellular trafficking of the 
nanoparticle containing or carrying the therapeutic agent (175). PLGA nanoparticles 
can be formulated to encapsulate low molecular weight drugs or macromolecules such 
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as proteins or plasmid DNA (175). The polymer matrix helps to prevent premature 
degradation of the drug allowing a slower release. Usually around 100 nm in diameter, 
PLGA nanoparticles are taken up by cells via endocytosis and the material inside the 
nanoparticle released slowly as the particle degrades. However around 85% of the 
internalized nanoparticles have been found to undergo exocytosis, i.e. become released 
again from the cells without release of the drug (176). Adequate uptake by cells is also 
important if the nanoparticles are to deliver therapeutic agents intracellularly. In the 
study by Vasir and Labhasetwar (176), PLGA nanoparticles were functionalised with 
poly-L-lysine (PLL) on the surface and showed a three-fold increase in cellular uptake 
compared to unmodified PLGA nanoparticles.  
PLGA is already used for human drug delivery for a range of medications with FDA 
approval. A review by Wischke and Schwendeman (177) notes 21 products which have 
been/are marketed for slow release of compounds. For example, Risperdal Consta® 
which is used to treat schizophrenia is given 2 weekly while Lupron Depot® may be 
administered 1-3 monthly for endometriosis or fibroids and every 4 months for prostate 
cancer treatment.  These are all administered by the intra-muscular route while 
Arestin® microspheres which incorporate an antibiotic (mimocycline) in PLGA beads 
and are used to treat periodontal disease in adults, are administered into the periodontal 
socket. 
Parenteral administration of drugs involves safety concerns, is inconvenient and 
tiresome especially for the non-hospitalized person who requires frequent medication. 
Therefore oral delivery is sought and investigated by many research groups and 
companies. However, many drugs cannot presently be orally delivered due to 
difficulties related to degradation in the acidic and protease-rich environment of the 
gastrointestinal tract. Formulation strategies involving PLGA are being used to 
investigate oral delivery of many drugs (178), although none have yet been licensed for 
human use. Some examples showing the range of drugs being investigated are: 
Doxorubicin, a potent anticancer drug was loaded into orally delivered nanoparticles 
and results in rats showed enhanced bioavailability and lower toxicity (179); oral 
delivery of Eudragit® microparticles of PLGA entrapping insulin were evaluated in 
diabetes induced rats and successfully mediated stability of blood sugar levels (180).  
The anti-cancer drug 5-fluorouracil was incorporated into PLGA nanoparticles and 
showed enhanced bioavailability following oral delivery (181).  
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Topical use of PLGA loaded with flurbiprofen as a treatment for post-ophthalmic 
surgery pain and inflammation has been investigated in vitro and ex vivo with 
promising results (182). 
Vaccine delivery has utilised PLGA in different formulations (183). Although effective 
tuberculosis vaccines remain elusive, studies have used PLGA-based vaccines with 
some success (184). However, alternative delivery systems were still found to be more 
effective. Moreover PLGA is also being investigated for oral delivery of vaccines for 
oral immunotherapy (185), hepatitis B (186) and rotavirus vaccines (187). 
Also studied for gene delivery, nanoparticles as a carrier have the gene of interest 
encapsulated inside a polymer matrix, which could then be used for gene therapy (188). 
Gene silencing using si(RNA) which incorporates polyethylenimine (PEI) as a cationic 
polymer into the PLGA matrix has recently undergone evaluation (189). PLGA-coated 
plasmid DNA has applications in the fields of vaccine delivery and disease treatment. 
With regard to vaccine delivery, PLGA vaccinations using antigens relevant to human 
infections have been carried out in mice using different routes of administration (190).  
Specific targeting utilising PLGA particles has recently attracted interest by scientists. 
Magnetic PLGA nanoparticles have been developed and could be directed by externally 
applied magnetic fields to enable tissue-specific drug delivery (191). Similarly, 
magnetic targeting has also been applied for cochlear treatment (192). 
Delivery of chemotherapy drugs for treatment for retinoblastoma using PLGA 
nanoparticles has been studied and results indicated that PLGA loaded nanoparticles 
can provide a degree of sustained delivery (193).   
 
Polymalate 
 
Background 
Polymalate, the anion of poly(β-malic acid), is a biopolyester produced by slime 
moulds and some fungi (194). The polyester backbone is formed by condensation of the 
hydroxyl groups and the β-carboxyl groups of the linearly arranged malate monomers, 
while the α-carboxyl groups represent side groups of the polymer backbone (195). This 
polyester can also be chemically produced from the corresponding lactones (196). 
PMLA is water-soluble, biodegradable and biocompatible as well as it can be 
chemically modified to alter its properties. Recently, poly(β-malic acid) and its 
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derivatives have been investigated with regard to their potential for biomedical 
applications (197). PMLA is non toxic in vitro and in vivo, non-immunogenic, stable in 
the bloodstream and cells can easily take up the polymer (197-201). Polymalate is 
especially suitable for temporary therapeutic applications (197) and because of its 
properties more beneficial for repetitive treatment than, for example, viral delivery 
vectors (202-204). 
Natural production of poly(malic acid) was first reported for Penicillium cyclopium   
(205-207) and later also for Aureobasidium pullulans (208-210). The best studied 
producer is the slime mould Physarum polycephalum (195, 197, 211). Phylogenetically, 
P. polycephalum belongs to the multicellular eukaryotes (212). During their life cycle 
slime moulds (myxomycetes) develop a plasmodium that differentiates into spores and 
later into single-celled amoebae, which might again form a plasmodium after mating 
(213). The plasmodium is a vegetative multinuclear giant cell with synchronously 
dividing nuclei. Only in the plasmodium state myxomecetes produce PMLA, it 
accumulates to high concentrations in the nuclei (214-216).  
Although the biochemical pathways are not fully revealed yet, it seems that PMLA 
functions as a storage and carrier molecule for proteins required to maintain the 
synchronous division of the nuclei in the giant plasmodium cell (214, 217, 218). 
Polymalate mimics the distance of the phosphate groups in the DNA backbone (219) 
and therefore competes with DNA for the binding of histones, DNA polymerases and 
other nucleic proteins (195, 217-220). Binding to polymalate causes inactivation of the 
DNA polymerase (195). To maintain the synchronicity of the dividing nuclei a tight 
regulation between DNA polymerase, histones and other nucleic acid binding proteins 
is necessary. The level of polymalate remains constantly high in the nuclei and excess 
polymer is exported into the culture medium and cleaved to L-malate by polymalatase 
(211).  
So far, no PMLA synthase activity has been found in plasmodial lysates but in vivo 
studies indicated the existence of a PMLA synthetase with β-L-malyl-AMP ligase and 
PMLA polymerase activity. The results suggested that the polymerase activity is 
regulated by a GTPase-dependent signal pathway which leads to inactivation of the 
enzyme when the plasmodium is injured (221). 
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Preparation of Polymalate particles 
Polymalate is a water-soluble polymer which can be easily modified at the α-carboxyl 
groups. Although it can be produced chemically, most applications favour to use the 
naturally produced optically pure material. In most cases, polymalate is isolated from 
the natural producer Physarum polycephalum. The polymalate producing plasmodia of 
this slime mould are grown in shaking Erlenmeyer flasks for 2 to 3 days at 21˚C to 
27˚C, depending on the production strain. The actual polymer is isolated from the liquid 
culture medium using adsorption to DEAE-cellulose as first purification step. Several 
batches can be combined and then further purified. Pure polymalate is obtained by 
repeated chromatography on DEAE-cellulose, alcohol precipitation, size exclusion 
chromatography and lyophilisation (222). It is advantageous to use relatively young 
cultures for the polymer purification as hydrolytic decomposition to L-malate starts 
from the onset of the growth. Early stage cultures also assure a polymer with a high-
average molecular mass, ranging from 50 kDa to several hundred kDa (194, 222). 
Different methods are used to form water insoluble polymalate particles; most of them 
involve at least one chemical modification step. In the emulsion solvent evaporation 
method, naturally produced polymalate is modified to a methyl ester which can then be 
dissolved in chloroform. Depending on the application the drug to be loaded is mixed 
into the polymer solution and stirred until the solvent evaporated completely. 
Emulsifiers can be added to facilitate mixing. During the solvent evaporation, water-
insoluble microspheres are formed which are rinsed in the end with distilled water and 
recovered by freeze-drying (223). The same method can be used to mould distinct 
shapes. Polymalic acid can be mixed with surfactants to form stable ionic complexes 
which are mixed with the respective application partner and dissolved in chloroform. 
The mixture can then be poured into moulding forms, e.g. discs, the solvent evaporates 
and the remaining spheres are available for the designed application (224). 
In chromatographic applications, sepharose displaying polymalate is employed to 
purify polymalate-binding proteins from cell extract. For this purpose the polymer 
needs to be highly pure. Minimization of covalent binding of malyl residues to the 
sepharose is necessary and can be achieved using different amines and amides as 
supplements (225). 
The two-step precipitation-dialysis method is used to form nanoparticles of different 
organic esters of polymalic acid. The polymer is dissolved in a water-miscible solvent; 
the solution obtained is then slowly stirred into water. The nanoparticles will precipitate 
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and can be filtered and concentrated using rotary evaporation (226, 227) or dialysis 
against distilled water using a cellulose membrane (9). Depending on the chemical 
properties of the product and the desired purity, additional alcohol extraction and 
washing steps might be necessary, as well as adding stabilisers to the original solution 
(228). 
 
Applications of Polymalate particles 
To date, all studies looking at possible applications of PMLA particles have been 
aiming at drug delivery, trying to benefit from the excellent biocompatibility and 
biodegradability of PMLA (which is metabolized via the tricarboxylic acid cycle). As 
pure PMLA is highly water soluble and rapidly hydrolyzed in an aqueous environment, 
micro- or nano-particles were in all cases generated from modified PMLA, i.e. from 
copolymers.  
Stochiometric ionic complexes of PMLA and alkyltrimethylammonium surfactants 
(nATMA·PMLA) were considered to have interesting properties for controlled drug 
release. These copolymers were found to adopt a well defined supramolecular structure 
with alternating layers of both components (paraffinic and polyester phase) (229). Discs 
of 5 mm diameter, either pure or loaded with erythromycin, were used to investigate 
hydrolytic degradation and antibiotic release (224). Apart from a relatively high 
degradability of nATMA·PMLA complexes in general (compared to similar complexes 
made with polyglutamic acid), the length of the surfactant alkyl side chain was shown 
to influence hydrolysis (by determining hydrophobicity and crystallinity). This should 
enable precise adjustment of the hydrolytic degradability. The only slight reduction of 
molecular weight during degradation and the detection of malic acid but not medium 
size polymer chains as degradation products led to the conclusion that nATMA·PMLA 
complexes are depleted primarily by surface erosion (instead of bulk degradation) 
which was considered to be favourable for even drug release. Up to 30 wt% 
erythromycin could be dispersed in the nATMA·PMLA complex where it was found to 
localize in the paraffinic subphase. The experimental data further indicated that 
erythromycin release was due to degradation, not diffusion.  
In a similar study, microspheres were generated from methylated PMLA (PMLA-Me) 
and degradation and drug release compared for different methylation degrees (223). 
The particle diameter could be adjusted in the range of 1-20 µm. Interestingly, PMLA-
Me microspheres appeared to degrade more slowly than films of the same polymer. 
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Both surface and bulk erosion seemed to contribute to the degradation mechanism. As 
for nATMA·PMLA complexes (224), erythromycin release from PMLA-Me 
microspheres was found to be determined by polymer degradation, the role of diffusion 
being negligible (223).  
PMLA-Me nanoparticles prepared from 75% methylated PMLA were investigated as 
protein delivery carriers (9). This copolyester was insoluble in water, but still quite 
hydrophilic and readily degradable. Nanoparticles prepared in DMSO displayed the 
most narrow size distribution of all solvents tested (diameter approx. 100 nm) and a 
high negative value of zeta-potential which was considered to be advantageous as it 
allows modification of surface-exposed carboxyl groups and prevents nanoparticle 
aggregation by electrostatic repulsion. The hydrolytic degradation behaviour was 
similar to that reported for PMLA-Me microspheres (9, 223). Six proteins with 
different molecular weights and/or isoelectric points were used to load the nanoparticles 
by encapsulation (coprecipitation of protein and polymer), physical absorption 
(incubation of freeze-dried nanoparticles in protein solution) or chemical 
immobilization (activation of surface carboxyl groups of nanoparticles, followed by 
covalent binding of protein) (9). The loading efficiency was found to depend on both 
the protein and the entrapment method, and loading affected nanoparticle size and zeta-
potential. Similar to the antibiotics in previous studies (223, 224), protein release took 
place in a time frame corresponding to the hydrolytic degradation of the nanoparticles 
(9). Conclusions drawn from a comparison of all protein release profiles included: 
Independent of the loading method, the rate of protein release decreased with increasing 
isoelectric point, at a constant pH 7.4, at 37˚C. Release profiles for encapsulated and 
chemically immobilized proteins were similar and suggested that a certain amount of 
particle degradation was required for protein release. Release profiles of physically 
absorbed proteins could be divided into two groups according to their isoelectric point. 
Basic proteins behaved similar to those loaded by the other two methods, while acidic 
ones were released faster and more evenly. In addition, the effect of loading and release 
on protein activity was studied and was also found to depend on the loading method.  
Martinez Barbosa and coworkers investigated degradation mechanism and in vitro 
cytotoxicity of nanoparticles prepared from another group of PMLA hydrophobic 
derivatives, poly(benzyl malate) (PMLABe), poly(hexyl malate) (PMLAHe) and 
poly(malic acid-co-benzyl malate) (PMLAH/Be) (226). Nanoparticles were between 
100 and 200 nm in diameter. While particles seemed more prone to aggregation at 
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acidic pH, the pH was not found to have a major influence on degradation rates. The 
observed decrease in molecular weight was fastest for PMLAH/Be and slowest for 
PMLABe particles. NMR studies indicated that degradation of all polymers occurred 
by random hydrolysis. For the in vitro cytotoxicity studies, the different nanoparticles 
and their degradation products, respectively, were incubated with J774 A1 murine 
macrophage-like cells and the IC50 (concentration required to kill 50% of cells) 
determined. For all polymers, the IC50 decreased with increasing degradation time (and 
thus increasing amount of degradation products) and with increasing incubation time 
with cells. PMLAH/Be nanoparticles were reported to display the highest and PMLABe 
particles the lowest toxicity. The authors concluded that the observed cytotoxicity of 
PMLABe, PMLAHe and PMLAH/Be nanoparticles is caused by degradation products 
and not by simple contact of nanoparticles with the cell. They further stated that the 
overall in vitro cytotoxicity was relatively low for all tested nanoparticles, but a direct 
comparison e.g. to pure PMLA was said not to be feasible due to its high water 
solubility. 
With the aim of developing a sustained release formulation, microspheres of the 
biodegradable polyester poly-vephyllinemalate (Veph-malate) were generated by cross-
linking the bronchial dilator Vephylline with malic acid (228). Particle diameters 
ranged from 1 to 10 µm (230). In comparison to Vephylline itself Veph-malate was 
found to be essentially non-toxic (228). In addition, release of the drug from Veph-
malate microspheres was slower and more even than from Vephylline hydrogels. 
Further investigation of the release mechanism revealed that a two-step degradation 
process initially only led to the formation of oligomers and only later to the release of 
active Vephylline monomer, resulting in a delayed and prolonged effect of the drug 
compared to pure Vephylline (231). This two-step release profile was found to be pH 
dependent (230). Overall, the Veph-malate microspheres were considered to be useful 
as a prodrug, a term used to describe the carrier-attached chemical prior to its sustained 
release. The Veph-malate microspheres were also considered to be suitable for 
parenteral application (228, 231). 
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Conclusion 
 
Biodegradable micro- and nano-particles have become vital tools for a wide variety of 
applications in research, biotechnology and medicine (Figure 2). This review has 
addressed the main groups of biopolyester particles in current use, with respect to their 
composition, preparation and applications. It is very evident from the ever-increasing 
range of patents and publications, that this is an area of exceptional growth and 
development. 
One promising approach is the engineering of microbial cells for the manufacture of 
custom-made beads by hijacking the natural storage granule biogenesis system (6). This 
in particular allows the one-step production of polymer beads with a protein-based 
function at high density and functional orientation already attached to its surface. This 
intracellular production also provides the unique advantage of utilizing a natural 
environment for the functional attachment of the relevant protein, hence enabling the 
functional display of difficult to express proteins. 
 
Polyester particle
Drug delivery
Protein purification
Enzyme immobilization
Antibody/antigen display
Protein production
Diagnostics
 
Figure 2: Schematic of biopolyester particle applications  
 
Recently, the use of supercritical fluids (SCF) has gained attention as an advanced 
method for many biotechnological processes, including the formation of drug 
encapsulated PLA and PGLA particles (232-234). In addition, SCF has been used to 
incorporate food materials into biopolyester particles, such as the incorporation of β-
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carotenoid into particles of the PHB co-polymer with 3-hydroxyvalerate (PHBV) (235). 
In these methods, carbon dioxide and/or water in the supercritical state are used to co-
precipitate a bioactive substance and the biopolymer, such as in the microencapsulation 
of the corticosteroid budesonide into PLA particles (136, 236). The use of carbon 
dioxide in the supercritical state is reported as being useful for producing particles in a 
more controlled fashion than the conventional methods (232) and to enhance the 
solubility of drugs which are poorly soluble in aqueous and organic media (234). 
While the use of biopolyester particles continues to grow in many areas, there are 
several challenges that remain to be overcome. For example, it seems that the size and 
uniformity of the particles have been identified as particularly important parameters in 
many contexts. In addition, the reduction of initial burst and solubility improvement are 
critical issues in drug delivery. In industrial settings, product quality is often dependent 
on the level of existing control over the physical characteristics of the particulate 
vehicles. Similarly, medical applications require particle characteristics that promote 
consistency and reproducibility. Therefore, much effort is now being invested in 
improving and tailoring particle properties, for bacterial as well as synthetically 
produced biopolymer particles. There is no doubt that the development and fine-tuning 
of these particles, and their potential applications, will continue to expand well into the 
future. 
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Abstract 
 
Polyhydroxyalkanoates (PHAs) are naturally occurring organic polyesters that are of 
interest for industrial and biomedical applications. These polymers are synthesized by 
most bacteria in times of unbalanced nutrient availability from a variety of substrates 
and they are deposited intracellularly as insoluble spherical inclusions or PHA granules. 
The granules consist of a polyester core, surrounded by a boundary layer with 
embedded or attached proteins that include the PHA synthase, phasins, depolymerizing 
enzymes, and regulatory proteins. Apart from ongoing industrial interest in the material 
PHA, more recently there has also been increasing interest in applications of the PHA 
granules as nano-/micro-beads after it was conceived that fusions to the granule 
associated proteins (GAPs) provide a way to immobilize target proteins at the granule 
surface. This review gives an overview of PHA granules in general, including 
biogenesis and GAPs, and focuses on their potential use as nano-/micro-beads in 
biotechnological and biomedical applications. 
 
Introduction 
 
Bacterial polyhydroxyalkanoate (PHA) granules, which are found as naturally 
occurring spherical inclusions, are becoming increasingly recognized as potential 
functionalized beads for use in biotechnological and biomedical applications. 
PHAs are polyesters which serve as carbon and energy storage for bacteria and become 
deposited as insoluble spherical inclusions in the cytoplasm. Most bacterial genera and 
even members of the family Halobacteriaceae of the Archaea are known to synthesize 
PHA1-6 which is produced in conditions of nutrient limitation but where carbon is 
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available in excess7-10. Bacteria are able to accumulate as much as 80% of their dry 
weight in PHA11, 12, with reversal of the PHA polymerisation process in conditions of 
carbon starvation13, 14. One of the most common PHAs is poly(3-hydroxybutyrate) 
(PHB) which is synthesized from 3-hydroxybutyrate (3HB), but different bacteria use 
hydroxy fatty acids of varying chain length, generating a range of PHAs.  
Due to properties such as biocompatibility, biodegradability and production from 
renewable resources, there is considerable interest in the potential applications of 
PHAs. With chemical modification or through the creation of copolymers, a range of 
material properties can be achieved, for example, PHAs that are less brittle and more 
flexible while retaining tensile strength. These polymers have been developed for use in 
industrial or medical applications and have been shown to be well tolerated by 
mammalian systems.15 Due to the comparatively high production costs, PHAs are 
currently mainly attractive for use in the medical field, for example, for sutures or 
implants like heart valves, stents and bone scaffolding.15, 16  
The key enzyme for PHA biosynthesis is the PHA synthase. This enzyme polymerizes 
(R)-3-hydroxyacyl-CoA thioester monomers into polyester with the release of 
coenzyme A. Depending on the organism, there are several classes of PHA synthases 
using different (R)-3-hydroxyacyl-CoA precursors which can be provided by different 
pathways.17 In Cupriavidus necator, the most investigated PHB producer,18 (R)-3-
hydroxybutyryl-CoA monomers are generated from acetyl-CoA by the action of two 
other enzymes16, 19, 20. The three PHB biosynthesis genes are organized in one operon, 
the phaCAB operon. β-Ketothiolase (encoded by phaA) condenses two molecules of 
acetyl-CoA to acetoacetyl-CoA and this is subsequently reduced to (R)-3-
hydroxybutyryl-CoA by the NADPH-dependent acetoacetyl-CoA reductase (encoded 
by phaB). The PHB synthase (encoded by phaC in C. necator) then converts the 
thioester monomers into the polyoxoester PHB. The polymer aggregates to form a 
spherical inclusion or granule of usually 50 - 500 nm in diameter with the amorphous 
hydrophobic PHA polyester at the core and attached or embedded proteins at the 
surface, including the PHA synthase, PHA depolymerases, structural, and regulatory 
proteins.21, 22 
In this review, we summarize the current literature on PHA granules, their biogenesis 
and structure, and on protein engineering approaches of associated proteins aiming at 
the design of PHA granules as biobeads for use in various biomedical applications.  
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Structure of PHA Granules 
 
The structure of PHA granules has not been fully determined but the major constituent 
of granules is PHA, often PHB, with small amounts of protein and lipid.23 In vivo the 
hydrophobic polyester core is largely amorphous,24 with water as a component that 
prevents crystallization by acting as a plasticizer25. This is the mobile state of PHA, that 
is, the form that is subject to the action of synthesizing and degrading enzymes. After 
isolation, PHA is often crystalline (see below).  
Initial studies, including electron microscopy in the 1960s,26 have shown the polyester 
core to be surrounded by a 4 nm boundary layer, which most likely comprises a 
phospholipid monolayer27 with embedded and attached proteins22, 28. While most data 
seem to be consistent with a monolayer, alternative membrane models, for example, 
comprising inner and outer protein layers sandwiching phospholipids, have been 
suggested.29 More recent electron microscopy data indicated that the thickness of the 
surface layer surrounding the PHA granules to be 14 nm, which the authors took as an 
indication of the size of the associated proteins.30 However, it cannot entirely be ruled 
out that the boundary layer primarily consists of proteins and that attachment of 
membrane material is only an isolation artefact.  
In addition to EM, a variety of techniques have been used to investigate PHA, including 
wide-angle X-ray scattering,31 nuclear magnetic resonance spectroscopy,32 and confocal 
microscopy30 (Figure 1). Using wide-angle X-ray scattering, Kawaguchi and Doi 
confirmed that PHA in native granules is amorphous, even after isolation, and that 
certain treatments seemed to initiate crystallization, presumably by removing a lipid 
component.31 Recently, contrast-variation small-angle neutron scattering was used to 
probe granule organization, and results were consistent with the phospholipid 
monolayer model.33, 34 Atomic force microscopy (AFM) allows imaging at nanoscale 
while being rapid and less damaging to preparations than EM.35, 36 Recently, analysis of 
PHA granules by AFM has shown an additional network layer with globular areas, 
most likely also incorporating structural phasin proteins.37 AFM was also used to show 
porin-like structures in the surrounding membrane, which were suggested to provide a 
portal to the amorphous polymer core and be the site of PHA metabolism and 
depolymerisation.38 
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Investigation of PHA granules is strongly influenced by the preparation technique 
because denaturation and crystallization of PHA often occurs through physical stress 
such as excessive sonication,37 freeze-thaw cycles, or exposure to solvents, detergents, 
or alkalis39. To avoid denaturation during the purification process, PHA granules can be 
purified using mechanic (e.g., French Press) or enzymatic cell lysis followed by density 
gradient centrifugation. These techniques should allow accurate analysis and consistent 
end-use of PHA granules. 
 
 
Figure 1. Different representations of PHA granules. (A) TEM image of C. necator cell filled with 
PHA granules. Bar, 500 nm. (Journal of Bacteriology, 2005, 187, 3814-3824, 
doi:10.1128/JB.187.11.3814-3824.2005 54, reproduced with permission from American Society for 
Microbiology.) (B) TEM image of single PHA granule isolated from C. latum zooming in on the 
paracrystalline-like layer of particles covering the granule. Bar, 50 nm. (Applied and Environmental 
Microbiology, 2007, 73, 586-593, doi:10.1128./AEM.01839-06 30, reproduced with permission from 
American Society for Microbiology.) (C) Schematic depiction of a PHA granule with granule 
associated proteins. (Reproduced with permission, from Rehm, B. H. A., 2003, Biochemical Journal, 
376, 15-33, DOI 10.1042/BJ20031254 58. © the Biochemical Society.) 
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PHA Granule Assembly 
 
The process of PHA biosynthesis, the polymerization of (R)-3-hydroxyacyl-CoA to 
PHA, leads to the formation of spherical inclusions, which start to assemble as the PHA 
synthase converts soluble substrate monomers into insoluble high molecular weight 
polymer. Two different models have been discussed to explain this process, which will 
be described below. During the polymerization process, the synthase remains 
covalently attached to the growing polyester chain and continues to incorporate more 
substrate until metabolic or spatial constraints terminate the polymerization procedure, 
that is, the substrate has been depleted or all available space in the cell has been used. 
The size of PHA granules and the number of inclusions per cell seem to vary between 
organisms (with the diameter usually ranging between 100 and 500 nm diameter and 5-
10 granules per cell) and it has been debated if fusions between granules occur or if 
they are successfully prevented by the granule associated proteins (GAPs), in particular, 
the phasin PhaP22, 40. PhaP also impacts on the granule surface to volume ratio and thus 
the number of granules per cell40, 41 and on PHA synthase activity42, 43 (see below).  
Apart from the metabolic background (which determines the provision of suitable 
substrate), factors which could potentially influence the molecular weight of the 
polymer include the PHA synthase concentration and presence of PHA depolymerising 
enzymes. The latter are only present in the native host and there are indeed indications 
that recombinant production yields higher molecular weight polymer than the native 
system.44 An inverse correlation between PHA synthase concentration and molecular 
weight has so far only been shown for in vitro as well as recombinant production in E. 
coli and not for production in the native host.45-47 
The exact mechanism by which the nascent polyester chains with attached synthesizing 
enzymes (enzyme-nascent polyester units) congregate to form the boundary layer-
covered PHA granule has not been elucidated. Two models for granule biogenesis have 
mainly been discussed.48 The first one is the “micelle” model, which is based on the 
assumption that the PHA synthase is present in the cell as a soluble enzyme, more or 
less randomly distributed in the cytoplasm. Once polymerization starts, the nascent 
polyester chain converts the initially soluble enzyme into an amphipathic molecule and 
the increasingly hydrophobic PHA chains aggregate into a micelle-like structure. In this 
model, the constituents of the boundary layer, that is, phospholipids and other GAPs 
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apart from the synthase, would gradually become incorporated as the self-assembled 
PHA inclusion increases in size. The second model is the more recent “budding” 
model, which suggests that the PHA synthase localizes to the inner face of the 
cytoplasmic membrane, either inherently or as soon as a PHA chain emerges from the 
enzyme. In this case, biosynthesis of the polyester would be directed into the 
intermembrane space where the extending chains would accumulate until eventually 
PHA inclusions surrounded by a phospholipid monolayer would bud off the membrane. 
While the “micelle” model is supported by the fact that PHA granules can be produced 
in vitro in the absence of membranes,45, 49, 50 most of the recently emerging evidence is 
in favor of the “budding” model.  
Jendrossek et al. analyzed early stages of PHB accumulation in vivo in Rhodospirillum 
rubrum, C. necator, and in recombinant E. coli by confocal laser scanning fluorescence 
microscopy (CLSM), visualizing PHB granules by Nile red staining and fusion of 
EYFP (enhanced yellow fluorescent protein) to a phasin.51 In young cultures in the 
initial stages of PHB production, they observed PHB granules predominantly at or near 
the cell poles and near the cell wall. Jendrossek similarly analyzed Caryophanon latum 
by CLSM in combination with Nile red staining and by TEM in combination with 
immunogold staining and found that PHB granules in early stages of formation were 
localized close to the cytoplasmic membrane.30 Also, in 2005, Peters and Rehm 
reported their fluorescence microscopy studies of emerging PHA granules in 
Pseudomonas aeruginosa PAO1 and recombinant E. coli, employing either the PHA 
synthase from P. aeruginosa or C. necator, which were both fused to GFP (green 
fluorescent protein) at their N terminus.52 In both organisms, nascent PHA granules 
were observed to localize to the cell poles and occasionally to the poles and to the 
center of the cell, that is, to the future cell poles. This localization occurred 
independently of septum formation but seemed to require proper nucleoid structure and 
segregation as was demonstrated by analysing PHA granule formation in a mukB 
mutant, which is affected in nucleoid structure and segregation. This study suggested 
that nucleoid occlusion, that is, spatial competition between nucleoid and PHA granules 
might play a role in intracellular localization of granule formation. This was the first 
evidence that the cytoskeleton might be involved in PHA granule formation.52 Further 
investigations revealed no evidence that the nascent polyester chain is responsible for 
subcellular localization of the synthase (e.g., by anchoring it to the membrane), as even 
an inactive mutant of the C. necator PHB synthase still localized to the cell poles.53 The 
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deletion of either the N or the C terminus of the synthase, respectively, did also not 
affect proper positioning. These results indicate that the core region of the C. necator 
PHB synthase might be responsible for polar localization. The observations of 
Jendrossek et al. and Peters et al. provide support for the budding model as early stage 
PHA granules were localized at the cell poles and thus (a) close to the membrane and 
(b) not randomly distributed. However, these findings might also indicate that the 
situation is more complex as according to the model one would expect PHA granules to 
emerge along the circumference of the entire cell, not only at the poles.  
Tian et al. have suggested a third model based on their kinetic studies of PHB granule 
biogenesis in C. necator by TEM.54 They observed dark-stained elongated structures or 
“mediation elements” in the center of the cell with small granules attached. In older 
cultures, these elements were no longer visible, which could either mean that they had 
been degraded or that they were covered by granules. The authors proposed these 
mediation elements to serve as scaffolds for the initiation of granule formation, which 
would be analogous to the cellulosome. Although the observations of Tian et al. are 
currently not compatible with the polar localization of nascent PHA granules described 
by other researchers as described above, they also support a non-random distribution.  
Another question is how synthesis of the PHA chain is terminated. In particular, does it 
happen in a way which enables the PHA synthase to reinitiate synthesis and generate 
more than one polymer chain? Calculations addressing this question have mainly been 
based on data derived from in vitro PHA biosynthesis. Based on the amount and 
molecular weight of the PHA produced in vitro by different organisms, it was 
calculated that both the PHA synthase from C. necator (class I) and from P. aeruginosa 
(class II) synthesized not more than one polyester chain per molecule of enzyme, while 
the Allochromatium vinosum synthase (class III) produced multiple chains.42, 45, 49 Tian 
et al. made an attempt to determine this ratio for the in vivo situation in C. necator and 
obtained a ratio of PHB molecules to PHB synthase molecules of 60 to 1.47 Thus, some 
indications for chain transfer have been obtained in single cases but no definite 
conclusions could be drawn so far. Comparison of the molecular weight of PHA 
produced from different carbon sources led to the suggestion that some of them might 
act as chain transfer agents in chain termination and that the actual chain transfer agent 
in vivo might be 3-hydroxybutyric acid, which is not enzyme bound.55 
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Granule-Associated Proteins 
 
Proteins associated with the phospholipid granule surface play a major role in PHA 
synthesis and degradation and in granule formation.56 These proteins have been 
designated to four classes (names in brackets for C. necator), namely the polyester or 
PHA synthases (PhaC), the depolymerases (PhaZ), regulatory proteins (PhaR) and 
phasins (PhaP) (Figure 1).  
 
PHA synthase  
The PHA synthase, which is the key enzyme of PHA biosynthesis, catalyzes the stereo-
selective conversion of (R)-3-hydroxyacyl CoA thioester substrates to PHA, with the 
concomitant release of coenzyme A.57, 58 The ongoing increase in the number of 
published bacterial genomes has resulted in a corresponding increase in the number of 
putative PHA synthases. Currently, the nucleotide sequences of at least 88 PHA 
synthases have been obtained, including two potential PHA synthase genes from the 
halobacterial species Haloarcula marismortui and Haloferax mediterranei.2, 6. Based on 
their primary structures, as well as the number of subunits and substrate specificity, 
PHA synthases have been assigned to four major classes.58 
Class I and class II PHA synthases consist of only one type of subunit (PhaC) with 
molecular weights between 61 and 73 kDa.59 The PHA synthases belonging to class I 
(e.g., C. necator) utilize (R)-3-hydroxy fatty acid substrates consisting of 3-5 carbon 
atoms and produce PHA composed of short length monomers (PHASCL),58, 60 whereas 
those of class II (e.g., P. aeruginosa) utilize (R)-3-hydroxy fatty acids with 6-14 carbon 
atoms and synthesize medium chain length PHA (PHAMCL).61, 62 PHA synthases of 
class III (e.g., A. vinosum) consist of two subunits, namely PhaC of 40 kDa with 
similarity to classes I and II polyester synthases and PhaE with no similarity to these, 
also of 40 kDa.63, 64 Class IV PHA synthases, found in the genus Bacillus, also consist 
of two subunits, one being the 40kDa PhaC subunit and the other a 20kDa PhaR 
subunit.65 The PHA molecules synthesised by the enzymes in classes III and IV are 
made of PHASCL. A small number of bacterial PHA synthases do not fit into the above 
classification.66, 67 The archaeal PHA synthases investigated so far seem to be similar to 
class III enzymes.2, 6 
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Among the proteins associated with the granule surface, only the PHA synthase is 
required for PHA granule formation, in the presence of a suitable substrate. This not 
only allows in vitro synthesis,45 it also makes recombinant production of PHA, for 
example, in E. coli relatively straightforward.68 In addition, the PHA synthase stays 
covalently attached to the granule surface and tolerates N-terminal fusions with other 
proteins. Therefore, it is possible to engineer PhaC fusions for the immobilization and 
functional display of these proteins on the granule surface (see below).69-72  
Comparison of the primary sequences of the PHA synthases has shown six conserved 
blocks and eight identical amino acids.58 While the N-terminal region has no conserved 
sequences, this region may have a role in the level of PHA synthase expressed and in 
the yield of PHA.73 The C-terminal region of approximately 40 amino acids is more 
conserved in classes I and II PHA synthases, consisting mainly of hydrophobic amino 
acids which suggests a role for this region in binding of the synthase to the hydrophobic 
granule core.58 With regard to secondary structure, predictions from multiple sequence 
alignments have indicated that the PHA synthases mainly contain variable-loop and α-
helical secondary structures.74 The α/β hydrolase region, which has been shown to be 
essential for enzymatic activity75 has been strongly suggested to exist in the C-terminal 
portion of the protein, based on a conserved domain homology search.76 In addition, the 
presence of a conserved lipase-like box in the primary structure, where the catalytic site 
serine of the lipase is replaced by a cysteine in the PHA synthase (G-X-[S/C]-X-G), 
further indicates homology to lipases.77 Three conserved amino acid residues (cysteine, 
aspartic acid, and histidine) are thought to be critical for the catalytic mechanism by 
forming a catalytic triad. PHA synthases exist in an equilibrium of monomeric and 
dimeric forms in vitro, however, when the (R)-3-hydroxyacyl-CoA substrate is 
provided, significant dimerization is suggested to occur, with one subunit of the active 
dimer attaching to the growing polyester chain while the other subunit binds a new (R)-
3-hydroxyacyl CoA substrate molecule.78 Evidence has also been presented by 
mutational studies of the PHA synthase of A. vinosum, that the conserved aspartic acid 
residue plays an important role in chain elongation, while digestion of the polyester 
chain-enzyme complex and HPLC analysis have shown that the polyester chain stays 
covalently attached to the conserved cysteine of the enzyme.79, 80 
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PHA depolymerases 
PHA depolymerases, enzymes which degrade PHA, consist of two groups, namely the 
intracellular depolymerases that degrade the amorphous PHA within granules of the 
accumulating bacteria, and the extracellular depolymerases, which are secreted by most 
bacteria to utilize denatured PHA present in the environment from, for example, other 
non-living cells.81 PhaZ refers to the intracellular depolymerases found on the PHA 
granule surface. These are necessary for the mobilization of the PHA granules as a 
source of energy.14  
Intracellular depolymerases have been investigated much less than the extracellular 
depolymerases and the mechanism by which intracellular native PHA granules can be 
reutilized is not well understood. There are some studies which have addressed the 
mobilization of intracellular PHA and the PhaZ encoding genes of C. necator.14, 82-84 
While the first described PhaZ of C. necator was designated PhaZ1,83 subsequent 
(putative) depolymerases have been identified in C. necator and designated PhaZ2 to 
PhaZ5.84-86 The genome sequence of C. necator revealed seven genes for PHA 
depolymerase isoenzymes and two for PHA oligomer hydrolases,87 but for few there is 
actual direct evidence for their in vivo function. Following an alternative nomenclature, 
these putative depolymerases have also been designated PhaZa1 to PhaZa5, PhaZb, 
PhaZc and PhaZd1/2.88  
Saegusa et al. reported the cloning and sequencing of the intracellular phaZ of 
C. necator and the demonstration of PHA degrading activity when amorphous PHA 
granules were provided as the substrate.83 Although PHB metabolism has been reported 
to be cyclic in nature with PHB synthesis and degradation occurring at the same time,82, 
89
 it has been a matter of discussion that simultaneous synthesis of PHB from acetyl-
CoA and degradation of PHB to 3HB would be a waste of energy.83 Very recently, 
Uchino et al. presented evidence that the PHA depolymerase PhaZa1 from C. necator is 
responsible for the degradation of PHB granules, albeit not exclusively, and that the 
enzyme degrades the polymer by thiolysis into 3HB-CoA instead of 3HB which would 
help to explain the previously apparently futile cycle of simultaneous PHB biosynthesis 
and degradation.88, 90 
PHA depolymerases investigated in bacteria other than C. necator include the recently 
described PhaZ of Pseudomonas putida and Azotobacter chroococcum.91, 92 
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Phasins 
Phasins are the most abundant protein found at the PHA granule surface and are 
synthesized in very large quantities under storage conditions, representing as much as 
5 % of the total cellular protein.40, 93-96 Phasins are noncatalytic proteins, consisting of a 
hydrophobic domain, which associates with the PHA granule surface and a 
predominantly hydrophilic domain exposed to the cytoplasm of the cell. There is 
evidence that this amphiphilic layer of phasins stabilizes PHA granules and prevents 
coalescence of separated granules.40, 94, 95 
Phasins are low-molecular-weight proteins (mostly between 11 and 25 kDa) and have 
been identified and isolated from many PHASCL-producing bacteria due to their 
association with PHA granules.40, 93-97 Phylogenetically, phasins are non related and 
share no sequence homology.93 The phasin protein of Rhodococcus ruber binds to the 
PHA granule surface via two hydrophobic domains at the C terminus of the protein.95, 97 
In contrast, no distinct region in the PhaP1 protein from C. necator could be identified 
to be responsible for the binding of this protein to the granule surface.93, 98 Therefore, 
binding capacity due to secondary or maybe also tertiary and quaternary structure of the 
protein has been suggested.98 PhaP1 of C. necator is the most investigated member of 
this class of proteins. Genome analysis of C. necator identified three PhaP homologues 
which need to be further investigated.85 Initial studies confirmed that PhaP1 is the 
major phasin protein and was recently characterized as a planar triangular protein that 
occurs as trimer.98 Mutants defective in one of the phaP1 homologues did not show any 
differences in phenotype compared to the wild type.21 Phasins are not essential for PHA 
accumulation, but strains unable to produce any phasin protein accumulate only one 
single large PHA granule, taking up all available space in the cell.40 Overproduction of 
PhaP leads to the formation of many small granules.41 The influence on granule size has 
been demonstrated both in vivo and in vitro.49, 95, 96, 99, 100 Although phasins are not 
necessarily required for PHA production their synthesis and abundance is closely 
correlated to PHA accumulation.10 Phasins are only produced under accumulating 
conditions40, 41, 101 and the amount of protein produced parallels the level of PHA in the 
cell.43, 47, 101, 102 Additionally, phasins are thought to positively influence synthase 
activity although no evidence for direct interaction was reported so far.42, 49, 103, 104 The 
occurrence of phasins on the granule surface obviously prevents other proteins not 
related to PHA metabolism from binding in an unspecific manner to the PHA granule 
surface which could be disadvantageous for the overall metabolism of the cell.40 In the 
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absence of PhaP this protective function can be partially resumed by other phasin like 
proteins such as BSA42, 49 or HspA105. 
Recombinantly produced PhaP1 protein from C. necator was shown to be able to bind 
to triacylglycerol (TAG) inclusions in Rhodococcus opacus and Mycobacterium 
smegmatis, indicating the capability of PhaP to bind to any type of hydrophobic 
inclusion, irrespective of the compound stored in the core of the inclusion.106 
First crystals of the phasin protein PhaP from Aeromonas hydrophila were obtained in 
2006.107 
 
Regulatory proteins 
PHA granule synthesis and phasin production are tightly regulated by the effectiveness 
of the transcriptional regulator PhaR. Genes encoding proteins homologous to PhaR are 
widely distributed among PHASCL-producing bacteria, indicating an important role in 
the regulation of PHASCL biosynthesis.94, 95 So far, the PhaR proteins from C. necator 
and Paracoccus denitrificans have been further investigated and binding of the 
regulatory protein to DNA sequences upstream of the respective phaP and phaR genes 
could be shown for both organisms.41, 108, 109 Additional evidence was derived from 
mutagenesis studies performed in C. necator, where no PhaP protein could be detected 
in a phaC deletion strain, whereas a phaC/phaR deletion strain as well as a phaR 
deletion strain synthesized large amounts of PhaP protein.102 Deletion of phaR 
completely disconnected PhaP accumulation from PHB production in C. necator.102 
Based on these findings the following regulatory model has been suggested for 
C. necator:41, 56, 102 Under conditions non-permissive for PHA biosynthesis, PhaR binds 
to the phaP promoter region and inhibits transcription. Under PHA-accumulating 
conditions, the PHA synthase starts synthesizing polyester chains, and PHA granules 
are formed. PhaR, with high binding capacity to hydrophobic surfaces, binds to the 
PHA granule surface, hence lowering the cytoplasmic concentration to a point too low 
to sufficiently repress the transcription of phaP. This leads to synthesis of PhaP, which 
immediately binds to PHA granules; no soluble PhaP is detectable in the cytoplasm. In 
later stages of the accumulation, when PHA granules reached the maximum size, most 
of the granule surface will be covered with PhaP protein, leaving no space for efficient 
PhaR binding. Increasing cytoplasmic concentration of PhaR again allows binding to 
the respective DNA sequences and repressing transcription of phaP and its own gene, 
indicating an efficient autoregulation of phaR expression to prevent synthesis of more 
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PhaR than is required for sufficient repression of phaP expression.41, 56, 102 The same 
type of PhaP/PhaR regulation was found for P. denitrificans.109 Additionally, 
simultaneous binding of PhaR to DNA and PHA granule surface in vitro as well as in 
vivo could be shown for this organism.109, 110 These results indicated a bifunctional 
character for PhaR and implied that the protein has two separate domains for binding to 
the two molecules. Binding of PhaR to the PHA granule surface seems to be 
irreversible and mainly driven by nonspecific hydrophobic interactions, implying high 
affinity but low specificity. PhaR of P. denitrificans was the first regulatory protein 
reported to interact directly with PHA granules. In contrast to PHA binding, DNA 
binding is reversible and highly specific, presumably involving the N-terminal region 
of the PhaR protein, which shows high sequence homology among PhaR 
homologues.110 Recent studies suggested PhaR to be a more global PHA-responsive 
repressor, involved not only in the expression of phaP but also in the expression of 
genes involved in other metabolic pathways.102, 109, 111 
PhaF and PhaI have been reported to be granule-associated proteins with regulatory 
function for Pseudomonas oleovorans and a model similar to the C. necator PhaP/PhaR 
system has been suggested.112 However, PhaR does not show sequence homology to 
PhaF or PhaI and, unlike PhaR, PhaF is also involved in the regulation of PHA synthase 
production in P. oleovorans.112, 113 
 
Applications of PHA Granules 
 
As mentioned briefly in the introduction, PHAs have been considered as bio-based and 
biodegradable alternatives to conventional petroleum-based plastics for over 20 years 
and have more recently, over approximately the last 10 years, attracted increasing 
interest for medical applications.114-117 PHAs are used because of their biocompatibility, 
their modifiable physical and thermal properties and also because of their 
biodegradability, but they are generally used as a chemically extracted bulk material. 
Only very recently, researchers have started to exploit the particular spherical structure 
or “bead” nature of PHA granules. The general properties of PHA as a material in 
combination with the size and shell-core composition of PHA granules open up a broad 
range of applications in biotechnology and medicine, from protein purification to drug 
delivery (Figure 2).  
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Protein purification 
Protein purification methods typically aim to recover a high yield of protein, free of 
contaminants, and without denaturing the biological activity. Consequently, separation 
methods must be sufficiently mild so as not to irreversibly alter the protein’s structure. 
Techniques that meet these requirements include affinity-based methods that take 
advantage of bonding interactions between a protein analyte and an immobilizing 
matrix. These methods must be individually optimized for each protein which can be 
expensive and time consuming.118 Producing the protein of interest fused to an affinity 
tag generally simplifies the purification procedure. Following purification of the protein 
the tag can be easily removed enzymatically. Although this approach is widely used 
and considered reliable for purifying the native target protein, the cost and number of 
separation steps involved can make the method cumbersome.119 Recently, self-cleaving 
affinity tags based on inteins have been introduced to eliminate the need for expensive 
proteolytic enzymes.120, 121 Despite the success of the self-cleaving affinity tagged 
purification process, the cost of these methods, especially the cost of affinity resins, and 
the relatively low binding capacity for the tagged protein prohibit large scale industrial 
protein purification.122  
The large-molecular-weight spherical structure of PHA granules with the surface-
associated proteins (PHA synthase, phasins, etc.) and the low-cost production make the 
granules a useful tool for protein immobilization and purification.119, 123, 124 Banki et al. 
developed a protein purification system which combines two technologies, namely 
PHA production in recombinant E. coli and intein-mediated self-splicing, implementing 
the specific affinity of the C. necator phasin PhaP to the PHA granules.122 In this 
system, the protein of interest is produced fused to the C terminus of PhaP which acts 
as an affinity tag. Both the tagged protein and the PHA granules are co-produced in E. 
coli and the protein binds to the granules, which act as an affinity matrix, via the phasin 
tag. After cell disruption, granules with bound protein can be separated from other 
cellular components by simple centrifugation. Following appropriate washing, the 
protein of interest is released by intein self-cleavage. Banki et al. used multiple phasins 
(2-3 repeats) and reported the successful purification of several test proteins (maltose 
binding protein (MBP), β-galactosidase (LacZ), chloramphenicol acetyltransferase 
(CAT) and NusA) with yields of 30-40 mg of protein per litre of culture.122 The authors 
suggested that “fine-tuning”, for example, of the granule size might further improve 
results.  
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Barnard et al. developed an analogous system for C. necator with the aim of 
overcoming the general disadvantages of using E. coli as a protein production host 
(e.g., inclusion body formation).125 In addition, using a natural PHA producer has the 
advantage of having to recombinantly produce only one protein, the PhaP-tagged target 
protein. Barnard et al. demonstrated purification of GFP and LacZ from C. necator and 
further reported that PhaP is functional both as an N- and a C-terminal tag.  
Recently, Wang et al. chose a slightly different approach to the same goal of PHA-
based protein purification.126 The protein production step was separated from the PHA 
production step and the protein purification procedure. While the target proteins (EGFP 
(enhanced GFP), MBP and LacZ) were tagged with Aeromonas hydrophila PhaP and 
recombinantly produced in E. coli, the PHA beads were produced in vitro from 
chemically extracted PHA bulk material. Following incubation of the PHA beads with 
protein crude extract, the target proteins were also retrieved by intein-mediated 
cleavage. This suggested that phasins do not only bind to emerging native granules but 
also to crystalline PHA. Moreover, the authors suggested one main advantage of their 
system, namely, suitability for a wider range of target proteins, including eukaryotic 
proteins, as the tagged protein can be produced in any host organism independent of 
PHA granule formation. One might also expect stronger target protein production if this 
process does not have to compete with PHA biosynthesis in the cell. On the other hand, 
compared to the methods of Banki et al. and Barnard et al. the method of Wang et al. 
requires more steps and also additional processing of the PHA. For all the PHA-based 
protein purification methods described here, one has to keep in mind that they are not 
suitable for the purification of proteins which themselves have a high affinity for PHA 
granules. In this case one would expect problems with separation and poor yield as the 
target proteins would compete with the phasins in binding to the granules.127 
Banki et al. suggested that the self-contained system consisting of phasin tag and PHA 
affinity matrix is particularly suitable for large-scale purification with moderate purity 
requirements. Moldes et al. took an even simpler approach.128 They used the N-terminal 
region of the P. putida phasin PhaF as a tag for protein purification and simply released 
the purified tagged protein (fusion of PhaF and target protein) by detergent treatment. 
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Biological Nano- /Micro-beads  
The use of nanoparticles in drug delivery, target specific therapy, molecular imaging, 
and as biomarkers or biosensors, in diagnosis and many other biomedical fields is 
increasing rapidly.129, 130 Recently, it has been conceived that PHA granules have great 
potential for development towards these applications.  
In 2005 it was demonstrated that the fusion of GFP to the N terminus of the PHA 
synthase did not affect PHA granule formation52 which encouraged further studies to 
engineer the PHA synthase to enable immobilization of the enzyme β-galactosidase.131 
Immobilized β-galactosidase was stable for several months under various storage 
conditions. This proof-of-principle work showed that protein engineering of the PHA 
synthase to produce functionalized PHA granules could be a useful tool for developing 
biological nano-/micro-beads for various applications. The PHA synthase has the 
advantages of providing a covalent interaction with the granule as well as a simpler 
recombinant production system in which no other genes apart from the PHA 
biosynthesis genes have to be heterologously expressed.  
In order to develop a system for purification of immunoglobulin G (IgG), Brockelbank 
et al. engineered the PHA synthase by fusing the IgG binding ZZ domain of protein A 
from Staphylococcus aureus to the PhaC N terminus.69 The IgG binding capacity of the 
ZZ domain-displaying granules (ZZ-PHA granules) was confirmed by enzyme–linked 
immunosorbent assay (ELISA). ZZ-PHA granules enabled efficient purification of IgG 
from human serum and performed equally well compared to commercial protein A-
Sepharose beads with regard to both purity and yield.69 In another recent work an anti-
β-galactosidase scFv (single-chain variable fragment of an antibody) was immobilized 
at the surface of PHA granules following the same principle of using PhaC as a self-
assembly promoting fusion partner.70 The scFv-displaying beads were successfully 
used for specific binding and elution of their antigen β-galactosidase. The functional 
display of the scFv was further assessed by a quantitative enzyme linked assay 
measuring β-galactosidase activity. Both approaches indicated the functional display of 
the antibody fragment at the bead surface which makes these scFv-displaying beads a 
potential tool for diagnostic or therapeutic applications.70 The main advantage of this 
system is the simple one-step production as opposed to laborious multiple steps 
required for immobilization of antibodies using conventional methods. 
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Figure 2. Potential applications for PHA granules. (A) Different approaches for the generation of 
functionalized PHA beads. (1) A plasmid encoded fusion of the target protein and a GAP is 
recombinantly produced in a PHA synthesizing host strain. (PHA synthesis can be natural or 
recombinant.) The fusion protein associates with PHA granules as they form and functionalized PHA 
granules are isolated from the cell. (2) and (3) Native PHA granules are formed by a natural PHA 
producing organism. This is either followed by isolation of these native granules (2) or by chemical 
extraction of the PHA and subsequent in vitro bead production (3). In a last step, the separately 
produced (and purified) GAP fusion protein is allowed to bind to the PHA granules/beads in vitro (2 
and 3). (B) Schematic overview of the different proteins and other compounds which have so far 
been immobilized and functionally displayed at the PHA granule surface, pointing out potential 
applications. 
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The strong streptavidin-biotin bond can be used to attach various biomolecules to one 
another or onto a solid support. This is a powerful tool for purification or detection of 
these molecules. Protein engineering of streptavidin for in vivo assembly of streptavidin 
beads was recently published by Peters and Rehm.72 Different variants of streptavidin 
(mature full length, core and monomeric) were tested as C-terminal fusions to the PHA 
synthase, and the performance of the enzyme and the resulting streptavidin beads was 
analyzed. The PHA synthase retained its activity in all fusions, but the mature full 
length streptavidin performed best with regard to biotin binding. It was demonstrated 
that the in vivo generated streptavidin beads are applicable for ELISA, DNA 
purification, enzyme immobilization and flow cytometry.72 In another study, Jahns et 
al. employed PHA granules as biological template structures for molecular 
biomimetics.71 The PHA synthase was fused to genetically engineered proteins for 
inorganics (GEPIs) and additionally to the ZZ domain of S. aureus. This approach 
resulted in the production of PHA granules with a multifunctional surface displaying 
both specific binding sites for certain inorganic substances (gold or silica) and for IgG. 
These biobeads could serve as suitable tools for medical bioimaging procedures where 
an antibody-mediated targeted delivery of an inorganic contrast agent is desired.71 
The examples of functionalized biobeads described so far are based on fusions to the 
PHA synthase and recombinant production mainly in E. coli. In order to expand the 
range of possible applications, the feasibility of displaying immunologically relevant 
eukaryotic proteins on the surface of the PHA granules was explored by Bäckström et 
al.132 In this study, mouse myelin oligodendrocyte glycoprotein (MOG) and 
interleukin-2 (IL2) were individually immobilized at the granule surface in vivo in E. 
coli by generating fusions to the C terminus of PhaP.132 Isolated beads displaying either 
MOG or IL2 were analyzed by fluorescence activated cell sorting (FACS) using 
monoclonal antibodies that recognize correctly folded MOG or IL2, respectively. 
Although both proteins are secreted proteins which normally form inclusion bodies 
when produced in the E. coli cytoplasm, they could be successfully produced in a 
properly folded state at the surface of PHA granules in this host. When an enterokinase 
recognition site was incorporated between PhaP and IL2, the latter could be cleaved off, 
demonstrating that the system enables purification of eukaryotic proteins. Moreover, 
the excellent long-term storage performance further supports the potential of these 
beads for diagnostic applications.132 
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In a follow-up proof-of-concept study, bifunctional PHA granules were generated 
which simultaneously displayed two protein-based functions suitable for FACS 
analysis.133 GFP was either displayed fused to the N terminus of PhaC and MOG to the 
C terminus of PhaP or both proteins were fused to the N and C terminus of the phasin, 
respectively. This showed that bifunctional PHA nanobeads displaying e.g. a 
fluorescent protein and a protein with a specific interaction partner (antigen, receptor) 
could be used in diagnostics.  
While most of the published reports on functionalised PHA nano- /micro-beads have 
involved protein engineering of the phasins or the PHA synthase, Lee et al. targeted the 
substrate binding domain (SBD) of the PHA depolymerase from Alcaligenes 
faecalis.124 They reported the in vitro production of microbeads from extracted PHA to 
which separately synthesized GAP-tagged target proteins could subsequently be bound. 
Beads of 2µm diameter were generated and the model proteins EGFP, RFP (red 
fluorescent protein) and SARS-CoV (severe acute respiratory syndrome corona virus) 
envelope protein were immobilized at the surface via a fusion to the N terminus of the 
SBD. All model proteins, including the SARS-CoV envelope protein were successfully 
detected by FACS, which demonstrates the suitability also of this method for 
generating functionalized PHA beads for e.g. immunoassays or, as the authors 
suggested, the study of protein-protein interactions.  
 
Targeted Drug Delivery 
There is now general agreement based on a large amount of data that PHA-based 
medical devices are indeed well tolerated by the human body.134, 135 Thus, 
functionalized PHA granules seem to be excellent candidates for targeted drug delivery 
as they combine the properties of a biocompatible polymer with the properties of a 
biobead. Though the in vivo PHA production system has the advantage of being 
relatively cost-effective compared to other drug carrier systems on the market, medical 
applications naturally require materials of extreme purity. Therefore, suitable methods 
would be needed for endotoxin removal from bacterially produced PHA 
bionanobeads.16, 136 To date, the biocompatibility of PHA granules has not been 
specifically studied, but when considering the major constituent of the granules, the 
PHA, it is expected to be similar to the biocompatibility of PHA alone, pending the 
biological activity (toxicity, immunogenicity) of the surface proteins. Various drug 
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delivery and drug targeting systems based on biodegradable polymers are currently 
under development.137, 138 Several of the functionalized PHA biobeads described above 
would be suitable for targeted drug delivery, but so far there has only been one report of 
in vivo animal tests139. 
Recently, Yao et al. exploited one of the C. necator phasins as a tag to develop a 
receptor-mediated drug delivery system.139 PhaP was fused to the cell-specific ligands 
mannosylated human α1-acid glycoprotein (hAGP) and human epidermal growth factor 
(hEGF). hAGP is recognized by receptors on macrophages, hEGF by receptors on 
hepatocellular carcinoma cells. The fusion proteins were produced in Pichia pastoris 
and E. coli, respectively, purified and immobilized on in vitro generated and rhodamine 
B isothiocyanate (RBITC)-loaded PHA beads. Fluorescence microscopic examination 
showed that both ligand-PhaP-nanobeads were taken up by the correct type of cell in 
vitro and directed to the correct tissue in in vivo mouse experiments, demonstrating 
targeted delivery of the model drug RBITC.  
 
Outlook 
 
To date, a range of proteins and other molecules have been successfully immobilized at 
the surface of PHA granules, indicating that these bacterial storage compounds have 
potential to be developed into powerful tools for diagnostic and therapeutic biomedical 
applications. A particular advantage of PHA granules as functionalized nano-/micro-
beads, apart from the simple and cost-effective production, is the oriented 
immobilization of, for example, proteins via the GAP-tag and thus high binding 
capacity of the resulting beads. Future work should include improved strategies for size 
control of in vivo produced beads as well as improved methods for pyrogen removal.  
 
References 
 
(1) Brandl, H.; Gross, R. A.; Lenz, R. W.; Fuller, R. C. Appl. Environ. 
Microbiol., 1998, 54, 1977-1982. 
(2) Han, J.; Lu, Q.; Zhou, L.; Zhou, J.; Xiang, H. Appl. Environ. Microbiol., 
2007, 73, 6058-6065. 
Chapter I C 
75 
(3) Hezayen, F. F.; Rehm, B. H. A.; Eberhardt, R.; Steinbüchel, A. Appl. 
Microbiol. Biotechnol., 2000, 54, 319-325. 
(4) Hezayen, F. F.; Steinbüchel, A.; Rehm, B. H. A. Arch. Biochem. Biophys., 
2002, 403, 284-291. 
(5) Hezayen, F. F.; Tindall, B. J.; Steinbüchel, A.; Rehm, B. H. A. Int. J. Syst. 
Evol. Microbiol., 2002, 52, 2271–2280. 
(6) Lu, Q.; Han, J.; Zhou, L.; Zhou, J.; Xiang, H. J. Bacteriol., 2008, 190, 4173-
4180. 
(7) Campisano, A.; Overhage, J.; Rehm, B. H. A. J. Biotechnol., 2008, 133, 
442-452. 
(8)  Hoffmann, N.; Rehm, B. H. A. Biotechnol. Lett., 2005, 27, 279-282. 
(9) Kim, Y., R.; Paik, H. J.; Ober, C. K.; Coates, G. W.; Batt, C. A. 
Biomacromolecules, 2004, 5, 889-891. 
(10) Kuchta, K.; Chi, L.; Fuchs, H.; Pötter, M.; Steinbüchel, A. 
Biomacromolecules, 2007, 2, 657-662. 
(11) Lee, S. Y. Trends Biotechnol., 1996, 14, 98-105. 
(12) Madison, L. L.; Huisman, G. W. Microbiol. Mol. Biol. Rev., 1999, 63, 21-
53. 
(13) Gao, D.; Maehara, A.; Yamane; T.Ueda, S. FEMS Microbiol. Lett., 2001, 
196, 159-164. 
(14) Handrick, R.; Reinhardt, S.; Jendrossek, D. J. Bacteriol., 2000, 20, 5916-
5918. 
(15) Hazer, B.; Steinbüchel, A. Appl. Microbiol. Biotechnol., 2007, 74, 1-12. 
(16) Furrer, P.; Panke, S.; Zinn, M. J. Microbiol. Methods, 2007, 69, 206-213. 
(17) Rehm, B. H. A. Biotechnol. Lett., 2006, 28, 207-213. 
(18) Reinecke, F.; Steinbüchel, A. J. Mol. Microbiol. Biotechnol., 2009, 16, 91-
108. 
(19) Peoples, O. P.; Sinskey, A. J. J. Biol. Chem., 1989, 264, 15298-15303. 
(20) Slater, S. C.; Voige, W. H.; Dennis, D. E. J. Bacteriol., 1988, 170, 4431-
4436. 
(21) Pötter, M.; Müller, H.; Steinbüchel, A. Microbiology, 2005, 151, 825-833. 
(22) Steinbüchel, A.; Aerts, K.; Babel, W.; Follner, C.; Liebergesell, M.; 
Madkour, M. H.; Mayer, F.; Pieper-Fürst, U.; Pries, A.; Valentin, H. E.; 
Wieczorek, R. Can. J. Microbiol., 1995, 41, 94-105. 
Chapter I C 
76 
(23) Griebel, R.; Smith, Z.; Merrick, J. M. Biochemistry (Mosc). 1968, 7, 3676-
3681. 
(24) de Koning, G. J. M.; Lemstra, P. J. Polymer, 1992, 33, 3292-3294. 
(25) Horowitz, D. M.; Sanders, J. K. M. J. Am. Chem. Soc., 1994, 116, 2695-
2702. 
(26) Ellar, D.; Lundgren, D. G.; Okamura, K.; Marchessault, R. H. J. Mol. Biol., 
1968, 35, 489-502. 
(27) Mayer, F.; Madkour, M. H.; Pieper-Fürst, U.; Wieczorek, R.; Liebergesell, 
M.; Steinbüchel, A. J. Gen. Appl. Microbiol., 1996, 42, 445-455. 
(28) Mayer, F.; Hoppert, M. J. Basic Microbiol., 1997, 37, 45-52. 
(29) Stuart, E. S.; Tehrani, A.; Valentin, H. E.; Dennis, D.; Lenz, R. W.; Fuller, 
R. C. J. Biotechnol., 1998, 64, 137-144.  
(30) Jendrossek, D.; Selchow, O.; Hoppert, M. Appl. Environ. Microbiol., 2007, 
73, 586-593. 
(31) Kawaguchi, Y.; Doi, Y. FEMS Microbiol. Lett., 1990, 70, 151-156. 
(32) Barnard, G. N.; Sanders, J. K. J. Biol. Chem., 1989, 264, 3286-3291. 
(33) Russell, R. A.; Holden, P. J.; Garvey, C. J.; Wilde, K. L.; Hammerton, K. 
M.; Foster, L. J. Physica B, 2006, 385-386, 859-861. 
(34) Russell, R. A.; Holden, P. J.; Wilde, K. L.; Hammerton, K. M.; Foster, L. J. 
R. J. Biotechnol., 2007, 132, 303-305. 
(35) Matsumoto, K.; Matsusaki, H.; Taguchi, K.; Seki, M.; Doi, Y. 
Biomacromolecules, 2002, 3, 787-792. 
(36) Sudesh, K.; Gan, Z.; Matsumoto, K. i.; Doi, Y. Ultramicroscopy, 2002, 91, 
157-164. 
(37) Dennis, D.; Sein, V.; Martinez, E.; Augustine, B. J. Bacteriol., 2008, 190, 
555-563. 
(38) Dennis, D.; Liebig, C.; Holley, T.; Thomas, K. S.; Khosla, A.; Wilson, D.; 
Augustine, B. FEMS Microbiol. Lett., 2003, 226, 113-119. 
(39) Griebel, R. J.; Merrick, J. M. J. Bacteriol., 1971, 108, 782-789. 
(40) Wieczorek, R.; Pries, A.; Steinbüchel, A.; Mayer, F. J. Bacteriol., 1995, 
177, 2425-2435. 
(41) Pötter, M.; Madkour, M. H.; Mayer, F.; Steinbüchel, A. Microbiology, 2002, 
148, 2413-2426. 
Chapter I C 
77 
(42) Qi, Q.; Steinbüchel, A.; Rehm, B. H. A. Appl. Microbiol. Biotechnol., 2000, 
54, 37-43. 
(43) York, G. M.; Stubbe, J.; Sinskey, A. J. J. Bacteriol., 2001, 183, 2394-2397. 
(44) Kusaka, S.; Abe, H.; Lee, S. Y.; Doi, Y. Appl. Microbiol. Biotechnol., 1997, 
47, 140-143. 
(45) Gerngross, T. U.; Martin, D. P. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 
6279-6283. 
(46) Sim, S. J.; Snell, K. D.; Hogan, S. A.; Stubbe, J.; Rha, C.; Sinskey, A. J. 
Nat. Biotechnol., 1997, 15, 63-67. 
(47) Tian, J.; He, A.; Lawrence, A. G.; Liu, P.; Watson, N.; Sinskey, A. J.; 
Stubbe, J. J. Bacteriol., 2005, 187, 3825-3832. 
(48) Stubbe, J.; Tian, J. Nat. Prod. Rep., 2003, 20, 445-457. 
(49) Jossek, R.; Reichelt, R.; Steinbüchel, A. Appl. Microbiol. Biotechnol., 1998, 
49, 258-266. 
(50) Rehm, B. H. A.; Qi, Q. S.; Beermann, B. B.; Hinz, H. J.; Steinbüchel, A. 
Biochem. J., 2001, 358, 263-268. 
(51) Jendrossek, D. Biomacromolecules, 2005, 6, 598-603. 
(52) Peters, V.; Rehm, B. H. A. FEMS Microbiol. Lett., 2005, 248, 93-100. 
(53) Peters, V.; Becher, D.; Rehm, B. H. A. J. Biotechnol., 2007, 132, 238-245. 
(54) Tian, J.; Sinskey, A. J.; Stubbe, J. J. Bacteriol., 2005, 187, 3814-3824. 
(55) Madden, L. A.; Anderson, A. J.; Shah, D. T.; Asrar, J. Int. J. Biol. 
Macromol., 1999, 25, 43-53. 
(56) Pötter, M.; Steinbüchel, A. Biomacromolecules, 2005, 6, 552-560. 
(57) Grage, K.; Peters, V.; Palanisamy, R.; Rehm, B. H. A. In Microbial 
production of biopolymers and biopolymer precursors, Rehm, B. H. A., Ed. 
Caister Academic Press: 2009; pp 255-287. 
(58) Rehm, B. H. A. Biochem. J., 2003, 376, 15-33. 
(59) Qi, Q.; Rehm, B. H. A. Microbiology, 2001, 147, 3353-3358. 
(60) Ren, Q.; De Roo, G.; Kessler, B.; Witholt, B. Biochem. J., 2000, 349, 599-
604. 
(61) Amara, A. A.; Rehm, B. H. A. Biochem. J., 2003, 374, 413-421. 
(62) Qi, Q.; Rehm, B. H. A.; Steinbüchel, A. FEMS Microbiol. Lett., 1997, 157, 
155-162. 
Chapter I C 
78 
(63) Liebergesell, M.; Schmidt, B.; Steinbüchel, A. FEMS Microbiol. Lett., 1992, 
78, 227-232. 
(64) Liebergesell, M.; Steinbüchel, A. Eur. J. Biochem., 1992, 209, 135-150. 
(65) McCool, G. J.; Cannon, M. C. J. Bacteriol., 2001, 183, 4235-4243. 
(66) Fukui, T.; Doi, Y. J. Bacteriol., 1997, 179, 4821-4830. 
(67) Matsusaki, H.; Manji, S.; Taguchi, K.; Kato, M.; Fukui, T.; Doi, Y. J. 
Bacteriol., 1998, 180, 6459-6467. 
(68) Lee, S. Y.; Lee, K. M.; Chan, H. N.; Steinbüchel, A. Biotechnol. Bioeng., 
1994, 44, 1337-1347. 
(69) Brockelbank, J. A.; Peters, V.; Rehm, B. H. A. Appl. Environ. Microbiol., 
2006, 72, 7394-7397. 
(70) Grage, K.; Rehm, B. H. A. Bioconj. Chem., 2008, 19, 254-262. 
(71) Jahns, A. C.; Haverkamp, R. G.; Rehm, B. H. A. Bioconj. Chem., 2008, 19, 
2072-2080. 
(72) Peters, V.; Rehm, B. H. A. J. Biotechnol., 2008, 134, 266-274. 
(73) Normi, Y. M.; Hiraishi, T.; Taguchi, S.; Abe, H.; Sudesh, K.; Najimudin, 
N.; Doi, Y. Macromol. Biosci., 2005, 5, 197-206. 
(74) Cuff, J. A.; Clamp, M. E.; Siddiqui, A. S.; Finlay, M.; Barton, G. J. 
Bioinformatics, 1998, 14, 892-893. 
(75) Pham, T. H.; Webb, J. S.; Rehm, B. H. A. Microbiology, 2004, 150, 3405-
3413. 
(76) Rehm, B. H. A. Curr. Issues Mol. Biol., 2007, 9, 41-62. 
(77) Jia, Y.; Kappock, T. J.; Frick, T.; Sinskey, A. J.; Stubbe, J. Biochemistry 
(Mosc). 2000, 39, 3927-3936. 
(78) Jia, Y.; Yuan, W.; Wodzinska, J.; Park, C.; Sinskey, A. J.; Stubbe, J. 
Biochemistry (Mosc). 2001, 40, 1011-1019. 
(79) Tian, J.; Sinskey, A. J.; Stubbe, J. Biochemistry (Mosc). 2005, 44, 8369-
8377. 
(80) Tian, J.; Sinskey, A. J.; Stubbe, J. Biochemistry (Mosc). 2005, 44, 1495-
1503. 
(81) Jendrossek, D.; Handrick, R. Annu. Rev. Microbiol., 2002, 56, 403-432. 
(82) Doi, Y.; Segawa, A.; Kawaguchi, Y.; Kunioka, M. FEMS Microbiol. Lett., 
1990, 55, 165-169. 
Chapter I C 
79 
(83) Saegusa, H.; Shiraki, M.; Kanai, C.; Saito, T. J. Bacteriol., 2001, 183, 94-
100. 
(84) York, G. M.; Lupberger, J.; Tian, J. M.; Lawrence, A. G.; Stubbe, J.; 
Sinskey, A. J. J. Bacteriol., 2003, 185, 3788-3794. 
(85) Pötter, M.; Müller, H.; Reinecke, F.; Wieczorek, R.; Fricke, F.; Bowien, B.; 
Friedrich, B.; Steinbüchel, A. Microbiology, 2004, 150, 2301-2311. 
(86) Schwartz, E.; Henne, A.; Cramm, R.; Eitinger, T.; Friedrich, B.; Gottschalk, 
G. J. Mol. Biol., 2003, 332, 369-383. 
(87) Pohlmann, A.; Fricke, W. F.; Reinecke, F.; Kusian, B.; Liesegang, H.; 
Cramm, R.; Eitinger, T.; Ewering, C.; Pötter, M.; Schwartz, E.; Strittmatter, 
A.; Voss, I.; Gottschalk, G.; Steinbüchel, A.; Friedrich, B.; Bowien, B. Nat. 
Biotechnol., 2006, 24, 1257-1262. 
(88) Uchino, K.; Saito, T.; Jendrossek, D. Appl. Environ. Microbiol., 2008, 74, 
1058-1063. 
(89) Taidi, B.; Mansfield, D. A.; Anderson, A. J. FEMS Microbiol. Lett., 1995, 
129, 201-205. 
(90) Uchino, K.; Saito, T.; Gebauer, B.; Jendrossek, D. J. Bacteriol., 2007, 189, 
8250-8256. 
(91) de Eugenio, L. I.; Garcia, P.; Luengo, J. M.; Sanz, J. M.; Roman, J. S.; 
Garcia, J. L.; Prieto, M. A. J. Biol. Chem., 2007, 282, 4951-4962. 
(92) Saha, S. P.; Patra, A.; Paul, A. K. J. Biotechnol., 2007, 132, 325-330. 
(93) Hanley, S. Z.; Pappin, D. J.; Rahman, D.; White, A. J.; Elborough, K. M.; 
Slabas, A. R. FEBS Lett., 1999, 447, 99-105. 
(94) Liebergesell, M.; Steinbüchel, A. Biotechnol. Lett., 1996, 18, 719-724. 
(95) Pieper-Fürst, U.; Madkour, M. H.; Mayer, F.; Steinbüchel, A. J. Bacteriol., 
1995, 177, 2513-2523. 
(96) Schultheiss, D.; Handrick, R.; Jendrossek, D.; Hanzlik, M.; Schüler, D. J. 
Bacteriol., 2005, 187, 2416-2425. 
(97) Pieper-Fürst, U.; Madkour, M. H.; Mayer, F.; Steinbüchel, A. J. Bacteriol., 
1994, 176, 4328-4337. 
(98) Neumann, L.; Spinozzi, F.; Sinibaldi, R.; Rustichelli, F.; Pötter, M.; 
Steinbüchel, A. J. Bacteriol., 2008, 190, 2911-2919. 
(99) Jurasek, L.; Marchessault, R. H. Appl. Microbiol. Biotechnol., 2004, 64, 
611-617. 
Chapter I C 
80 
(100) Seo, M. C.; Shin, H. D.; Lee, Y. H. Biotechnol. Lett., 2004, 26, 617-622. 
(101) York, G. M.; Junker, B. H.; Stubbe, J. A.; Sinskey, A. J. J. Bacteriol., 2001, 
183, 4217-4226. 
(102) York, G. M.; Stubbe, J.; Sinskey, A. J. J. Bacteriol., 2002, 184, 59-66. 
(103) de Almeida, A.; Nikel, P. I.; Giordano, A. M.; Pettinari, M. J. Appl. Environ. 
Microbiol., 2007, 73, 7912-7916. 
(104) Jurasek, L.; Marchessault, R. H. Biomacromolecules, 2002, 3, 256-261. 
(105) Tessmer, N.; König, S.; Malkus, U.; Reichelt, R.; Pötter, M.; Steinbüchel, A. 
Microbiology, 2007, 153, 366-374. 
(106) Hänisch, J.; Wältermann, M.; Robenek, H.; Steinbüchel, A. Microbiology, 
2006, 152, 3271-3280. 
(107) Zhao, M.; Li, Z.; Zheng, W.; Lou, Z.; Chen, G. Q. Acta Crystallograph. 
Sect. F Struct. Biol. Cryst. Commun., 2006, 62, 814-819. 
(108) Maehara, A.; Doi, Y.; Nishiyama, T.; Takagi, Y.; Ueda, S.; Nakano, H.; 
Yamane, T. FEMS Microbiol. Lett., 2001, 200, 9-15. 
(109) Maehara, A.; Taguchi, S.; Nishiyama, T.; Yamane, T.; Doi, Y. J. Bacteriol., 
2002, 184, 3992-4002. 
(110) Yamada, M.; Yamashita, K.; Wakuda, A.; Ichimura, K.; Maehara, A.; 
Maeda, M.; Taguchi, S. J. Bacteriol., 2007, 189, 1118-1127. 
(111) Povolo, S.; Casella, S. Arch. Microbiol., 2000, 174, 42-49. 
(112) Prieto, M. A.; Bühler, B.; Jung, K.; Witholt, B.; Kessler, B. J. Bacteriol., 
1999, 181, 858-868. 
(113) Hoffmann, N.; Rehm, B. H. A. FEMS Microbiol. Lett., 2004, 237, 1-7. 
(114) Chen, G. Q.; Wu, Q. Biomaterials, 2005, 26, 6565-6578. 
(115) Misra, S. K.; Valappil, S. P.; Roy, I.; Boccaccini, A. R. Biomacromolecules, 
2006, 7, 2249-2258. 
(116) Sodian, R.; Sperling, J. S.; Martin, D. P.; Egozy, A.; Stock, U.; Mayer, J. E., 
Jr.; Vacanti, J. P. Tissue Eng., 2000, 6, 183-188. 
(117) Williams, S. F.; Martin, D. P.; Horowitz, D. M.; Peoples, O. P. Int. J. Biol. 
Macromol., 1999, 25, 111-121. 
(118) Freitag, R.; Horváth, C. In Downstream processing, biosurfactants, 
carotenoids, Barzana, E., Ed. Springer-Verlag: 1996; pp 17-59. 
(119) Banki, M. R.; Wood, D. W. Microb. Cell Fact., 2005, 4. 
Chapter I C 
81 
(120) Chong, S. R.; Mersha, F. B.; Comb, D. G.; Scott, M. E.; Landry, D.; Vence, 
L. M.; Perler, F. B.; Benner, J.; Kucera, R. B.; Hirvonen, C. A.; Pelletier, J. 
J.; Paulus, H.; Xu, M. Q. Gene, 1997, 192, 271-281. 
(121) Gillies, A. R.; Mahmoud, R. B.; Wood, D. W. In High throughput protein 
expression and purification, Doyle, S. A., Ed. Springer-Verlag: 2009; pp 
173-183. 
(122) Banki, M. R.; Gerngross, T. U.; Wood, D. W. Protein Sci., 2005, 14, 1387-
1395. 
(123) Anderson, A. J.; Dawes, E. A. Microbiol. Rev., 1990, 54, 450-472. 
(124) Lee, S. J.; Park, J. P.; Park, T. J.; Lee, S. Y.; Lee, S.; Park, J. K. Anal. 
Chem., 2005, 77, 5755-5759. 
(125) Barnard, G. C.; McCool, J. D.; Wood, D. W.; Gerngross, T. U. Appl. 
Environ. Microbiol., 2005, 71, 5735-5742. 
(126) Wang, Z.; Wu, H.; Chen, J.; Zhang, J.; Yao, Y.; Chen, G.-Q. Lab on a Chip, 
2008, 8, 1957-1962. 
(127) Maehara, A.; Ueda, S.; Nakano, H.; Yamane, T. J. Bacteriol., 1999, 181, 
2914-2921. 
(128) Moldes, C.; Garcia, P.; Garcia, J. L.; Prieto, M. A. Appl. Environ. 
Microbiol., 2004, 70, 3205-3212. 
(129) Panyam, J.; Labhasetwar, V. Adv. Drug Del. Rev., 2003, 55, 329-347. 
(130) Salata, O. J. Nanobiotechnology, 2004, 2, 3. 
(131) Peters, V.; Rehm, B. H. A. Appl. Environ. Microbiol., 2006, 72, 1777-1783. 
(132) Bäckström, B. T.; Brockelbank, J. A.; Rehm, B. H. A. BMC Biotechnol., 
2007, 7, 3. 
(133) Atwood, J. A.; Rehm, B. H. A. Biotechnol. Lett., 2009. 31. 131-137 
(134) Martin, D. P.; Williams, S. F. Biochem. Eng. J., 2003, 16, 97-105. 
(135) Park, S. J.; Lee, S. Y. J. Bacteriol., 2003, 185, 5391-5397. 
(136) Zinn, M.; Witholt, B.; Egli, T. Adv. Drug Del. Rev., 2001, 53, 5-21. 
(137) Langer, R. Nature, 1998, 392, 5-10. 
(138) Langer, R.; Tirrell, D. A. Nature, 2004, 428, 487-492. 
(139) Yao, Y.-C.; Zhan, X.-Y.; Zhang, J.; Zou, X.-H.; Wang, Z.-H.; Xiong, Y.-C.; 
Chen, J.; Chen, G.-Q. Biomaterials, 2008, 29, 4823-4830. 
 
  
 
Chapter I 
 
Introduction 
 
Aims and Scope of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Scope 
83 
Aims and Scope of the thesis 
 
Polyhydroxyalkanoates (PHAs) are receiving considerable attention because of their 
potential as renewable and biodegradable plastics. Polyhydroxybutyrate (PHB), a 
representative compound of the family of PHAs, has many potential applications in 
medicine, veterinary practice, and agriculture due to its biodegradability and 
biocompatibility. Moreover, PHB is also an intracellular storage compound that 
provides a reserve of carbon and energy for many microorganisms. The key enzyme in 
the process of PHB granule formation is the PHA synthase. The objective of this PhD 
project is to introduce additional attachment functionality by modifying this 
polymerising enzyme to bind different metals and non-metals and hence to establish a 
technology platform to create high value products. Genetically engineered peptides for 
binding inorganics (GEPIs) will be fused to the N terminus of the PHA synthase, and 
the ability of the fusion protein to bind gold or silica will be evaluated. The bio-beads 
will be tailored for potential biomedical applications. 
Previous work has shown that the PHA synthase PhaC from Ralstonia eutropha can be 
genetically engineered at its N terminus without affecting the polymerising activity of 
this enzyme. The research of this thesis aims to investigate whether the C terminus of 
PhaC can be modified in the same way. The C terminus is thought to be essential for 
activity and therefore no engineering or modifying was attempted so far. In a first 
experiment the maltose binding protein MalE will be fused to the C terminus of the 
PHA synthase. Both proteins will be connected via a specially designed linker region to 
maintain the hydrophobic environment in the vicinity of the C terminus of the PHA 
synthase. It is our view that this might be important to ensure activity of this enzyme. 
Establishing a technique to manipulate the N as well as the C terminus of the PHA 
synthase would broaden the biotechnological applicability of the PHA beads displaying 
the engineered protein at the bio-bead surface. 
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The class I polyhydroxyalkanoate synthase from Ralstonia 
eutropha tolerates translational fusions to its C terminus: A 
new mode of functional display 
 
Anika C. Jahns and Bernd H. A. Rehm 
 
Abstract 
 
Here, the class I PHA synthase (PhaC) from Ralstonia eutropha was investigated 
regarding the functionality of its conserved C-terminal region and its ability to tolerate 
translational fusions to its C terminus. MalE, the maltose binding protein, and GFP, the 
green fluorescent protein were considered as reporter proteins to be translationally 
fused to the C terminus. Interestingly, only when a linker was inserted between PhaC 
and MalE, PhaC remained active, whereas MalE was not functional. However, the 
extension of the PhaC N terminus by 458 amino acid residues was required to achieve 
functionality of MalE. These data suggested a positive interaction of the extended N 
terminus with the C terminus. To assess whether a linker and/or N-terminal extension is 
in general required for a functional C-terminal fusion, the GFP was fused to the C 
terminus of PhaC. Both fusion partners were active without the requirement of a linker 
and/or N-terminal extension. A further reporter protein, the IgG binding ZZ domain of 
protein A was translationally fused to the N terminus of the fusion protein PhaC-GFP 
and resulted in a tripartite fusion protein mediating production of polyester granules 
displaying two functional protein domains. 
 
Introduction 
 
Polyhydroxyalkanoates (PHAs) are biopolyesters, synthesized by many bacteria and 
some archaea in times of unbalanced nutrient availability (7, 14-16, 22). These 
polyesters are stored as water-insoluble inclusions inside the cells and serve as energy 
and carbon storage (11, 29, 30). PHA synthases catalyse the stereo-selective conversion 
of (R)-3-hydroxyacyl-CoA to PHAs while CoA is released and intracellular PHA 
granules are formed (32). The PHA synthase remains covalently attached to the PHA 
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granule surface and has been targeted by protein engineering, i.e. translational fusion to 
the dispensable and variable N-terminus, to enable display of various protein functions 
without affecting the synthase activity (8, 26). PHA granules displaying certain 
functionalities have been considered as bio-beads for biotechnological and medical 
applications (11). 
PHA synthases can be divided into four classes. Class I and class II enzymes consist of 
only one subunit (PhaC) (28) and produce short-chain-length PHAs (class I) or 
medium-chain-length PHAs (class II) respectively (30, 33). Polyester synthases 
belonging to class III consist of two subunits, PhaC and PhaE and produce short-chain-
length PHAs (20, 21). Class IV PHA synthases are similar to enzymes belonging to 
class III. The synthases of this class comprise the two subunits PhaC and PhaR (23, 24). 
It has previously been shown that the N terminus of PhaC is a highly variable region 
and not essential for PHA synthase activity (30, 35). In contrast, the C terminus is a 
rather conserved region among class I and class II PHA synthases and is essential for 
enzyme activity (31). Alignments of the amino acid sequences of different PHA 
synthases revealed that the C terminus of these enzymes is hydrophobic and therefore 
suggested to interact with the hydrophobic core of PHA granules (30). The PhaC 
subunits of class III and class IV PHA synthases do not show a high hydrophobicity for 
their C-terminal regions. Previous studies showed that the PhaC subunit of the class IV 
PHA synthase from Bacillus megaterium tolerates fusions to its C terminus without loss 
in activity as long as the hydrophobic second subunit PhaR is present as well (23). 
The aim of this study was to assess the effect on enzyme activity of the conserved 
hydrophobic C terminus of PhaC with regard to the possibility of translationally fusing 
protein functions for the display at the PHA granule surface. This will be of interest for 
the display of proteins that require their free C terminus for activity. 
 
Materials and Methods 
 
Bacterial strains, plasmids and oligonucleotides 
Bacterial strains, plasmids and oligonucleotides used in this study are listed in Table 1. 
E. coli XL1 Blue was grown at 37˚C, BL21(DE3) at 25˚C. Antibiotics were added in 
the respective concentration, ampicillin 75 µg/ml, tetracycline 12.5 µg/ml or 
chloramphenicol 50 µg/ml.  
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Construction of plasmids encoding C-terminal synthase fusions  
General cloning procedures and isolation of DNA were performed as described 
elsewhere (34). Deoxynucleoside triphosphate, T4 DNA ligase and Pfx polymerase 
were purchased from Invitrogen TM (CA, USA), primers were purchased from Sigma-
Aldrich (St. Louis, Mo., USA). DNA sequences of new plasmid constructs were 
confirmed by DNA sequencing according to the chain termination method using an 
automatic sequencer (Applied Biosystems, 3730 DNA Analyzer).  
The nucleic acid sequence of phaC was PCR amplified using the oligonucleotides PhaC 
XbaI and PhaC no stop and the plasmid pCWE as template. The sequence of MalE was 
amplified from the vector pMAL-c2G, using the oligonucleotides MalE XhoI and MalE 
BamHI. The GFP sequence was amplified from plasmid pCWESpeGFP, using the 
oligonucleotides GFP no start XhoI and GFP stop BamHI. To obtain the sequences of 
the complete fusion proteins, all respective fragments were ligated step by step into the 
respective restriction enzyme sites of vector pET-14b. The two linker sequences were 
encoded in the respective forward and reverse primers and used for direct primer-dimer 
ligation (linker: VLAVIDKRGGGGG; SG-linker: SGGGSGGGSGGGGS). Hence, 
plasmids pET-14b PhaC-linker-MalE, pET-14b PhaC-linker-SG-linker-MalE, pET-14b 
PhaC-linker-GFP and pET-14b PhaC-linker-SG-linker-GFP were obtained. To 
construct a direct linker-free fusion the 3’ part of phaC was amplified by PCR using the 
oligonucleotides AscI PhaC and XhoI PhaC no stop. The respective fragment was 
exchanged to create plasmids pET-14b PhaC-MalE and pET-14b PhaC-GFP. In order 
to further expose the MalE protein a non-functional N-terminal extension to PhaC was 
obtained. The sequence of this M extension was amplified from plasmid pMAL-Mpl-
EC (gift from Dr Peilin Xu), and plasmid pCWESpeMpl-EC was obtained. Further 
subcloning led to the plamids pET-14b M-PhaC-MalE, pET-14b M-PhaC-linker-MalE 
and pET-14b M-PhaC. Plasmid pET-14b ZZ-PhaC-GFP codes for the double 
functionalised synthase. The ZZ-fragment was subcloned from plasmid pET-14b ZZ(-
)phaC and inserted into the respectively prepared plasmid pET-14b PhaC-GFP. All 
plasmids and oligonucleotides are listed in Table 1. The respective plasmids were used 
to transform competent E. coli BL21 (DE3) cells harbouring plasmid pMCS 69. The 
plasmid pMCS69 encodes the β-ketothiolase (phaA) and the acetoacetyl-CoA-reductase 
(phaB) which are required for the formation of the precursor R-3-hydroxybutyryl-CoA, 
the substrate of the polyester synthase (1). 
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Table 1. Bacterial strains, plasmids, and oligonucleotides used in this study 
E. coli strain, plasmid or 
oligonucleotide 
genotype Source or reference 
 
 Strains  
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17(r-k, m+k), (8) 
 supE44, relA1, -, lac[F’, proAB, lacIq, lacZ∆M15,  
 Tn10(Tcr)]  
BL21(DE3) F-, ompT, hsdSB (rB- mB-), gal, dcm (DE3) Novagen 
 Plasmids  
pMCS69 pBBR1MCS derivative containing genes phaA (13) 
 and phaB of R. eutropha colinear to lac promoter  
pET-14b Arr, T7 promoter Novagen 
pETC pET-14b derivative, coding for PhaCwt under (22) 
 T7 promoter control  
pCWE pBluescriptSK- derivative containing the (21) 
 NdeI/BamHI inserted phaC gene from R. eutropha  
pMAL-c2G Plasmid for expression and purification of New England Biolab 
 maltose-binding protein fusions  
pCWESpeGFP pCWESpe containing SpeI-inserted gfp gene (20) 
pET-14b ZZ(-)phaC pET-14b containing XbaI/BamHI fragment (7) 
 comprising gene ZZ-phaC  
pET-14b PhaC-linker-MalE pET-14b derivative containing malE fused to This study 
 the 3’ end of phaC via a linker sequence  
pET-14b PhaC-MalE pET-14b derivative containing malE directly This study 
 fused to the 3’ end of phaC  
pET-14b M-PhaC-linker-MalE pET-14b PhaC-linker-MalE derivative containing This study 
 the Mpl sequence fused to the 5’ end of phaC  
pET-14b M-PhaC-MalE pET-14b PhaC-MalE derivative containing the This study 
 Mpl sequence fused to the 5’ end of phaC  
pMAL-Mpl-EC pMAL-c2x derivative, containing Mpl sequence (30) 
pCWESpeMpl-EC pCWE derivative containing the Mpl sequence This study 
 fused to the 5’ end of phaC  
pET-14b M-PhaC pETC derivative, containing the Mpl sequence This study 
 fused to the 5’ end of phaC  
pET-14b PhaC-linker pET-14b PhaC-linker-MalE derivative containing This study 
-SG-linker-MalE the SG-linker sequence upstream of malE  
pET-14b PhaC-linker-GFP pET-14b derivative containing gfp fusded to This study 
 the 3’ end of phaC via a linker sequence  
pET-14b PhaC-linker pET-14b PhaC-linker-GFP derivative containing This study 
-SG-linker-GFP the SG-linker sequence upstream of gfp  
pET-14b PhaC-GFP pET-14b derivative containing gfp directly This study 
 fused to the 3’end of phaC  
pET-14b ZZ-PhaC-GFP pET-14b PhaC-GFP derivative containing the This study 
 ZZ sequence 5’ of phaC  
 Oligonucleotides  
linker I 5’-P-TAT GGT GCT GGC GGT GGC GAT TGA This study 
 TAA ACG CGG AGG CGG TGG AGG CC-3’  
linker II 5’-P’TCG AGG CCT CCA CCG CCT CCG CGT This study 
 TTA TCA ATC GCC ACC GCC AGC ACC A-3’  
MalE XhoI 5’-CTC GAG ATG AAA ATC GAA GAA GGT This study 
 AAA CTG GTA ATC-3’  
MalE BamHI 5’-GGA TCC TTA CTT GGT GAT ACG AGT This study 
 CTG CGC GTC TTT CAG GGC TTC ATC GAC-3’  
PhaC XbaI 5’-TCT AGA AAT AAG GAG ATA CTA GTA This study 
 TGG CGA CCG GCA AAG GCG CGG CAG  
 CTT CCA CGC AG-3’  
PhaC no stop 5’-CAT ATG TGC CTT GGC TTT GAC GTA This study 
 TCG CCC AGG-3’  
GFP no start XhoI 5’-ATG ACC TCG AGA GTA AAG GAG AAG This study 
 AAC TTT TCA CTG GAG TTG TC-3’  
GFP stop BamHI 5’-GGA TCC TCA TTT GTA TAG TTC ATC This study 
 CAT GCC ATG TGT AAT-3’  
SG linker I 5’-P-TCG AGA GCG GCG GTG GCG GTA (11), modified 
 GCG GTG GCG GTG GCA GCG GCG GTG  
 GCG GTA GCC CCG GGC-3’  
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SG linker II 5’-TCG AGC CCG GGG CTA CCG CCA (11), modified 
 CCG CCG CTG CCA CCG CCA CCG CTA  
 CCG CCA CCG CCG CTC-3’  
AscI PhaC 5’-GGC GCG CCG TGC GCG CTG CT-3’ This study 
XhoI PhaC no stop 5’-CTC GAG TGC CTT GGC TTT GAC GTA T-3’ This study 
 
PHA granule isolation, polyester and protein analysis  
Polyhydroxybutyrate (PHB) granule isolation was carried out as described previously 
(18), the polyester production was confirmed by gas chromatography/mass 
spectrometry (GC/MS) (7). PHB granule protein profiles were analyzed by SDS-PAGE 
as described elsewhere (19). The gels were stained with Coomassie brilliant blue G250.  
 
MALDI-TOF mass spectrometry  
The bead proteins were separated by SDS-PAGE and protein bands of interest were cut 
off the gel. Proteins were subjected to MALDI-TOF mass spectrometry. Identification 
of tryptic peptides was performed by collision induced dissociation tandem mass 
spectrometry and enabled identification of fusion proteins. 
 
Microscopy  
Solution of cells containing PHB granules and isolated granules were examined for 
GFP fluorescence as described previously (25). 
 
ELISA  
Enzyme-linked immunosorbent assays were normalized according to the protein 
concentration, which was determined by Bradford (6). The wells of microtiter plates 
were coated with 100 µl of a granule suspension and incubated overnight at 4˚C. After 
blocking with 3% (w/v) bovine serum albumine, each well was washed with phosphate 
buffered saline containing 0.05% Tween 20. The wells were then incubated with mouse 
monoclonal to maltose binding protein (HRP) conjugate (abcam, Cambridge, UK) for 1 
h. After extensive washing 100 µl of an o-phenylenediamine substrate solution was 
added to each well, and after 15 min the reaction was stopped by adding 100 µl of  1 N 
H2SO4. The substrate conversion was measured at 490 nm using a microtiter plate 
reader (Biotek ELX808, Biostrategy, Auckland, NZ). The IgG binding ability was 
determined as described previously (18). 
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Maltose binding assay  
PHB granule suspensions were normalized to protein concentration. 2 mg/ml protein 
was incubated with 0.6 mg/ml maltose, for 4 h at 25˚C, in small shaking Erlenmeyer 
flasks. The assay solution was centrifuged and the maltose concentration of the 
supernatant was determined using a colorimetric assay from Sigma (Sigma A3403).  
 
Results 
 
The specifically designed linker is required to allow translational fusions to the C 
terminus of the PHA synthase 
E. coli BL21(DE3) cells harbouring the plasmids pMCS69 and pET-14b PhaC-MalE 
were not able to produce detectable amounts of PHB. However, cells containing the 
plasmids pMCS69 and pET-14b PhaC-linker-MalE produced PHB, as was confirmed 
by GC/MS analysis. The linker sequence was designed to maintain the hydrophobic 
environment close to the carboxy terminus of the synthase. Hydrophobic amino acid 
residues are followed by charged amino acid residues (VLAVIDKRGGGGG) to 
facilitate proper surface display of the fusion partner. Isolated PHB granules displayed 
the fusion protein, as shown by SDS-PAGE analysis and ELISA. Despite the detection 
of MalE by ELISA, no maltose binding could be shown using the maltose binding 
assay. Hence, the linker region between PhaC and MalE was further extended and the 
respective plasmid pET-14b PhaC-linker-SG-linker-MalE encoding the fusion protein 
was constructed. The second linker sequence was inserted behind the original linker 
and consisted of a repeated serine-glycine motive (SGGGSGGGSGGGGS) which was 
already previously successfully employed as linker between PhaC and a respective 
fusion partner (12).  This plasmid also mediated PHB granule formation in recombinant 
E. coli (pMCS69) and the PHB granules displayed the fusion protein (Figure S1 in 
Supplemental Material). However, the activity of the fusion partner MalE could not be 
confirmed. 
 
An N-terminal extension of the PHA synthase restores its activity when directly 
fused to MalE  
A 458 aa long non-functional extension, designated M, of the N terminus of the 
synthase protein restored PHB granule forming activity even when the C terminus of 
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the synthase was directly fused to MalE. Cells harbouring the plasmid pET-14b M-
PhaC-MalE produced detectable amounts of PHB in recombinant E. coli (pMCS69). 
The respective fusion protein was attached to the PHB granules (Figure S1 in 
Supplemental Material, ELISA data not shown) and identified by MALDI-TOF/MS 
analysis (data not shown). Although PhaC was active, activity of the fusion partner 
MalE could not be demonstrated with the maltose binding assay. A slightly modified 
hybrid gene encoding a fusion protein with the N-terminal extension and the linker 
sequence between PhaC and MalE mediated functionality of both fusion partners Cells 
harbouring plasmids pMCS69 and pET-14b M-PhaC-linker-MalE produced PHB 
granules, as was verified by GC/MS analysis. The fusion protein was identified by 
MALDI-TOF/MS (Table ST1 in Supplemental Material) and the isolated PHB granules 
displayed the fusion protein, as demonstrated by  anti-MalE ELISA (Figure 1, Figure 
S1 in Supplemental Material). The maltose binding activity of the MalE protein was 
demonstrated using the maltose binding assay. These beads reduced the maltose 
concentration by up to 20%; control beads included in the experiment did not show any 
binding. 
 
 
 
Figure 1. Display of the maltose binding protein assessed by ELISA. PHB granules were isolated from 
BL21(DE3)(pMCS69) harbouring pET-14b M-PhaC-linker-MalE (black columns) or pETC (white 
columns). All measurements were conducted in triplicates; standard deviations are indicated. 
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The activity of the entire fusion protein is dependent on the C terminal fusion 
partner  
In order to assess whether the fusion protein data described above can be applied to 
various fusion partners, GFP was chosen as an alternative C-terminal fusion partner. 
Recombinant E. coli (pMCS69) harbouring the plasmid pET-14b PhaC-linker-GFP did 
not produce PHB, but cells showed non-localized green fluorescence, as observed by 
fluorescence microscopy (data not shown). Extending the linker region between both 
proteins resulted in detectable synthase and GFP activity. Recombinant E. coli 
(pMCS69) cells harbouring plasmid pET-14b PhaC-linker-SG-linker-GFP were able to 
synthesize PHB granules which displayed the fusion protein (Figure S2 in 
Supplemental Material). Green fluorescence of the isolated PHB beads as well as of 
cells containing granules displaying the fusion protein could be observed (data not 
shown). The fusion protein was identified by MALDI-TOF/MS (Table ST1 in 
Supplemental Material). 
To assess whether a linker would be required for the functionality of both fusion 
partners, a direct fusion of the reporter protein GFP to the C terminus of the PHA 
synthase was constructed. This enabled the production of the fusion protein which was 
identified by MALDI-TOF/MS (Table ST1 in Supplemental Material). Recombinant E. 
coli (pMCS69) harbouring plasmid pET-14b PhaC-GFP produced PHB granules, as 
was confirmed by GC/MS analysis. SDS-PAGE analysis (Figure S2 in Supplemental 
Material) and fluorescence microscopy confirmed the display and functionality of the 
respective fusion protein at the granule surface (data not shown). 
 
Translational fusions to the N and C terminus of the PHA synthase mediate 
simultaneous display of two protein function at the bead surface  
After the successful engineering of the synthase C terminus for the display of one 
protein function, the possibility of the simultaneous display of two protein functions by 
generating one tripartite fusion protein was assessed. Therefore, plasmid pET-14b ZZ-
PhaC-GFP was constructed and recombinant E. coli BL21 (pMCS69) harbouring this 
plasmid were able to produce PHB beads as verified by GC/MS. The fusion protein 
comprising the IgG-binding domain ZZ, the PHA synthase PhaC and the GFP protein 
was displayed at the polyester bead surface (Figure S3 and Table ST1 in Supplemental 
Material). These multifunctional PHB beads showed green fluorescence (data not 
shown) and were also able to bind IgG, as was shown by ELISA (Figure 2). 
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Figure 2. IgG binding ability of the tripartite synthase fusion protein assessed by ELISA. PHB granules 
were isolated from BL21(DE3)(pMCS69) harbouring either pETC (black columns), pET-14b ZZ(-)phaC 
(white columns) or pET-14b ZZ-PhaC-GFP (grey columns). All measurements were conducted in 
triplicates; standard deviations are indicated. 
 
Discussion 
 
This study provided insights into a new mode of functional display at the PHA granule 
surface, employing the C terminus of the class I PHA synthase as fusion target. The 
nature of the protein translationally fused to the C terminus of PhaC affects the activity 
of both fusion partners. Maintaining the hydrophobic environment around the C 
terminus of the synthase was found to be required to retain activity (30, 31).  In contrast 
to N-terminal fusions some C-terminal fusions were inactivating the PHA synthase 
(Figure 3). MalE directly fused to the synthase C terminus led to inactivation, while a 
direct fusion of GFP to the C terminus of PhaC led to PHB granule formation and 
display of the functional fusion partner. A hydrophobicity analysis of the N-terminal 
regions of MalE and GFP showed that GFP comprises an extended hydrophobic region 
similar to the designed linker region (5, 10), whereas the N-terminal region of MalE 
was found to be hydrophilic. This suggested that the hydrophobic N terminus of GFP, 
when directly fused to PhaC, does not interfere with the proposed anchor function of 
the hydrophobic C terminus of the PHA synthase. However, MalE was shown to be 
compatible with various proteins when translationally fused to the N and C terminus of 
the respective protein (13). Intriguingly, the insertion of the designed linker between 
PhaC and GFP inactivated PhaC, whereas a further extension of the linker by an 
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additional SG-linker did not interfere with PHA synthase activity. These data implied 
that the N terminus of GFP provides inherently the hydrophobic environment needed 
by the synthase protein to remain active and the linker length inserted between PhaC 
and GFP is critical for PHA synthase activity.  
 
 
Figure 3. Schematic overview of hybrid genes used in this study. PHB production was assessed by 
GC/MS analysis. The activity of the fusion partner was either assessed by fluorescence microscopy for 
GFP or maltose binding for MalE. The surface display of the fusion partner MalE was assessed by 
ELISA. * The IgG binding acitivity as well as the surface display of ZZ was assessed by ELISA. 
 
Previously, the immobilization of proteins which needed a free carboxy terminus for 
activity, to the surface of PHA granules, was only possible when fused to the granule 
associated structural protein PhaP (2-4). In contrast to the phasin proteins, the PHA 
synthase, which is the only essential protein for granule formation, is covalently 
attached to the polyester granule surface. Therefore, utilizing the PhaC protein to fuse 
proteins of interest either N- or C-terminally, would allow a variety of proteins to be 
displayed on the PHA granule surface. In addition, simultaneous fusions to the N and C 
terminus, as shown with the tripartite fusion protein ZZ-PhaC-GFP, enables the display 
of two functionalities without the need for any additional protein anchor. 
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Figure S1. Protein profile of different PHB granules demonstrated by SDS-PAGE analysis. M, 
molecular mass standard (New England Biolabs, UK); lane 1, BL21(DE3)(pETC); lane 2, 
BL21(DE3)(pET-14b M-PhaC); lane 3, BL21(DE3)(pET-14b M-PhaC-MalE); lane 4, BL21(DE3)(pET-
14b M-PhaC-linker-MalE); lane 5, BL21(DE3)(pET-14b PhaC-linker-SG-linker-MalE). 
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Figure S2. Protein profile of different PHB granules demonstrated by SDS-PAGE analysis. M, 
molecular mass standard (New England Biolabs, UK); lane 1, BL21(DE3)(pETC); lane 2, 
BL21(DE3)(pET-14b PhaC-linker-SG-linker-GFP); lane 3, BL21(DE3)(pET-14b PhaC-GFP). 
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Figure S3. Protein profile of different PHB granules demonstrated by SDS-PAGE analysis. M, 
molecular mass standard (New England Biolabs, UK); lane 1, BL21(DE3)(pETC); lane 2, 
BL21(DE3)(pET-14b ZZ-PhaC-GFP). 
 
 
 
 
Table ST1. Identified peptide fragments of protein analyzed by MALDI-TOF/MS 
Protein identified peptide fragments 
PhaC-linker-SG-linker-GFP V21-R36, I63-R74, T109-R125, F115-R125, A126-R141, F146-R169, 
  L170-R180, G193-R207, I195-R207, N208-K234, Y250-R263, 
 H264-R278, N279-R299, L456-R478, F501-K518, A564-R573, 
 G630-K652, T723-R735 
M-PhaC-linker-MalE T21-R48, A53-R67, Y68-R79, A118-R143, E207-R234, L368-R376, 
 L442-K464, V480-R495, I522-R533, F574-R584, F605-R628,  
 L629-R639, I654-R666, N667-K693, Y709-R722, H723-R737, 
 E830-R845, G846-K872, L915-R937, L1168-K1192, G1317-K1338, 
 G1392-R1409 
PhaC-GFP I63-R74, T109-R125, F115-R125, A126-R141, L170-R180, L170-R184, 
 G193-R207, R563-R573, A564-R573, Y574-K586, A576-K586,  
 T687-R699 
ZZ-PhaC-GFP S149-R169, V154-R169, I196-R207, Y208-K223, A224-R234, F248- 
 R258, A259-R274, I277-R302, F279-R302, L303-R313, G326-R340, 
 I328-R340, N341-K367, Y383-R396, H397-R411, N412-R432, D439- 
 R468, E504-R519, G520-K546, L589-R611, E612-K631, F634-K651, 
 A697-R706, S809-R819, T820-R832, A833-R845, A833-K849, G850- 
 K863, D939-K961 
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Multifunctional Inorganic-Binding Beads Self-Assembled 
Inside Engineered Bacteria 
 
Anika C. Jahns, Richard G. Haverkamp and Bernd H. A. Rehm 
 
Abstract 
 
Multifunctional shell-core nano/micro-beads with a hydrophobic biopolymer core and a 
designed protein coat for selective binding of an inorganic substance and antibodies 
were self-assembled inside engineered bacteria. Hybrid genes were constructed to 
produce tailor-made bead-coating proteins in the bacterium Escherichia coli. These 
fusion proteins contained a binding peptide for an inorganic material, the antibody 
binding ZZ domain and a self-assembly promoting as well as biopolymer synthesizing 
enzyme. Production of these multi-domain fusion proteins inside E. coli resulted in 
self-assembly of beads comprising a biopolyester core and displaying covalently bound 
binding sites for specific and selective binding of an inorganic substance and any 
antibody belonging to the immunoglobulin G class. Engineered beads were isolated and 
purified from the respective E. coli cells by standard cell disruption procedures. Bead 
morphology and the binding functionalities displayed at the bead surface were assessed 
by the enzyme-linked immunosorbent assay, transmission electron microscopy, 
elemental analysis, backscattering electron density, analytical density 
ultracentrifugation, and atomic force microscopy. These analyses showed that bacteria 
can be engineered to produce fusion proteins mediating self-assembly of spherical 
biopolymer beads with binding affinity to gold and/or silica and antibodies. Spherical 
structures of this type could conceivably serve as nano/micro-devices for bioimaging in 
medical approaches where an antibody mediated targeted delivery of an inorganic 
contrast agent would be desired. 
Introduction 
Biological structures that specifically bind inorganics exert numerous potential 
biomedical applications. Therefore, the exploration of nature’s structures for this 
purpose and the establishment of novel production methods is of great interest. In 
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particular, beads (nano- or micro-beads) made of biological and inorganic materials are 
suitable for a variety of applications such as, e.g., diagnostics (1, 2), imaging (3), and 
drug delivery (4). In binding assays, it was demonstrated that nanobeads displaying an 
antibody at high density show a higher binding affinity than the antibody itself 
enhancing the sensitivity of a diagnostic assay (5). Molecular biomimetic approaches 
have been used to specifically coat biological nanostructures, such as, e.g., self-
assembling virus beads, with various inorganics for applications in imaging, biosensing, 
laboratory methods, and electronics (6, 7). Genetically engineered proteins for 
inorganics (GEPI) have been obtained using combinatorial approaches including phage 
display or cell surface display in order to select peptides binding inorganics (8). 
Peptides were isolated specifically binding (noble) metals, semiconducting oxides, and 
other technological compounds (7-11). This ultimately enabled the use of biological 
structures with protein components as templates for the defined nanoscale deposition of 
inorganics as well as control of geometrical shapes and sizes of inorganic nanobeads. 
This was achieved by engineering of proteins contributing to these structures enabling 
display of GEPIs for binding of inorganics (7-11). This resembles the morphogenesis in 
hard tissues (such as bones, dental tissues, mollusk shells, spicules) which is controlled 
by inorganic-binding proteins.  
In this study, microbial polymer inclusions (50-300 nm) were conceived as biological 
template structures (12-14). These spherical inclusions are self-assembled inside the 
bacterial cell mediated by a single protein, the polyester synthase (PhaC) (15, 16). The 
polymer inclusions serve as reserve materials and comprise a hydrophobic polyester 
core surrounded by at least the PhaC protein (17). This natural polyester is composed of 
(R)-3-hydroxy fatty acids. Interestingly, PhaC catalyzes the core polymer synthesis as 
well as is required for the self-assembly. Moreover, PhaC has been found to remain 
covalently attached to the polymer core (18, 19). Further structural proteins (e.g., PhaP) 
have been found to specifically hydrophobically interact with the polymer core, but are 
not required for self-assembly (15, 20-22). Protein engineering of the synthase or 
structural proteins demonstrated that various functional proteins can be displayed at the 
polymer inclusions surface and that these inclusions can be stably maintained outside 
the cell as beads (18, 23-28). Here, it was demonstrated that genetic fusions of GEPIs to 
PhaC or previously engineered PhaC enabled production of beads that bind inorganic 
and biological molecules simultaneously. In this study, the antibody binding domain of 
protein A from Staphylococcus aureus was used as an additional binding functionality, 
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which ultimately enabled the production of spherical nano/micro-beads that could 
specifically bind not only any specific antibody but also an inorganic as suitable 
contrast agent applicable for, e.g., bioimaging approaches (29) (Figure 1). Moreover, 
the use of engineered E. coli as cell factory to produce functionalized beads in one step 
provides an efficient and economic production strategy.   
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Figure 1. Schematic overview of polymer bead assembly.  
Experimental Procedures 
Bacterial Strains, Plasmids, Oligonucleotides, and DNA Constructs  
Bacterial strains, plasmids and oligonucleotides used in this study are listed in Table 1. 
E. coli XL1-Blue was grown at 37˚C, BL21(DE3) at 25˚C. When required, ampicillin 
75 µg/ml, tetracycline 12.5 µg/ml, or chloramphenicol 50 µg/ml were added. All 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
General cloning procedures and isolation of DNA were performed as described 
elsewhere (30). DNA primers, deoxynucleoside triphosphate, T4 DNA ligase and Taq 
polymerase were purchased from Invitrogen TM (CA, USA). DNA sequences of new 
plasmid constructs were confirmed by DNA sequencing according to the chain 
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termination method using an automatic sequencer (Applied Biosystems, 3730 DNA 
Analyzer).  
Gold-Binding Beads 
To enable production of fusion proteins mediating production of polymer beads 
selectively binding gold, the GBP1 (31) encoding DNA sequence was inserted as a 
DNA fragment, composed of hybridized oligonucleotides GNI and GNII (Table 2), into 
the restriction enzyme sites XbaI/NdeI of plasmid pCWE. The resulting pCWE-GN-
phaC contained the respective hybrid gene and was transformed into E. coli XL1-Blue 
harboring the plasmid pMCS69, which mediates synthesis of the polymer precursor 
required for bead production. A DNA sequence showing three repeats of the gold-
binding peptide (32) was synthesized (DNA 2.0, Inc., CA, USA). The corresponding 
XbaI/SunI fragment was inserted into plasmid pCWE, which was previously engineered 
to encode a pentaglycine linker and the ZZ domain of protein A both fused to the N 
terminus PhaC. The resulting plasmid pCWE-3xGN-G5-ZZ-phaC was used to 
transform E. coli XL1Blue (pMCS69). To enable overproduction of the respective 
fusion protein, the corresponding hybrid gene was overexpressed under the control of 
the strong T7 promoter. Therefore, the hybrid genes were inserted into the XbaI/BamHI 
site of vector pET-14b. The resulting plasmid pET-14b-3xGN-G5-ZZ-phaC was used to 
transform E. coli BL21(DE3) harboring plasmid pMCS69. 
Bead formation was assessed by analyzing the polyester constituting the bead core 
using gas chromatography-mass spectrometry as previously described (16). Moreover, 
beads formed inside the bacterial cell were stained with Nile red and observed using 
fluorescence microscopy as well as subjected to electron microscopy (16). 
Silica-Binding Beads  
To produce polymer beads with silica/antibody binding properties, the DNA sequence 
encoding the silica-binding peptide (33) encoding XbaI/NdeI DNA fragment, which 
was generated by hybridization of oligonucleotides SNI and SNII (Table 2), was ligated 
to the 5’ end of phaC in plasmid pCWE. Together with pMCS69, this construct led to 
bead formation in E. coli XL1Blue. To achieve overproduction of the respective fusion 
proteins at the bead surface and thereby enhance the binding density, hybrid genes 
encoding fusion proteins were expressed under control of the strong T7 promoter. 
Therefore, the 1838 bp XbaI/BamHI fragment was inserted into the respective sites of 
plasmid pET-14b and then transformed into E. coli BL21(DE3) cells harboring the 
plasmid pMCS69. A hybrid gene similar to the hybrid gene encoding the extended 
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gold-binding fusion protein was also constructed by using the oligonucleotides SN+I 
and SN+II (Table 2). This hybrid gene was inserted into plasmid pCWE which resulted 
in plasmid pCWE-SN-G5-ZZ-phaC. The hybrid gene comprising the 2261 bp 
XbaI/BamHI fragment was then subcloned into the respective sites of pET-14b to 
enable overexpression under T7 promoter control. 
Multifunctional Beads  
To synthesize polymer beads with gold, silica and antibody binding capability, the SN-
G5-ZZ(-)phaC sequence was amplified by PCR using oligonucleotides 3’PhaC-BlpI and 
BamHI-SN+ (Table 2). The PCR product was confirmed by DNA sequencing and 
ligated into BamHI/BlpI site of plasmid pET-14b-3xGN-G5-ZZ(-)phaC which resulted 
in plasmid pET-14b-3xGN-G5-ZZ(-)phaC/SN-G5-ZZ(-)phaC. This new plasmid was 
used to transform competent E. coli BL21(DE3) cells harboring pMCS69 and to 
mediate production of multifunctional beads. 
 
Table 1. Bacterial Strains, Plasmids, and Oligonucleotides Used for the Generation of Hybrid Genes as 
Well as Engineered Bacteria in Order to Produce Designed Biopolymer Beads 
E. coli strain, plasmid, or 
oligonucleotide 
genotype source or reference 
 Strains  
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17 (r-k, m+k), (47) 
 supE44, relA1, -, lac[F', proAB, lacIq, lacZ∆M15, 
 
 Tn10(Tcr)] 
 
BL21(DE3) F-, ompT, hsdSB (rB- mB-), gal, dcm (DE3) Novagen 
 Plasmids  
pBHR68 PHB biosynthesis operon from Cupriavidus (48) 
 necator in  pBluescript SK-  
pHAS pET-14b containing NdeI/BamHI-inserted phaC (49) 
 gene from C. necator  
pET-14b Apr, T7 promoter Novagen 
pET-14b-ZZ(-)phaC pET-14b containing XbaI/BamHI fragment (28) 
 comprising gene ZZ-phaC  
pCWE pBluescript SK- derivative containing the PHA (16) 
 synthase gene from C. necator  
pCWE-ZZ(-)phaC pCWE derivative containing the ZZ domain-encoding (28) 
 NdeI fragment lacking the signal sequence-encoding  
 region  
pMCS69 pBBR1MCS derivative containing genes phaA and (50) 
 phaB of C. necator colinear to lac promoter  
pCWE-GNphaC pCWE derivative containing a XbaI/NdeI fusion this study 
 of GN to 5' end of phaC  
pCWE-SNphaC pCWE derivative containing a XbaI/NdeI fusion this study 
 of SN to 5' end of phaC  
pCWE-3xGN-G5-ZZ(-)phaC pCWE derivative containing XbaI/SunI fusion of this study 
 3GN to 5' end of ZZ(-)phaC  
pCWE- SN-G5-ZZ(-)phaC pCWE derivative containing XbaI/SunI fusion of this study 
 SN+ to 5' end of ZZ(-)phaC  
pET-14b-3xGN-G5-ZZ(-)phaC pET-14b derivative containing 2345 bp XbaI/BamHI this study 
 fragment of pCWE-3xGN-G5-ZZ(-)phaC  
pET-14b-SN-G5-ZZ(-)phaC pET-14b derivative containing 2261 bp XbaI/BamHI this study 
 fragment of pCWE-SN-G5-ZZ(-)phaC  
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pET-14b-SNphaC pET-14b derivative containing 1838 bp XbaI/BamHI this study 
 fragment of pCWE-SNphaC  
pET-14b-3xGN-G5-ZZ(-)phaC / pET-14b-3xGN-G5-ZZ(-)phaC derivative containing this study 
SN-G5-ZZ(-)phaC BamHI/BlpI SN-G5-ZZ(-)phaC PCR product  
 Oligonucleotides  
GNI 5’-P-CTA GAA ATA AGG AGA TAT AGC AAT this study 
 GCA TGG CAA AAC CCA GGC GAC CAG CGG  
 CAC CAT TCA GAG CCA -3’  
GNII 5’-P-TAT GGC TCT GAA TGG TGC CGC TGG this study 
 TCG CCT GGG TTT TGC CAT GCA TTG CTA TAT  
 CTC CTT ATT T -3’  
SNI 5’-P-CTA GAA ATA AGG AGA TAT AGC AAT this study 
 GAG CCC GCA TCC GCA TCC GCG CCA TCA  
 TCA TAC CCA -3’  
SNII 5’-P-TAT GGG TAT GAT GAT GGC GCG GAT this study 
 GCG GAT GCG GGC TCA TTG CTA TAT  
 CTC CTT ATT T -3’  
SN+I 5’-P-CTA GAA ATA AGG AGA TAC TAG TAT this study 
 GAG CCC GCA TCC GCA TCC GCG CCA TCA  
 TCA TAC CCT CGA GC -3’  
SN+II 5’-P-GTA CGC TCG AGG GTA TGA TGA TGG this study 
 CGC GGA TGC GGA TGC GGG CTC ATA CTA  
 GTA TCT CCT TAT TT -3’  
3’PhaC-BlpI 5’- GCT CAG CGG TCA TGC CTT GGC TTT this study 
 GAC GTA TCG CCC -3’  
BamHI-SN+ 5’- GGA TCC AAT AAG GAG ATA CTA GTA this study 
 TGA GCC CGC ATC CGC AT -3’  
 
 
Isolation of Polymer Beads  
The polymer beads were isolated by harvesting respective cells using centrifugation for 
20 min at 6000 x g and 4˚C. The sediment was washed and suspended in 3 volumes of 
50 mM phosphate buffer (pH 7.5). Cells were passed through a French Press two times 
at 16 kpsi. The cell lysate (0.75 ml) was loaded onto a glycerol gradient (88% and 44% 
(v/v) glycerol in phosphate buffer). After ultracentrifugation for 2.5 h at 100 000 x g 
and 10˚C, beads could be isolated from a white layer above the 88% glycerol layer. The 
PHA beads were washed with 10 volumes phosphate buffer (50 mM, pH 7.5) and 
centrifuged at 100 000 x g for 60 min at 10˚C. The sediment containing the PHA beads 
was suspended in phosphate buffer and stored at 4˚C. 
 
Gold-Binding Assay  
The gold-binding was carried out at 20oC in PKT buffer (10 mM KPO4 (pH 7), 0.1 M 
KCl, 1% TritonX-100) with 250 µM HAuCl4 and 200 µM sodium ascorbate according 
to Brown (31). For a 10 ml assay, a 1 mg/ml bead protein solution was used. The whole 
assay was incubated on a shaker until a pink color appeared, indicating the formation of 
colloidal gold. To let the gold bind to the peptides, the solution was further incubated. 
To wash the unbound gold out of the sample, the assay was centrifuged at 4000 x g for 
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15 min. The resulting sediment was suspended in 1 ml PKT buffer and loaded on a 
sucrose gradient (2.25 M – 0 M, 0.25 M increments, sucrose in PKT buffer). This 
gradient was undergoing ultracentrifugation for approximately 16 h at 100 000 x g. The 
resulting layer at 2 or 2.25 M sucrose, consisting of beads and gold, was washed with 
PKT buffer and centrifuged in an ultracentrifuge for 1 h at 100 000 x g. The sediment 
was used for TEM analysis and AFM measurements.  
 
Silica-Binding Assays  
The silica-binding assay was performed at room temperature according to Dickerson et 
al. (34). 1 mg/ml bead protein was dissolved in 50 mM potassium phosphate buffer, pH 
7.5. The silica solution was freshly prepared by dissolving tetramethyl orthosilicate 
(TMOS, Sigma-Aldrich, St. Louis, MO) in 1 mM HCl to a final concentration of 1 M. 
The silica solution was then added to the protein solution so that the final concentration 
of TMOS in the silica-binding assay was 0.1 M. This mixture was then incubated on a 
shaker for 10 min and centrifuged for 5 min at 13 000 rpm. The sediment was washed 
three times with 50 mM potassium phosphate buffer, pH 7.5, to remove unbound silica. 
To investigate the bead density changes due to silica binding, the washed sediments 
were suspended in 50 mM potassium phosphate buffer, pH 7.5, and separated using a 
sucrose gradient (0 – 2.25 M sucrose in 0.25 M increments, sucrose in 50 mM 
potassium phosphate buffer, pH 7.5). These gradients underwent ultracentrifugation at 
100 000 x g for 16 h at 10˚C. The resulting layers or sediments were washed in 50 mM 
potassium phosphate buffer, pH 7.5, and used for further investigations. In another 
silica binding assay, 0.5 mg/ml bead protein suspension was mixed with 0.003 g/ml 
SiO2 (silica beads with a size range of 1-5 µm) in potassium phosphate buffer and 
incubated on a shaker at room temperature for 4 h. The mixture was separated by 
sucrose gradient ultracentrifugation. The protein concentration of resulting layers and 
sediments was determined by Bradford (35). To qualitatively assess the binding of the 
engineered polymer beads to silica beads, fluorescence microscopy was used. For this 
purpose, the polymer beads were selectively stained with the hydrophobic fluorescent 
dye Nile red.  
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 ELISA  
For the enzyme-linked immunosorbent assay (ELISA), the wells of microtiter plates 
were coated with 100 µl of a polymer bead suspension (normalized to protein 
concentration, in a range from 0.05 µg/µl to 0.4 x 10-3 µg/µl) and incubated overnight 
at 4˚C. After being blocked with 3% (w/v) bovine serum albumin for 2 h, each well was 
incubated with 10 nm Gold-biotin (Nanocs Inc., New York, USA) for 2 h followed by 1 
h incubation with streptavidin-horseradish peroxidase conjugate (streptavidin-HRP; 
Sigma-Aldrich, St. Louis, MO). After each step, the wells were washed several times 
with phosphate-buffered saline containing 0.05% Tween 20. As substrate, 100 µl of an 
o-phenylenediamine solution (Abbott Diagnostics, IL, USA) was added to each well, 
and after 15 min, the reaction was stopped by adding 100 µl of 1 N H2SO4. The amount 
of substrate conversion was measured at a wavelength of 490 nm using a microtiter 
plate reader.  
 
Protein Analysis  
Bead protein profiles were routinely analyzed by sodium dodecyl sulphate (SDS)-
polyacrylamide gel electrophoresis (PAGE) as described elsewhere (36). The gels were 
stained with Coomassie brilliant blue G250.  
In order to identify proteins linked to the polymer beads, the bead proteins were 
separated by SDS-PAGE and protein bands of interest were cut off the gel. Proteins 
were subjected to MALDI-TOF mass spectrometry. Identification of tryptic peptides 
was performed by collision-induced dissociation tandem mass spectrometry and 
enabled identification of fusion proteins. 
To identify N-terminally fused GEPIs, fusion proteins were subjected to N terminal 
sequencing using Edman degradation. 
 
Microscopic Analysis  
Atomic force microscopy imaging was performed on an Asylum Research MFP-3D 
instrument (Asylum Research, Santa Barbara, CA) in ac mode. All images were 
recorded in potassium phosphate buffer solution at a concentration of beads 
corresponding to 1-10 µg protein/ml. Higher bead concentrations were not used, as they 
resulted in scattering of the laser, which obscured the signal reflected from the 
cantilever and inhibited AFM operation. Approximately 100 µl of bead suspension was 
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placed on a gold-coated mica substrate shortly before imaging. AFM cantilevers were 
either silicon Ultrasharp NSG11 (NT–MDT Co, Moscow, Russia) with force constants 
in the range 5 – 25 N/m and a tip radius around 10 nm, or silicon nitride TR400PSA 
(Olympus Corporation, Japan) with a force constant around 0.08 N/m and a tip radius < 
20nm. Images of 512 x 512 points were collected at line scan frequencies of 1 – 8 Hz.  
For transmission electron microscopy (TEM) analysis, cells or beads were prepared as 
described previously (26). Sections were stained and assessed using a Philips CM10 
TEM. To visualize the gold-binding, the beads were incubated with colloidal gold as 
described above in the gold-binding assay. Beads with bound colloidal gold or control 
beads not binding colloidal gold were then subjected to TEM sample preparation. 
For elemental analysis, freeze-dried bead samples were mounted, using double- sided 
tape, on an aluminum specimen stub and then carbon-coated for EDS (energy 
dispersive spectrometry). Analysis was done using EDAX EDS system (EDAX, 
Mahwah, USA) in a FEI Quanta 200 SEM (scanning electron microscope; FEI, 
Eindhoven, The Netherlands). For imaging the gold in the samples, the BSED (back 
scattered electron detection) mode was used. 
 
 Table 2. Identified Peptide Fragments of Proteins Analyzed by MALDI-TOF/MS 
Protein Identified peptide fragments     
SN-G5-ZZ-PhaC F34-R56, E37-R56, V175-R190, I217-R228, F269-R279, F300-R323,   
 L324-R334, I349-R361, N362-K388, Y404-R417, H418-R432, N433-R453,  
 G541-K567, L551-K567, E633-K652    
3xGN-G5-ZZ-PhaC T5-K32 or F120-R142 or F62-R84, E65-R84 or E123-R142,    
 N85-K106 or N143-K164, V174-R181, V203-R218, Q219-K244, I245-R256,   
 Y257-K272, D260-K272, D260-R282, R283-R290, F284-R290, T291-R307, 
  F297-R307, A308-K321, I326-R351, F328-R351, L352-R362, N367-R374,  
 G375-R389, I377-R389, N390-K416, Y432-R445, H446-R460, N461-R481, 
  I488-L517, Q553-A568, L569-N595, Y625-N633, P638-H660, I661-F680,  
  G683-R700           
 Results 
Design and Production of Bifunctional Gold/Antibody Binding Beads 
The capability of bacteria to produce intracellular granules with a hydrophobic 
biopolymer core and proteins attached to its surface from various cheap carbon and 
energy sources, such as, e.g., glucose, was utilized in this study to produced tailor-made 
nano/micro-beads suitable for molecular biomimetics.  
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The bead-forming and coating protein PhaC was engineered to enable simultaneous 
bead surface display of the gold-binding peptide GBP1 (31) and the antibody (IgG) 
binding ZZ domain (37). This strategy harnesses nature’s capability to covalently cross-
link the PhaC protein to polymer inclusions, which can be isolated and maintained as 
spherical beads with defined surface binding functionality (26). In order to produce the 
various multi-functional fusion proteins in the bacterium E. coli that mediate 
production of gold-binding polymer beads, the respective hybrid genes were 
constructed and inserted into an overexpression vector under control of the strong T7 
promoter. In general, bead formation was monitored by polyester accumulation 
analysis, fluorescence microscopy of Nile red stained cells, and TEM. A fusion protein 
with only one gold-binding peptide did not mediate production of beads showing gold-
binding affinity (data not shown). However, the use of three gold-binding peptide 
repeats, a pentaglycine spacer region followed by the IgG-binding domain fused to 
PhaC, mediated formation of beads with specific gold and antibody binding properties. 
This fusion protein 3xGN-G5-ZZ-PhaC at the bead surface was demonstrated by SDS-
PAGE and was confirmed by MALDI-TOF/MS and N-terminal sequencing (Figure 2, 
Table 2). The SDS-PAGE analysis also showed an additional but less abundant 97 kDa 
protein, which was identified as copurified ATPase (Accession No. P0ABB9) derived 
from the production host E. coli. 
 
M 1 2
ZZ-PhaC
3xGN-ZZ-PhaC
kDa
97.2
66
43
56
 
Figure 2. Protein profile of polymer beads displaying gold binding peptides. M, molecular mass standard 
(New England Biolabs, United Kingdom); Lane 1, polymer beads from E. coli BL21(DE3) (pET-14b-
ZZ(-)phaC); lane 2, polymer beads from E. coli BL21(DE3) (pET-14b-3xGN-G5-ZZ(-)phaC).  
 
To quantitatively assess the gold-binding activity of these novel polymer beads, an 
enzyme-linked immunosorbent assay was established employing the binding of 
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biotinylated gold particles. Biotinylated gold particles bound to the beads were detected 
using streptavidin-HRP conjugate. The absorbance at 490 nm was increased at least 10-
fold using the gold-binding peptide displaying beads when compared to the control 
beads not displaying the peptide (Figure 3A). Furthermore, elemental analysis and 
back-scattered electron density analysis was applied to confirm the presence of gold 
bound to the engineered beads (data not shown). The bead shape and size distribution 
was assessed by atomic force microscopy (data not shown). 
The triple gold-binding peptide-ZZ-PhaC fusion protein additionally showed IgG 
binding activity due to a functional ZZ domain between the gold-binding peptides and 
PhaC. This activity was assessed by ELISA as previously described (28) (Figure 3B).  
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Figure 3. (A) Gold binding of various polymer beads assessed by ELISA. Polymer beads were isolated 
from E. coli BL21(DE3) harboring pET-14b-3xGN-G5-ZZ(-)phaC (black columns) or pET-14b-ZZ(-
)phaC (white columns). Streptavidin-HRP conjugate was used to detect bound 10 nm Biotin-Gold. 
Measurements were conducted in triplicates, the standard deviation is indicated. (B) Impact of gold-
binding on IgG binding of various polymer beads assessed by ELISA. Polymer beads were isolated from 
E. coli BL21(DE3) harboring pET-14b-3xGN-G5-ZZ(-)phaC and incubated with gold followed by an 
incubation with human IgG (3xGN-ZZ-PhaC + Au&IgG, black columns). As controls beads isolated 
from E. coli BL21(DE3) harboring pET-14b-ZZ(-)phaC were used and treated in the same way (gold 
incubation followed by human IgG incubation as ZZ-PhaC + Au&IgG, white columns). Goat polyclonal 
anti-human IgG-horseradish peroxidase conjugate was used for detection of bound human IgG. All 
measurements were conducted in triplicates, standard deviations are indicated. 
 
The gold-binding was visualized by transmission electron microscopy (TEM) (Figure 
4). To further study gold-binding and its impact on bead density, sucrose density 
gradients using ultracentrifugation were applied. The incubated samples as well as 
control samples were analyzed by sucrose gradient ultracentrifugation. Samples that 
were not incubated with colloidal gold formed a layer located at a density 
corresponding to < 2 M sucrose (d =1.33 g/ml). Control beads, PhaC(-)ZZ beads only 
displaying the IgG binding domain, when incubated with gold did not show a shift in 
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density. In contrast, beads displaying the gold-binding peptides migrated further in the 
density gradient and formed a layer corresponding to a density of < 2.25 M sucrose (d = 
1.4 g/ml) when incubated with gold (Figure 5). Overall, these data suggested that the 
engineered beads displayed both binding functionalities (Figure 6). 
 
           
200 nm
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Figure 4. TEM images of polymer beads after incubation with colloidal gold. (A) Polymer beads 
displaying ZZ(-)phaC protein at the surface. (B) Polymer beads coated with the engineered protein 
3xGN-G5-ZZ(-)phaC mediating display of the gold-binding peptide. The pictures show slices through 
polymer beads embedded in BSA. 
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Figure 5. Gold-binding to polymer beads demonstrated by density dependent migration in a sucrose 
gradient using ultracentrifugation. Arrows indicate where the beads accumulated in the sucrose 
gradient after ultracentrifugation after incubation with 250 µM  colloidal gold (+) and without (-). 
Lanes 1, 2, polymer beads from E. coli BL21(DE3)(pET-14b-3GN-G5-ZZ(-)phaC); lanes 3, 4, 
polymer beads from E. coli BL21(DE3)(pET-14b-ZZ(-)phaC). 
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Figure 6. Scheme of the surface of a bifunctional gold/antibody binding polymer bead. 
 
Design and Production of Bifunctional Silica/Antibody Binding Beads  
As described above for the design of the gold/antibody-binding peptide displaying 
beads, hybrid genes were constructed to enable production of multifunctional fusion 
proteins mediating formation of silica/antibody-binding polymer beads. Hybrid genes 
were overexpressed in E. coli and the resulting beads were isolated and characterized 
(Figure 7).  The fusion protein SN-G5-ZZ-PhaC was confirmed by MALDI-TOF/MS 
and N terminal sequencing (Table 2). The SDS-PAGE analysis also showed an 
additional but less abundant 97 kDa protein, which was identified as copurified ATPase 
(accession no. P0ABB9) derived from the production host E. coli. 
The ability of the respective beads displaying silica-binding peptides to bind silica was 
shown using two different methods assessing either binding of silica to the bead surface 
or binding of the engineered polymer beads to commercially available silica beads. 
Beads displaying silica-binding peptides and control beads were incubated with TMOS 
dissolved in HCl and then separated by sucrose density ultracentrifugation as described 
in the Experimental Procedures. Different migration behavior of the engineered and 
control beads was observed representing a change in bead density (Figure 8A). PhaC(-
)ZZ beads formed a layer at the 2 M sucrose  (d = 1.33 g/ml) independent on treatment 
with TMOS. The respective beads self-assembled using fusion protein SN-G5-ZZ-PhaC 
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Figure 7. Protein profile of polymer beads displaying silica binding peptides. M, molecular mass 
standard (Amersham Biosciences, USA); lane 1, polymer beads from E. coli BL21(DE3) (pHAS); lane 2,  
polymer beads from E. coli BL21(DE3) (pET-14b-ZZ(-)phaC); lane 3, polymer beads from E. coli 
BL21(DE3) (pET-14b-SN-G5-ZZ(-)phaC). 
 
showed a density greater than the control beads and assembled at 2.25 M sucrose (d = 
1.4 g/ml) after treatment with TMOS. These findings were additionally confirmed by 
elemental analysis showing silica only present in the engineered bead samples (data not 
shown). The direct fusion of the silica binding peptide to the N terminus of PhaC 
resulting in SN-PhaC did not result in an increased density. These beads always 
behaved like the control beads without binding peptide.  
Commercially available silica beads (Silicon dioxide, 1-5 µm; Sigma-Aldrich, St. 
Louis, MO) were used as second method to qualitatively assess silica binding by 
the engineered beads. Fusion and control beads were incubated with silica beads 
and separated using sucrose density ultracentrifugation as described in the 
Experimental Procedures. Protein determination by Bradford (35) was used to 
quantify binding. The respective control beads PhaC(-)ZZ showed about 85% of 
the protein content at a density corresponding to the polymer beads not bound to 
the commercial silica beads, and about 15% was found at much greater density in 
the sediment colocalizing with the commercial silica beads. In contrast, about 70% 
of beads displaying the silica-binding peptide employing fusion protein SN-G5-
ZZ-PhaC colocalized with the commercial silica beads when separated in sucrose 
density ultracentrifugation (Figure 8B).  
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Figure 8. Silica-binding to polymer beads demonstrated by density dependent migration in a 
sucrose gradient using ultracentrifugation. (A) Images of tubes used for density assessment. 
Arrows indicate where the beads accumulated in the sucrose gradient after (+) and without (-) 
TMOS incubation. Lanes 1, 2, polymer beads from E. coli BL21(DE3) (pET-14b-SN-G5-ZZ(-
)phaC); lanes 3, 4, polymer beads from E. coli BL21(DE3) (pET-14b-ZZ(-)phaC). (B) Images of 
tubes used for density assessment. Arrows indicate the areas where the main part of the beads 
accumulated after SiO2 binding (+) and without (-). Lanes 1, 2, polymer beads from E. coli 
BL21(DE3) (pET-14b-SN-G5-ZZ(-)phaC); lanes 3, 4, polymer beads from E. coli BL21(DE3) 
(pET-14b-ZZ(-)phaC).  
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Design and Production of Multifunctional Gold/Silica/Antibody Binding Beads  
As described for the design of the bifunctional beads, hybrid genes mediating 
production of multifunctional gold/silica/antibody-binding polymer beads were 
constructed and overexpressed in E. coli. Two different hybrid genes each encoding a 
fusion protein comprising bead forming and inorganic binding domain were co-
expressed to mediate production of multifunctional beads (Figure 9). The fusion 
proteins were confirmed by MALDI-TOF/MS (data not shown).  
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Figure 9. Protein profile of polymer beads displaying both binding activities (gold and silica). 
Lane M, molecular mass standard (New England Biolabs, United Kingdom); lane 1, polymer 
beads from E. coli BL21 (DE3) (pET-14b-3xGN-G5- ZZ(-)phaC/SN-G5-ZZ(-)phaC). 
 
The gold and IgG binding ability of the respective beads was confirmed using 
ELISA as described above (data not shown). The silica-binding ability of the 
respective engineered beads was confirmed as described above (data not shown). 
To assess the multifunctionality, the respective engineered beads were incubated 
subsequently with colloidal gold and TMOS, and vice versa. After each incubation 
step, the samples were purified via sucrose density ultracentrifugation as described 
in the Experimental Procedures. As controls, the respective bifunctional polymer 
beads were incubated the same way as beads displaying the ZZ domain only. After 
incubation with colloidal gold followed by TMOS incubation, PhaC(-)ZZ beads 
accumulated in an area corresponding to 2 M sucrose (d = 1.33 g/ml), whereas 
bifunctional gold/antibody binding beads formed a layer located at a density of 
2.25 M sucrose (d = 1.4 g/ml). Multifunctional gold/silica/antibody binding beads 
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treated the same way migrated even further and formed a layer corresponding to a 
density of 2.5 M sucrose (d = 1.45 g/ml; Figure 10). 
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Figure 10. Different polymer beads were incubated with gold and silica and purified via 
ultracentrifugation of a sucrose gradient. Lane 1, pET-14b-ZZ(-)phaC; lane 2, pET-14b-3xGN-G5-ZZ(-
)phaC; lane 3, pET-14b-3xGN-G5-ZZ(-)phaC/SN-G5-ZZ(-)phaC. 
 
 
Discussion 
 
In this study, it was shown that microorganisms can be genetically modified to produce 
polymer inclusions that perform as beads displaying binding sites for antibodies and 
various inorganics at the same time. Thus, the bioengineering of polymer inclusions 
provides a valid molecular tool to generate novel hybrid materials that combine 
biological and inorganic agents suitable for numerous potential biomedical applications 
(2-5). Different hybrid genes were constructed (Figure 11) and successfully 
overexpressed, and the engineered protein functions could be displayed at the 
respective bead surfaces (Figures 2, 7 and 9). The gold/antibody binding polymer beads 
displaying the triple gold-binding peptide GBP1 (38, 39) showed strong gold binding in 
ELISA, which was established as a tool to quantitatively assess the gold binding. 
Control beads that did not display this special binding peptide showed no significant 
gold binding (Figure 3A). These findings were confirmed by density-based migration 
behavior of the different beads in a sucrose gradient. Only beads displaying the gold-
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binding peptide showed an increased density after incubation with colloidal gold. TEM 
assessment of the polymer beads indicated specific gold-binding to respectively 
engineered beads (Figure 4). However, the density of bound colloidal gold was rather 
low which could be due to the isolation procedure applied to beads after binding the 
colloidal gold as well as the TEM sample preparation method. Additionally, no 
interference of both displayed binding domains – gold-binding and IgG-binding – was 
found. Moreover, it could be demonstrated that polymer beads engineered to bind gold 
and antibodies bind as much IgG as polymer beads displaying only the antibody 
binding domain (Figure 3B). 
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Figure 11. Schematic overview of hybrid genes used in this study. The bracket combining the last two 
constructs illustrates that both genes are located on the same plasmid. Gold binding ability was assessed 
as described above and the silica-binding ability was assessed using TMOS precipitation as described 
above. Binding is indicated by +, non-binding by -, -* indicates a slightly increased unspecific silica 
binding compared to the control. 
 
To test the possibility that the polymer beads can be in general designed to bind any 
inorganic, the protein bead surface was designed to bind silica. The binding of silica, 
obtained as precipitate from an aqueous TMOS solution, increased the density of the 
respective engineered beads, whereas the control beads without engineered binding 
sites showed no increased density (Figure 8A,B). Further confirmation of the successful 
functional displaying of the silica-binding peptide was obtained by assessing the 
binding of engineered SN-G5-ZZ-PhaC and PhaC(-)ZZ control beads to commercial 
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silica particles. Control beads showed only a minor background reaction compared to 
the binding ability of the engineered beads (Figure 8 C,D). A direct fusion of the silica 
binding peptide to the N terminus of PhaC did not result in functional silica binding 
polymer beads. Therefore, the exposure of the binding peptide – gained by employing 
the IgG binding ZZ domain as spacer – seems to be required for functionality. 
Elemental analysis using energy dispersive spectrometry proved the existence of silica 
in samples that were expected to precipitate silica out of TMOS, e.g., silica-binding 
peptide displaying beads. Silica could not be detected in control samples treated the 
same way. Due to the displayed ZZ domain, the engineered beads were additionally 
able to bind IgG as well as the control beads only displaying the ZZ domain. In contrast 
to the gold-binding, it was not possible to obtain clear evidence that IgG-binding and 
silica-binding do not interfere with each other. This is due to the lack of an ELISA 
protocol for silica binding to the beads. 
The multifunctional beads designed in this study were not only able to bind IgG 
antibodies plus gold and/or silica, but were also able to specifically bind all three 
compounds. However, it was shown that a deposition of silica at the bead surface 
impaired binding of gold, whereas beads with gold attached to their surface showed no 
weaker silica deposition as in the absence of gold. These data suggested that the silica 
deposition could block the binding sites for gold at the bead surface. Additionally, 
multifunctional beads incubated with gold and silica showed a higher density in sucrose 
gradients than observed for bifunctional beads. This indicates a possible binding of the 
silica to the already bound gold particles. Overall, this study clearly demonstrated that 
bacterial polymeric inclusions can be engineered as biomimetic tools to specifically and 
simultaneously bind biological and inorganic compounds, which could enable 
applications of these beads in diagnostic medicine as well as biotechnology. Numerous 
particles composed of various materials such as organic polymers, semi-conductors, 
lipids, carbon- or silica-material have been produced and proposed for various 
biomedical applications (40-46). In contrast to the one-step manufacturing process 
described in this study for the production of new polymer beads, all other particles 
requiring functionalization were obtained by a process comprising at least two steps 
such as, e.g., bead production and chemical cross-linking of a functionality.  
This biomimetic approach offers a tool to produce beads with covalently cross-linked 
functionalities in one-step. These shell-core bio-beads with specific binding properties 
could, for example, be applicable in medical bioimaging procedures in which antibody-
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based targeting of contrast agents is of special interest. In a previous study, it was 
demonstrated that a scFv immobilized at the surface of these beads showed a 75-fold 
increase in binding affinity when compared with the respective soluble scFv (26). Thus, 
the engineered beads could provide a very sensitive diagnostic tool. Moreover, the 
module like composition of these small bio-beads offers versatile targeting of different 
tissues by simply incubating the beads with the relevant targeting antibody. Due to the 
displayed antibody binding functionality, an antibody of choice or even a combination 
of antibodies could be easily combined with bound gold to generate a contrast agent for 
bioimaging applications. 
 
Acknowledgement 
 
This work was supported by the New Zealand Foundation for Research Science 
and Technology and the Massey University Research fund. Ms. Anika Jahns 
received a Technology for Industry doctoral fellowship. This research has been 
facilitated by access to the Australian Proteome Analysis Facility established 
under the Australian Government’s Major National Research Facilities program. 
 
References 
 
(1) Addinall, S. G., Bi, E., and Lutkenhaus, J. (1996) FtsZ ring formation in fts 
mutants. J. Bacteriol. 178, 3877-84. 
(2) Karhanek, M., Kemp, J. T., Pourmand, N., Davis, R. W., and Webb, C. D. (2005) 
Single DNA molecule detection using nanopipettes and nanoparticles. Nano Let.t 
5, 403-7. 
(3) Jiang, W., Papa, E., Fischer, H., Mardyani, S., and Chan, W. C. (2004) 
Semiconductor quantum dots as contrast agents for whole animal imaging. Trends 
Biotechnol. 22, 607-9. 
(4) Panyam, J., and Labhasetwar, V. (2003) Biodegradable nanoparticles for drug and 
gene delivery to cells and tissue. Adv. Drug Deliveru Rev. 55, 329-47. 
(5) Soukka, T., Harma, H., Paukkunen, J., and Lovgren, T. (2001) Utilization of 
kinetically enhanced monovalent binding affinity by immunoassays based on 
multivalent nanoparticle-antibody bioconjugates. Anal. Chem. 73, 2254-60. 
Chapter III 
123 
(6) Mao, C., Solis, D. J., Reiss, B. D., Kottmann, S. T., Sweeney, R. Y., Hayhurst, A., 
Georgiou, G., Iverson, B., and Belcher, A. M. (2004) Virus-based toolkit for the 
directed synthesis of magnetic and semiconducting nanowires. Science 303, 213-
7. 
(7) Tamerler, C., and Sarikaya, M. (2007) Molecular biomimetics: utilizing nature's 
molecular ways in practical engineering. Acta Biomater. 3, 289-99. 
(8) Sarikaya, M., Tamerler, C., Jen, A. K., Schulten, K., and Baneyx, F. (2003) 
Molecular biomimetics: nanotechnology through biology. Nat. Mater. 2, 577-85. 
(9) Zin, M. T., Ma, H., Sarikaya, M., and Jen, A. K. (2005) Assembly of gold 
nanoparticles using genetically engineered polypeptides. Small 1, 698-702. 
(10) Oren, E. E., Tamerler, C., and Sarikaya, M. (2005) Metal recognition of 
septapeptides via polypod molecular architecture. Nano Lett. 5, 415-9. 
(11) Thai, C. K., Dai, H., Sastry, M. S., Sarikaya, M., Schwartz, D. T., and Baneyx, F. 
(2004) Identification and characterization of Cu(2)O- and ZnO-binding 
polypeptides by Escherichia coli cell surface display: toward an understanding of 
metal oxide binding. Biotechnol. Bioeng. 87, 129-37. 
(12) Rehm, B. H. A. (2006) Biopolyester particles produced by microbes or using 
polyester synthases: Self-assembly and potential applications.   
In Microbial Bionanotechnology: Biological self-assembly systems and 
biopolymer-based nanostructures, ed. Bernd H. A. Rehm, pp 1-34. 
(13) Rehm, B. H. A. (2006) Genetics and Biochemistry of Polyhydroxyalkanoate 
Granule Self-assembly: The Key Role of Polyester Synthases. Biotechnol. Lett. 
28, 207-13. 
(14) Rehm, B. H. A. (2007) Biogenesis of microbial polyhydroxyalkanoate granules: a 
platform technology for the production of tailor-made bioparticles. Curr. Issues 
Mol. Biol. 9, 41-62. 
(15) Peters, V., Becher, D., and Rehm, B. H. A. (2007) The inherent property of 
polyhydroxyalkanoate synthase to form spherical PHA granules at the cell poles: 
the core region is required for polar localization. J. Biotechnol. 132, 238-45. 
(16) Peters, V., and Rehm, B. H. A. (2005) In vivo monitoring of PHA granule 
formation using GFP-labeled PHA synthases. FEMS Microbiol. Lett. 248, 93-100. 
(17) Rehm, B. H. A. (2003) Polyester synthases: natural catalysts for plastics. 
Biochem. J. 376, 15-33. 
Chapter III 
124 
(18) Peters, V., and Rehm, B. H. A. (2006) In vivo enzyme immobilization by use of 
engineered polyhydroxyalkanoate synthase. Appl. Environ. Microbiol. 72, 1777-
83. 
(19) Hezayen, F. F., Steinbuchel, A., and Rehm, B. H. A. (2002) Biochemical and 
enzymological properties of the polyhydroxybutyrate synthase from the extremely 
halophilic archaeon strain 56. Arch. Biochem. Biophys. 403, 284-91. 
(20) Potter, M., Muller, H., Reinecke, F., Wieczorek, R., Fricke, F., Bowien, B., 
Friedrich, B., and Steinbuchel, A. (2004) The complex structure of 
polyhydroxybutyrate (PHB) granules: four orthologous and paralogous phasins 
occur in Ralstonia eutropha. Microbiology 150, 2301-11. 
(21) Jurasek, L., and Marchessault, R. H. (2004) Polyhydroxyalkanoate (PHA) granule 
formation in Ralstonia eutropha cells: a computer simulation. Appl. Microbiol. 
Biotechnol. 64, 611-7. 
(22) York, G. M., Stubbe, J., and Sinskey, A. J. (2001) New insight into the role of the 
PhaP phasin of Ralstonia eutropha in promoting synthesis of 
polyhydroxybutyrate. J. Bacteriol. 183, 2394-7. 
(23) Baeckstroem, T. B., Brockelbank, J. A., and Rehm, B. H. A. (2007) Recombinant 
Escherichia coli produces tailor-made biopolyester granules for applications in 
fluorescence activated cell sorting: Functional display of the mouse interleukin-2 
and myelin oligodendrocyte glycoprotein. BMC Biotechnol. 7, 3. 
(24) Banki, M. R., Gerngross, T. U., and Wood, D. W. (2005) Novel and economical 
purification of recombinant proteins: intein-mediated protein purification using in 
vivo polyhydroxybutyrate (PHB) matrix association. Protein Sci. 14, 1387-95. 
(25) Barnard, G. C., McCool, J. D., Wood, D. W., and Gerngross, T. U. (2005) 
Integrated recombinant protein expression and purification platform based on 
Ralstonia eutropha. Appl. Environ. Microbiol. 71, 5735-42. 
(26) Grage, K., and Rehm, B. H. A. (2008) In Vivo Production of scFv-Displaying 
Biopolymer Beads Using a Self-Assembly-Promoting Fusion Partner. 
Bioconjugate Chem. 19, 254-62. 
(27) Peters, V., and Rehm, B. H. A. (2008) Protein engineering of streptavidin for in 
vivo assembly of streptavidin beads. J. Biotechnol. 134, 266-74. 
(28) Brockelbank, J. A., Peters, V., and Rehm, B. H. A. (2006) Recombinant 
Escherichia coli strain produces a ZZ domain displaying biopolyester granules 
Chapter III 
125 
suitable for immunoglobulin G purification. Appl. Environ. Microbiol. 72, 7394-
7. 
(29) Sharma, P., Brown, S., Walter, G., Santra, S., and Moudgil, B. (2006) 
Nanoparticles for bioimaging. Adv. Colloid Interface Sci. 123-126, 471-85. 
(30) Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning: a 
laboratory manual Cold Spring Harbor Lab. Press, Plainview, NY. 
(31) Brown, S. (1997) Metal-recognition by repeating polypeptides. Nat. Biotechnol. 
15, 269-272. 
(32) Brown, S., Sarikaya, M., and Johnson, E. (2000) A genetic analysis of crystal 
growth. J. Mol. Biol. 299, 725-735. 
(33) Naik, R. R., Brott, L. L., Clarson, S. J., and Stone, M. O. (2002) Silica-
precipitating peptides isolated from a combinatorial phage display peptide library. 
J. Nanosci. Nanotechnol. 2, 95-100. 
(34) Dickerson, M. B., Naik, R. R., Sarosi, P. M., Agarwal, G., Stone, M. O., and 
Sandhage, K. H. (2005) Ceramic nanoparticle assemblies with tailored shapes and 
tailored chemistries via biosculpting and shape-preserving inorganic conversion. 
J. Nanosci. Nanotechnol. 5, 63-67. 
(35) Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal. Biochem. 72, 248-54. 
(36) Laemmli, U. K. (1970) Cleavage of Structural Proteins during Assembly of Head 
of Bacteriophage-T4. Nature 227, 680-685. 
(37) Lowenadler, B., Jansson, B., Paleus, S., Holmgren, E., Nilsson, B., Moks, T., 
Palm, G., Josephson, S., Philipson, L., and Uhlen, M. (1987) A gene fusion 
system for generating antibodies against short peptides. Gene 58, 87-97. 
(38) Tamerler, C., Duman, M., Oren, E. E., Gungormus, M., Xiong, X., Kacar, T., 
Parviz, B. A., and Sarikaya, M. (2006) Materials specificity and directed 
assembly of a gold-binding peptide. Small 2, 1372-8. 
(39) Tamerler, C., Oren, E. E., Duman, M., Venkatasubramanian, E., and Sarikaya, M. 
(2006) Adsorption kinetics of an engineered gold binding Peptide by surface 
plasmon resonance spectroscopy and a quartz crystal microbalance. Langmuir 22, 
7712-8. 
Chapter III 
126 
(40) Chenevier, P., Veyret, B., Roux, D., and Henry-Toulme, N. (2000) Interaction of 
cationic colloids at the surface of J774 cells: a kinetic analysis. Biophys. J. 79, 
1298-309. 
(41) Nayak, S., and Lyon, L. A. (2005) Soft nanotechnology with soft nanoparticles. 
Angew. Chem., Int. Ed. Engl. 44, 7686-708. 
(42) Schultz, D. A. (2003) Plasmon resonant particles for biological detection. Curr. 
Opin. Biotechnol. 14, 13-22. 
(43) Alivisatos, A. P., Johnsson, K. P., Peng, X., Wilson, T. E., Loweth, C. J., 
Bruchez, M. P., Jr., and Schultz, P. G. (1996) Organization of 'nanocrystal 
molecules' using DNA. Nature 382, 609-11. 
(44) Venkatesan, N., Yoshimitsu, J., Ito, Y., Shibata, N., and Takada, K. (2005) Liquid 
filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 
26, 7154-63. 
(45) Burns, A., Sengupta, P., Zedayko, T., Baird, B., and Wiesner, U. (2006) 
Core/Shell fluorescent silica nanoparticles for chemical sensing: towards single-
particle laboratories. Small 2, 723-6. 
(46) Burns, A., Ow, H., and Wiesner, U. (2006) Fluorescent core-shell silica 
nanoparticles: towards "Lab on a Particle" architectures for nanobiotechnology. 
Chem. Soc. Rev. 35, 1028-42. 
(47) Bullock, W. O., Fernandez, J. M., and Short, J. M. (1987) XL1-BLUE - A High-
Efficiency Plasmid Transforming RecA Escherichia-Coli Strain with Beta-
Galactosidase Selection. Biotechniques 5, 376-&. 
(48) Spiekermann, P., Rehm, B. H. A., Kalscheuer, R., Baumeister, D., and 
Steinbuchel, A. (1999) A sensitive, viable-colony staining method using Nile red 
for direct screening of bacteria that accumulate polyhydroxyalkanoic acids and 
other lipid storage compounds. Arch. Microbiol. 171, 73-80. 
(49) Yuan, W., Jia, Y., Tian, J. M., Snell, K. D., Muh, U., Sinskey, A. J., Lambalot, R. 
H., Walsh, C. T., and Stubbe, J. (2001) Class I and III polyhydroxyalkanoate 
synthases from Ralstonia eutropha and Allochromatium vinosum: 
Characterization and substrate specificity studies. Arch. Biochem. Biophys. 394, 
87-98. 
(50) Hoffmann, N., Amara, A. A., Beermann, B. B., Q, Q. S., Hinz, H. J., and Rehm, 
B. H. A. (2002) Biochemical characterization of the Pseudomonas putida 3-
Chapter III 
127 
hydroxyacyl ACP : CoA transacylase, which diverts intermediates of fatty acid de 
novo biosynthesis. J. Biol. Chem. 277, 42926-42936. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter IV 
 
 
 
Engineering of bacterial polyester inclusions towards the 
display of ten lysine residues and potential applications 
 
Anika C. Jahns, Verena Peters and Bernd H. A. Rehm* 
 
Institute of Molecular Biosciences, Massey University, Private Bag 11222, Palmerston North, New 
Zealand 
* Corresponding author: Bernd H. A. Rehm, phone: +64 6 350 5515 ext 7890; fax: +64 6 350 2267; e-
mail: b.rehm@massey.ac.nz 
 
Journal of Biomedicine and Biotechnology (2009), submitted in revised form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV 
129 
Engineering of bacterial polyester inclusions towards the 
display of ten lysine residues and potential applications 
 
Anika C. Jahns, Verena Peters and Bernd H. A. Rehm 
 
Abstract 
 
Lysine residues are positively charged and are known to enable silica binding. Silica is 
a very versatile element with various applications in biotechnology and biomedicine. In 
this study, Escherichia coli was engineered to produce polylysine displaying polyester 
beads, using one of the most dominant surface proteins, the phasins, which are naturally 
attached to these hydrophobic beads, as anchor. These shell-core beads were composed 
of a polyhydroxybutyrate core surrounded by hybrid gene encoded phasin-polylysine 
fusion proteins at a high density as was assessed by gas chromatography-mass 
spectroscopy and tryptic peptide fingerprinting using MALDI-TOF/MS, respectively. 
The resulting particles performed successfully in different silica binding assays and can 
be applied in processes where silica-coated biological particles are of special interest, 
e.g. DNA binding and delivery. The beads can also be used for applications where the 
display of a positive surface charge is advantageous.  
 
Introduction 
 
The element silicon is the second most abundant element in earth’s crust and ubiquitous 
throughout biological systems. Silica exhibits diverse and extraordinarily designed 
shapes and structures in Nature from diatom skeletons to sponge spicules. The proteins 
directing silica synthesis in biological systems have been studied extensively. Silaffins 
extracted from the cell wall of diatom Cylindrotheca fusiformis catalyze precipitation of 
silica from aqueous solutions of orthosilicic acid [1-4]. Silicatein extracted from the 
sponge spicules of Tethya aurantia [5-7] is another good example for these proteins. A 
second approach is to use polyaminoacids to induce silica synthesis. Polyaminoacids 
were proposed to bring the silicic acid monomers and oligomers closer to each other by 
electrostatic attractions, which may facilitate condensation to produce silica [8]. Using 
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biomimetics offers a tool to synthesize inorganic materials under mild conditions, 
favourable in the biological world. 
In this study microbial polyester inclusions were designed as biological matrix structure 
[9, 10]. These polyesters are composed of (R)-3-hydroxy fatty acids and serve as energy 
and carbon storage material [11]. The storage polyesters are deposited in the cytoplasm 
of bacteria or archaea as water-insoluble spherical inclusions and can contribute up to 
80% (w/w) of the cellular dry weight matter of cells. These polyester inclusions have 
recently been considered as nano/micro-beads, whereby the protein coat can be 
genetically designed, applying protein engineering to display specific functionalities 
[12-14]. A dominant coat protein, the so-called phasin, is hydrophobically interacting 
with the polyester core. These proteins show a rather low molecular-weight of about 25 
kDa and represent a class of non-catalytic proteins comprising a hydrophobic domain, 
which associates with the polyester core, and a hydrophilic domain exposed to the 
cytoplasm of the cell [15]. Phasin proteins are synthesized in very large quantities 
under storage conditions, representing as much as 5 % of the total protein [16].  
These main structural proteins can be engineered to display various functional proteins 
at the polymer surface (Figure 1) and the modified polymer inclusions can be stably 
maintained outside the cell as beads [14, 17]. 
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Figure 1. Scheme of the polyester bead surface displaying polylysine residues using engineered PhaP 
protein as anchor. 
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Materials and Methods 
 
Bacterial strains and growth conditions 
Bacterial strains, plasmids and oligonucleotides used in this study are listed in Table 1. 
Escherichia coli BL21(DE3) was grown at 25˚C. When required, ampicillin 75 µg/ml 
and chloramphenicol 50 µg/ml were added. All chemicals were purchased from Sigma-
Aldrich (St. Louis, Mo., USA). 
 
Isolation, analysis and manipulation of DNA 
General cloning procedures and isolation of DNA were performed as described 
elsewhere [18]. DNA primers, deoxynucleoside triphosphate, T4 DNA ligase and Pfx 
polymerase were purchased from Invitrogen TM (CA, USA). DNA sequences of new 
plasmid constructs were confirmed by DNA sequencing according to the chain 
termination method using the model ABI310 automatic sequencer.  
The sequence of phaP was PCR amplified from genomic DNA from Cupriavidus 
necator, using the oligonucleotides 5’-PhaP-Xba/SD and 3’-PhaP-Xho/Spe/Xba (Table 
1). The PCR product was ligated into the XbaI hydrolysed plasmid pHAS, resulting in 
plasmid pHAS+phaPwt. A C terminal fusion of 10 lysines to the hydrophobically bead 
binding protein PhaP was designed to enable silica-binding by the respective beads. 
Therefore, the oligonucleotides polylysine-adaptor and polylysine-adaptor rev (Table 1) 
were hybridised and inserted into the XhoI/SpeI sites of plasmid pHAS+phaPwt, 
resulting in plasmid pHAS+phaPpolylys.  
The plasmid pETC [19] was hydrolysed with XbaI/NdeI. The oligonucleotides 
polylysine XbaI and polylysine NdeI were hybridised and inserted into the respectively 
prepared plasmid, resulting in plasmid pET-14b polylys-PhaC. The plasmid pET-14b 
ZZ(-)phaC [20] was hydrolysed with the restriction enzymes SpeI and SunI. The 
oligonucleotides polylysine SpeI and polylysine SunI were hybridised and ligated into 
the prepared plasmid, resulting in plasmid pET-14b polylys-ZZ-PhaC.  
Competent E. coli BL21(DE3) cells containing the plasmid pMCS69 were transformed 
with the newly constructed plasmids, respectively. Plasmid pMCS69 encodes the β-
ketothiolase and acetyl-CoA reductase from C. necator. Together with the PHA 
synthase, encoded on pHAS or pET-14b derivatives, the activity of all three enzymes 
leads to polyester inclusion formation. 
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Table 1. Bacterial strains, plasmids and oligonucleotides used in this study 
Strain Genotype source or reference 
Strains   
Escherichia coli   
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17(r-k, m+k), supE44, relA1, -,  [37] 
 lac[F’, proAB, lacIq, lacZ∆M15, Tn10(Tcr)]  
BL21(DE3) F-, ompT, hsdSB (rB- mB-), gal, dcm (DE3) Novagen 
Cupriavidus necator H16 Wildtype DSMZ 428 
Plasmids   
pETC pET-14b derivative, coding for phaCwt under T7 promoter control [19] 
pET-14b-ZZ(-)phaC pET-14b containing XbaI/BamHI fragment comprising gene ZZ-phaC [20] 
pHAS pET-14b containing NdeI/BamHI-inserted phaC gene [38] 
 from C. necator  
pHAS+phaPwt pHAS plasmid containing phaP gene of C. necator This study 
pHAS+phaPpolylys pHAS+phaP derivative containing polylysine fusion 3’ to phaP This study 
pMCS69 pBBR1MCS derivative containing genes phaA and phaB of C.  [39] 
 necator colinear to lac promoter  
Oligonucleotides   
5’-PhaP-Xba/SD 5’-GGA AAT CTA GAA ATA AGG AGA TAT AGA TAT GAT This study 
 CCT CAC CCC GGA ACA AGT TGC AGC AGC GC-3’  
3’-PhaP-Xho/Spe/Xba 5’-AAA AAT CTA GAT CAA CTA GTT CAC TCG AGG GCA This study 
 GCC GTC GTC TTC TTT GCC GTG GCC GTA C-3’  
polylysine-adaptor 5’-P-TCG AGA AGA AGA AAA AGA AAA AAA AGA AGA  This study 
 AGA AGT AGA-3’  
polylysine-adaptor rev 5’-P-CTA GTC TAC TTC TTC TTC TTT TTT TTC TTT TTC TTC  This study 
 TTC-3’  
polylysine XbaI 5’-P-CTA GAA ATA AGG AGA TAC TAG TAT GAA GAA This study 
 GAA AAA GAA AAA AAA GAA GAA GAA GCA-3’  
polylysine NdeI 5’-P-TAT GCT TCT TCT TCT TTT TTT TCT TTT TCT TCT This study 
 TCA TAC TAG TAT CTC CTT ATT T-3’  
polylysine SpeI 5’-P-CTA GTA TGA AGA AGA AAA AGA AAA AAA AGA This study 
 AGA AGA AGC-3’  
polylysine SunI 5’-P-GTA CGC TTC TTC TTC TTT TTT TTC TTT TTC TTC TTC  This study 
 ATA-3’  
 
GC/MS 
The polyester content of isolated cells was determined by gas chromatography/mass 
spectrometry [21]. 
 
Isolation of polyester inclusions 
Polyester beads were isolated from E. coli cultures as described previously [22]. 
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Silica-binding assay 
The silica-binding assay was modified as described elsewhere [23] and as described 
previously [22]. 
To investigate the different migration behaviour due to bound silica, the washed pellets 
were suspended in 50 mM potassium phosphate buffer, pH 7.5 and loaded on a sucrose 
gradient (0 – 2.25 M sucrose in 0.25 M increments, sucrose in 50 mM potassium 
phosphate buffer, pH 7.5). These gradients were undergoing ultracentrifugation at 100 
000 x g for 16 h.  
Commercial silica beads in the range of 1-5 µm were used as well to assess the silica 
binding ability of the respective polyester beads. 0.5 mg/ml bead protein suspension 
was mixed with 0.003 g/ml SiO2 in potassium phosphate buffer and incubated on a 
shaker at room temperature for 4 h. The mixture was loaded on a sucrose gradient and 
undergoing ultracentrifugation for 16 h at 10˚C. The protein concentration of resulting 
layers and pellets was determined by Bradford [24]. 
 
SDS page 
Polyester bead protein samples were analyzed by sodium dodecyl sulphate (SDS)-
polyacrylamide gel electrophoresis (PAGE) as described elsewhere [25]. The gels were 
stained with Coomassie brilliant blue G250.  
 
MALDI-TOF mass spectrometry 
Protein bands of interest were cut off the SDS polyacrylamide gel and analyzed by 
tryptic peptide fingerprinting applying collision induced dissociation tandem mass 
spectrometry. 
 
DNA-binding 
Beads incubated with TMOS and washed with KPO4 were used in a DNA-binding 
assay. 35 µg of PhaPwt and PhaPpolylys (TMOS) beads were incubated with 675 ng 
DNA in 25 µl QG buffer (QIAquick® Gel Extraction Kit, QIAGEN, Hilden, Germany) 
for 1 h (RT, rocking). After washing with 50 µl PE buffer (QIAquick® Gel Extraction 
Kit, QIAGEN, Hilden, Germany), bound DNA was eluted in 25 µl EB buffer (10 mM 
Tris-HCl, pH 8.5). The assays were incubated on a rocker for 1 h, before the beads 
were sedimented by centrifugation. All supernatants were assessed for their DNA 
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content, using a QubitTM Fluorometer (InvitrogenTM, CA, USA) and DNA gel 
electrophoresis. 
 
Results 
 
Analysis of the polylysine fusion protein displaying beads 
The polyester inclusion coating protein PhaP, which specifically and hydrophobically 
binds to already formed polyester beads, was engineered to comprise 10 lysine residues 
at its C terminus. The respective hybrid gene and the polyester synthase were 
overexpressed under T7 promoter control in E. coli BL21 harbouring plasmid pMCS69, 
which mediated polyester synthesis and inclusion formation. The resulting beads were 
isolated and analyzed (Figure 2). All constructs were confirmed by DNA sequencing, 
the polyester content was measured by GC/MS and the fusion protein PhaPpolylys was 
confirmed by MALDI-TOF/MS (Table 2).  
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PhaPpolylys
 
Figure 2. Protein profile of polyester beads displaying polylysines. M, molecular mass standard 
(Amersham Biosciences, USA); lane 1, polyester beads from E. coli BL21(DE3)(pHAS+phaPpolylys); 
lane 2, polyester beads from E. coli BL21(DE3)(pHAS+phaPwt).  
 
Table 2. Identified peptide fragments of protein analyzed by MALDI-TOF/MS 
Protein Identified peptide fragments     
PhaPpolylys M1-K13, A14-K25, L33-K42, T43-K53, D60-K78, H85-K99, N111-K121,  
 S136-K156, Q154-K172, A173-R182    
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Silica-binding 
The ability of the respective polyester beads to bind silica was shown in two different 
assays by binding silica to the bead surface and by incubating polyester beads with 
commercially available silica beads. In the first approach, engineered beads and control 
beads were incubated with TMOS dissolved in HCl as described and then loaded on a 
sucrose gradient. After ultracentrifugation for 16 h different migration behaviour, i.e. 
different density due to silica binding, of engineered and control beads was observed. 
Plain polyester beads in which production was mediated by plasmid pHAS+phaPwt, 
formed a layer at a sucrose concentration of 2 M (d = 1.33 g/ml), and at 2.25 M (d = 1.4 
g/ml) after TMOS incubation. PhaPpolylys beads showed a layer at 2 M sucrose when 
non-incubated with TMOS and formed a pellet below the 2.25 M sucrose after TMOS 
incubation (Figure 3A).   
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Figure 3. Density dependent migration in a sucrose gradient using ultracentrifugation. A. Images of 
tubes used for density assessment of the distribution of polyester beads in sucrose gradients after 
(indicated as +) and without (indicated as -) TMOS incubation. Lanes 1, 2, polyester beads from E. coli 
BL21(DE3)(pHAS+phaPwt); lanes 3, 4, polyester beads from E. coli BL21(DE3)(pHAS+ phaPpolylys). 
B. Images of tubes used for density assessment of the distribution of polyester beads after SiO2 binding 
(indicated with +) and without (indicated with -). Lanes 1, 2, polyester beads from E. coli 
BL21(DE3)(pHAS+phaPwt); lanes 3, 4, polyester beads from E. coli BL21(DE3) (pHAS+ phaPpolylys). 
 
Commercially available silica beads (Silicon dioxide, 1-5 µm; Sigma-Aldrich) were 
used for the second approach. PhaPpolylys and control beads were incubated with these 
silica beads as described and loaded onto a sucrose gradient. Protein determination by 
Bradford was used to quantify binding of the protein coated polyester beads. The 
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respective control beads coated with the wild-type phasin only showed about 75% of 
the protein content in the respective polyester bead layer in the sucrose gradient 
whereas only 25% were found bound to the silica beads in the sediment. The 
PhaPpolylys beads showed only about 30% of the protein content in the polyester bead 
layer, while most of the protein was found attached to the silica beads in the sediment 
(Figure 3B). 
 
DNA-binding 
To demonstrate the applicability of silica coated beads, DNA-binding to the silicated 
bead surface was investigated. After successful binding of silica, respectively prepared 
beads were assessed for their DNA-binding ability. PhaPwt and PhaPpolylys beads 
with bound silica (TMOS assay) were incubated with DNA as described. 250.5 ng 
DNA (54%) were eluted from control beads, 547 ng DNA (72%) were eluted from 
PhaPpolylys beads, app. 1.3 times more compared to PhaPwt beads. Fluorometric 
quantification as well as agarose gel electrophoresis was employed to assess the DNA-
binding. 
 
M M M1 2 3 4 5 6 7 8
 
Figure 4. DNA-binding and elution from silica coated bio-beads. Beads were incubated with DNA, all 
supernatants and bead fractions were subjected to agarose gel electrophoresis. M, molecular weight 
standard (PstI digested lambda-DNA); lane 1, beads coated with PhaPwt, supernatant after DNA binding; 
lane 2, beads coated with PhaPwt, supernatant after wash; lane 3, beads coated with PhaPwt, supernatant 
after elution; lane 4, beads coated with PhaPwt, bead pellet in TE buffer; lane 5, beads coated with 
PhaPpolylys, supernatant after DNA binding; lane 6, beads coated with PhaPpolylys, supernatant after 
wash; lane 7, beads coated with PhaPpolylys, supernatant after elution; lane 8, beads coated with 
PhaPpolylys, bead pellet in TE buffer. 
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Analysis of polyester beads displaying the polylysine polypeptide via synthase 
fusion 
The synthase protein PhaC, which is covalently bound to the polyester beads, was also 
employed for the display of the polypeptide. Ten lysine residues were fused to the N 
terminus of PhaC. In order to further expose the polypeptide, the ZZ-PhaC protein was 
engineered by N terminal fusion of 10 lysine residues. The hybrid genes were 
overexpressed under T7 promoter control in E. coli BL21 containing plasmid pMCS69. 
Polyester beads were isolated and analyzed. The presence of the fusion protein on the 
polyester bead surface could be demonstrated by SDS-PAGE and MALDI-TOF/MS 
(data not shown). However, none of the polyester beads harbouring either of the 
polylys-synthase fusion protein showed activity regarding silica precipitation (data not 
shown). 
 
Discussion 
 
The chemical synthesis of silica-based materials like resins and catalysts requires 
extremes of temperature, pressure and pH. In contrast, biosilification processes take 
place at ambient temperatures and pressures, but still producing a wide diversity of 
nanostructures [26-29]. Most of the proteins directing silica synthesis in biological 
systems are rich in basic and hydroxyl amino acids [30]. Moreover, it could be shown 
that synthetic peptides and polyamines can also be used to mimic biosilification 
reactions [8, 31-34]. 
In this study it was demonstrated that a polyamine can be functionally displayed at the 
surface of a biological derived polyester bead when genetically fused to a structural 
surface protein. SDS-PAGE analysis clearly showed the presence of the fusion protein 
PhaPpolylys at the bead surface (Figure 2). Binding experiments proved the activity. 
Polylysine can precipitate silica out of an aqueous solution within minutes [35]. In a 
silica binding assay and following sucrose density gradient characterization it could be 
shown that this activity of the polylysine peptide was not decreased by fusing it to the 
protein anchor PhaP (Figure 3A). Control beads derived from pHAS+phaPwt showed 
some background reaction which might be due to proteins attached to the bead surface. 
In comparison, engineered beads displaying lysine residues showed a more intense shift 
in density after incubation with TMOS solution due a significantly enhanced silica 
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binding. Furthermore, the polypeptide enabled the engineered beads to bind specifically 
to commercially silicon dioxide particles (Figure 3B). In this assay only little 
background reaction of the control beads could be observed, emphasizing the role of 
polylysines for silica precipitation and binding. 
As proof-of-principle, silica coated beads were applied for specific DNA binding and 
elution. This assay needs some adjustments for future biomedical and biotechnological 
applications, as the background reaction was relatively high and not all DNA was 
eluted from the beads. Nevertheless, polylysine displaying beads incubated with TMOS 
were able to bind and elute 1.3 times more DNA than control beads (Figure 4). This 
clearly demonstrates the potential of biological, silicated beads. 
It was tried to also use the covalently granule bound polyester synthase protein for the 
display of the polypeptide. Fusion proteins mediating polyester bead formation and 
localized at high density at the bead surface could be obtained but none of those beads 
mediated silica precipitation (data not shown). These results suggested a distinct 
surface exposure of the polylysines when displayed attached at the C terminus of the 
phasin protein, whereas a fusion to the N terminus of the synthase protein might not be 
fully displayed at the bead surface or might allow conformational changes of the N 
terminal region interfering with its accessibility. Previous studies clearly demonstrated 
that various N-terminal fusion to the synthase resulted in displayed and accessible 
functionalities, but it had not been attempted to only display ten lysine residues which 
strongly enhance the surface charge suitable for binding of an inorganic compound 
[12].  
Future applications for silica-bound polyester beads could be in DNA purification 
processes while harnessing the adsorption of DNA molecules to silica. Another 
potential application could be the use of these silica-coated beads in drug delivery. In a 
recent study it has been shown that the uptake of encapsulated therapeutic agents might 
be facilitated by displayed polylysine residues [36]. Moreover, non-silicated beads 
could be used for cross-linking experiments due to the display of lysine residues which 
ε–amino group provides a target for various chemical reactions. 
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Conclusions 
 
One focus of this thesis was to investigate whether the PHA synthase PhaC from 
Ralstonia eutropha can be genetically engineered at its C terminus. Previous studies 
demonstrated the importance of the C terminus for activity of the protein and therefore 
no modification was ever attempted. The results described in Chapter II clearly show 
that PhaC can be employed as a multiple anchor by modifying the N and C terminus of 
this protein with different functionalities. In accordance with previous publications, the 
findings reported in Chapter II emphasise the importance of the hydrophobic 
environment around the synthase C terminus to maintain functionality. The ability to 
produce bio-beads displaying multiple functionalities originating from the one essential 
polymerising surface protein broadens the applicability of these beads as a greater 
variety of desired functions can be displayed. 
Furthermore, the research of this thesis demonstrated the applicability of functionalised 
bio-beads for molecular biomimetics approaches. The bio-bead surface was engineered 
to promote the specific binding of antibodies and inorganic materials, e.g. gold or silica. 
The capacity of the bead surface was not limited to the binding of only one type of 
inorganic material; two different inorganics could be bound at the same time. The 
results presented in Chapter III clearly demonstrate the binding of gold and silica to 
respectively engineered multi-functional beads. Genetically engineered peptides for 
inorganics (GEPIs) are available for a wide range of inorganic materials, and therefore 
the bead surface could be engineered to bind any desired combination of materials. 
In a different biomimetic approach, the bead surface associated protein PhaP was 
engineered to display 10 lysine residues. Bio-beads displaying these positively charged 
amino acid residues are very versatile in their applicability. As a proof-of-principle, 
silica binding to these engineered beads was investigated and employed to detect the 
correct display of the lysine residues.  
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Outlook 
 
Particles of a wide range of biopolyester materials are currently being investigated 
regarding their applicability especially in biomedicine and biotechnology. So far, the 
production costs of these bio-beads are high compared to well-established 
petrochemically derived products. Therefore, only high-value applications would 
justify the high production costs. Also, size and uniformity of the particles as well as 
consistency and reproducibility of the performance are demanded from every product. 
Although there are some insights into size control of PHB beads, further studies are 
necessary to provide an optimal product. This includes different growth media as well 
as different incubation temperatures and incubation times. The outcome of these studies 
might also provide further indication about how to reduce the production costs while 
maintaining or even improving the quality of the product. Using a two-plasmid system 
for the recombinant production of PHB bio-beads implements a greater performance 
variety and therefore a higher possibility of inconsistency and non-reproducibility. On 
the other hand, results reported so far and described in this thesis clearly show that this 
system is simple but allows a cost-effective one-step production and the resulting bio-
beads show little variability in their performance. As there are only three enzymes 
required for the production of these bio-beads, namely PhaA, PhaB and PhaC, all three 
genes encoding these enzymes could be transcribed from one plasmid. This would 
decrease the selection pressure, as only one antibiotic would be required and thereby 
also reducing production costs. In a future experiment pursuing this strategy all three 
genes could be encoded together on a pET-14b derivative. The synthase gene would be 
controlled by the strong T7 promoter, whereas the two genes for phaA and phaB would 
be controlled by the lac promoter.  
Biomedical applications of PHA derived biopolyester beads are widely emerging and 
might be the only field where high production costs are permitted at the moment. After 
first reports of experiments in mouse (Yao et al., 2008), it could well be imagined that 
specially designed biopolyester beads will find applications not only in diagnostics but 
in drug delivery as well. Beads loaded with the drug of interest, encapsulated into the 
hydrophobic core of the beads, could be delivered by antibody-targeting using the well 
characterized antibody binding capability (Brockelbank et al., 2006). For monitoring 
purposes, bioimaging using gold, as an inorganic contrast agent, bound via genetically 
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engineered peptides for inorganics to the particle surface (Jahns et al., 2008), can be 
performed. 
For bio-medical applications of the bio-beads an effective method for pyrogen removal 
would be necessary, as currently used methods are often harsh and might sometimes 
cause inactivation of the desired functionality. Mainly, recombinant E. coli cells are 
used as production hosts and consequently the beads are prone to contamination with 
host-specific lipopolysaccharides. However, E. coli has been approved by the U.S. 
Food and Drug Administration (FDA) for the production of biopharmaceuticals. 
Current research has shown that the lactic acid bacterium Lactococcus lactis can be 
genetically engineered to produce PHB beads (Mifune et al., 2009). L. lactis is 
classified as a food-grade, generally-regarded-as-safe organism and does not produce 
lipopolysaccharides. Therefore, this organism would be an ideal host for the production 
of bio-beads with medical applications. This technology is relatively new and still 
needs further investigation and improvement, and would not be favourable for the 
production of beads that are not required to be pyrogen-free. E. coli is a well 
established production host, the genome is well studied and a wide variety of 
techniques are available for easy manipulation and engineering. To date, beads purified 
from E. coli as well as L. lactis are contaminated with respective host proteins that bind 
unspecifically to the bead surface. The amount of these contaminating proteins can be 
reduced by strong overproduction of the desired fusion protein which results, 
presumably, in less space available on the bead surface for the unspecific binding 
proteins. High salt and mild detergent washing can also improve the purity of the beads 
but it has to be ensured that the bead itself and the protein of interest displayed at the 
bead surface remain active. 
More research concerning translational fusions to the C terminus of the PHA synthase 
is necessary in order to exploit the full capacity of the bead surface. The work of this 
thesis has provided a general insight into the possibilities, but for oriented tailoring of 
special products, a better and faster cloning strategy might be desirable. Additionally, 
determination of the crystal structure of PhaC might help to establish potential 
interactions and interferences between fusion partners. Further insights into the 
structure and folding mechanism might help to explain why some of the fusion proteins 
described in Chapter II remained inactive, especially the phenomena of the synthase 
and GFP protein separated by the designed linker sequence. So far, all attempts of 
enrichment of the synthase protein resulted in insoluble protein that cannot be used for 
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crystallization assays. New strategies are currently being pursued, e.g. addition of a 
solubility tag or expression of a shorter version of the protein, to enhance the solubility 
of the enriched protein. 
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Appendix 
 
SDS-PAGE 
Most of the SDS-PAGE pictures shown in this thesis are composite images. In some 
cases samples were run on the same gel but separated by additional, not shown, lanes. 
In any case, all samples were run under the same conditions, even when run on 
different gels. 
An average of 30 µg of total protein was loaded per lane. The protein concentration was 
determined following the method developed by M. M. Bradford (1976). 
The SDS-PAGE pictures always show, in addition to the fusion proteins of interest, 
contaminating protein bands. These proteins bind in an unspecific manner to the 
isolated beads, most likely during the isolation process. Some of these contaminating 
proteins were identified by MALDI-TOF/MS. The protein with an average molecular 
mass of 97 kDa was identified as E. coli derived ATPase. The smaller proteins with 
molecular masses between 30 and 40 kDa were identified as E. coli elongation factor 
TU (42 kDa), outer membrane protein OmpA (35 kDa) and β-Lactamase TEM 
precursor (32 kDa). 
 
Construction of plasmids encoding C-terminal synthase fusions (Chapter II) 
For better understanding and traceability, a schematic of the cloning strategy leading to 
the different plasmids employed in this study is shown in Figures 1 and 2. 
 
Construction of plasmids used for biomimetic studies (Chapter III) 
Figures 3 and 4 show schematics of the cloning strategy employed that led to the 
plasmids encoding fusion proteins that are able to bind inorganics. 
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Cut XhoI,
+ SG-linker
primer-dimer
PCR 3’phaC, cut
AscI/XhoI
Cut XbaI/NotI,
+ M extension
Cut XbaI/NotI,
+ M extension
 
Figure 1. Schematic overview of the cloning strategy leading to plasmids encoding MalE fusion 
proteins. The plasmid size is indicated in base pairs in brackets. The detailed description is given in 
Chapter II. 
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Cut XhoI, 
+ SG-linker
primer-dimer PCR 3’phaC, cut
AscI/XhoI
Cut XbaI/NotI,
+ ZZ fragment
 
Figure 2. Schematic overview of the cloning strategy leading to plasmids encoding GFP fusion proteins. 
The plasmid size is indicated in base pairs in brackets. The detailed description is given in Chapter II. 
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Cut XbaI/SunI, + synthesized DNA
3xGN
XbaI/BamHI fragment into pET-14b
 
Figure 3. Schematic overview of the cloning strategy leading to the plasmid pET-14b 3xGN-G5-
ZZPhaC. Similarly, the plasmid encoding the silica-binding synthase fusion was obtained. The plasmid 
size is indicated in base pairs in brackets. The detailed description is given in Chapter III. 
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Cut BamHI/BlpI, + PCR-amplified
SN-G5-ZZPhaC
SN-G5-ZZPhaC
(BamHI/BlpI)
3xGN-G5-ZZPhaC
(XbaI/BamHI)
 
Figure 4. Schematic of the cloning strategy leading to the plasmid pET-14b 3xGN-G5-ZZPhaC/SN-G5-
ZZPhaC, encoding two functionalised synthase proteins. The arrows indicate the individual fusion 
proteins. The plasmid size is indicated in base pairs in brackets. The detailed description is given in 
Chapter III. 
 
